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Over the past years early detection and intervention in schizophrenia have become a 
major objective in psychiatry. Early intervention strategies are intended to identify and 
treat psychosis prior to fulfilling diagnostic criteria for the disorder. To this aim, reliable 
early diagnostic biomarkers are needed in order to identify a high-risk state for psychosis 
and also predict transition to frank psychosis in those high-risk individuals destined to 
develop the disorder. Recently, machine learning methods have been successfully 
applied in the diagnostic classification of schizophrenia and in predicting transition to 
psychosis at an individual level based on magnetic resonance imaging (MRI) data and 
also neurocognitive variables. 
This work investigates the application of machine learning methods for the early 
identification of schizophrenia in subjects at high risk for developing the disorder. The 
dataset used in this work involves data from the Edinburgh High Risk Study (EHRS), 
which examined individuals at a heightened risk for developing schizophrenia for 
familial reasons, and the FePsy (Fruherkennung von Psychosen) study that was 
conducted in Basel and involves subjects at a clinical high-risk state for psychosis.  
The overriding aim of this thesis was to use machine learning, and specifically Support 
Vector Machine (SVM), in order to identify predictors of transition to psychosis in high-
risk individuals, using baseline structural MRI data. There are three aims pertaining to 
this main one.  (i) Firstly, our aim was to examine the feasibility of distinguishing at 
baseline those individuals who later developed schizophrenia from those who did not, 
yet had psychotic symptoms using SVM and baseline data from the EHRS study. (ii) 
Secondly, we intended to examine if our classification approach could generalize to 
clinical high-risk cohorts, using neuroanatomical data from the FePsy study. (iii) In a 
 x 
more exploratory context, we have also examined the diagnostic performance of our 
classifier by pooling the two datasets together. 
With regards to the first aim, our findings suggest that the early prediction of 
schizophrenia is feasible using a MRI-based linear SVM classifier operating at the 
single-subject level. Additionally, we have shown that the combination of baseline 
neuroanatomical data with measures of neurocognitive functioning and schizotypal 
cognition can improve predictive performance. The application of our pattern 
classification approach to baseline structural MRI data from the FePsy study highly 
replicated our previous findings. Our classification method identified spatially 
distributed networks that discriminate at baseline between subjects that later developed 
schizophrenia and other related psychoses and those that did not. Finally, a preliminary 
classification analysis using pooled datasets from the EHRS and the FePsy study 
supports the existence of a neuroanatomical pattern that differentiates between groups of 
high-risk subjects that develop psychosis against those who do not across research sites 
and despite any between-sites differences. 
Taken together, our findings suggest that machine learning is capable of distinguishing 
between cohorts of high risk subjects that later convert to psychosis and those that do not 
based on patterns of structural abnormalities that are present before disease onset. Our 
findings have some clinical implications in that machine learning-based approaches 
could advise or complement clinical decision-making in early intervention strategies in 
schizophrenia and related psychoses. Future work will be, however, required to tackle 
issues of reproducibility of early diagnostic biomarkers across research sites, where 
different assessment criteria and imaging equipment and protocols are used. In addition, 
future projects may also examine the diagnostic and prognostic value of multimodal 














One of the major goals in clinical psychiatry today is to diagnose individuals destined to 
develop a psychiatric disorder as early as possible and treat them accordingly, with the 
ultimate aim of either preventing disease onset or at least ameliorating clinical outcome 
and course. The work presented in this thesis focuses on examining the feasibility of 
achieving an early diagnosis for individuals considered at high risk for developing 
schizophrenia and other related psychoses. 
To do so, a machine learning method called Support Vector Machine (SVM), was 
implemented and structural imaging data from individuals at high risk for schizophrenia 
and other related psychoses were used. Two cohorts of high risk patients were utilised; 
the Edinburgh High Risk Study (EHRS) cohort, which examined individuals at a 
heightened risk for developing schizophrenia for familial reasons, and a cohort of 
individuals from the FePsy (Fruherkennung von Psychosen) study that was conducted in 
Basel and involved subjects at a clinical high-risk state for psychosis.  
Taken together, the findings produced suggest that machine learning is capable of 
distinguishing between cohorts of high risk subjects that later convert to psychosis and 
those that do not based on patterns of structural abnormalities that are present before 
disease onset.  
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Schizophrenia is one of the most severe and debilitating mental disorders, posing a 
huge burden on the affected person and the society as well, as most people with 
schizophrenia are unable to continue in employment or education. It is estimated that 
approximately 1% of the population worldwide suffers from the disorder, which 
generally manifests itself in adolescence and early adulthood although its symptoms 
are chronic and devastating. Schizophrenia has a variable phenotypic expression 
although its most common symptoms primarily include a severe decline in cognitive 
function and abnormal social behaviour. Despite numerous years of scientific 
research, the aetiology and the underlying pathophysiological mechanisms of 
schizophrenia still remain elusive. The risk for developing schizophrenia, however, 
primarily involves a major genetic contribution and environmental factors, possibly 




1.2 General overview 
 
Schizophrenia was first described by the German physician Emil Kraepelin. In 1887, 
Kraepelin introduced the term Dementia Praecox to describe a disease of early age of 
onset that was characterised by progressive decline of emotional and cognitive 
processes. Based on his clinical experience, Kraepelin observed various psychotic 
conditions that he thought were manifestations of a single disease entity (of a single 
aetiology) that ultimately resulted in cognitive deficits and executive dysfunctions 
(Kraepelin, 1919). Kraepelin distinguished schizophrenia from other types of 
psychoses, such as manic-depressive psychosis, and also developed a classification 
system of mental illnesses that influenced contemporary classification guidelines. 
It was in the early twentieth century, however, that the term Schizophrenia was first 
coined by the Swiss psychiatrist Eugen Bleuler who not only dissociated the disorder 
from a deteriorating course, but also hypothesised that the disease primarily involved 
a loosening of thoughts and feelings, in the context of a ‘split mind’ (Bleuler, 1911).  
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The term schizophrenia (from the greek words: ‘σχίζειν’ =split and ‘φρην’=mind) 
has, however, led to much confusion about the nature of the illness, in that it is often 
mistakenly thought of as a split personality disorder; a condition totally unrelated to 
schizophrenia. 
Bleuler believed that at the core of schizophrenia lies the loss of association between 
thought processes, emotion and behaviour. He introduced the concept of primary 
symptoms, which he thought were particularly characteristic of the disorder, and 
secondary symptoms of schizophrenia. Based on his clinical experience, he 
concluded that the four fundamental symptoms of schizophrenia included 
associational disturbances, ambivalence, affective disturbances and autistic 
behaviour (the so-called four A’s, now considered as negative symptoms) whereas 





1.3 Current diagnosis and clinical description 
 
Our current conceptualization of schizophrenia derives fundamentally from the 
descriptions of Kraepelin, Bleuler and Schneider, who described a number of first-
rank symptoms that are considered particularly characteristic of the disorder and now 
best describe the positive symptomatology (Schneider, 1959). 
Diagnosis of schizophrenia is nowadays typically attained through structured 
interviews and meeting criteria in the Diagnostic and Statistical Manual for Mental 
Disorders, fifth edition (DSM-5) established by the American psychiatric 
Association (APA, 2013) or the International Classification of Diseases and Related 
Health Problems, 10th edition (ICD-10), established by the World Health 
Organization (WHO, 1994). 
Both the ICD-10 and DSM-5 classifications are based on expert clinical observation 
and scientific research and provide operationalized criteria that are used to make a 
reliable diagnosis of schizophrenia. Tables 1.1 and 1.2 provide a summary of the 
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criteria needed to reach a diagnosis of schizophrenia. Differences between the DSM-
5 and ICD-10 exist in terms of symptom duration with the former suggesting a more 
chronic course (symptoms have to be present for 6 months whereas in ICD-10 one 
month is required) and requiring an accompanying deterioration in functioning in 
order to reach a diagnosis. In addition, both systems require that other diagnoses such 
as mood disorders with psychotic symptoms, schizoaffective disorders and drug-
induced psychoses should be first ruled out. Despite their discrepancies, however, 
definitions in both diagnostic systems are sufficiently similar to promote 
standardization across centers and ensure international agreement.   
Although the use of standardized criteria is clinically relevant and enhances 
reliability in the diagnostic process, most of the attributes defining schizophrenia are 
primarily inferential and depend on self-reported subjective experience. The clinical 
presentation of the disease itself is complex, with patients manifesting heterogeneous 
symptomatology, comorbidity with other psychiatric disorders, variable illness 
course and adherence to treatment.  
Two broad types of symptoms, including positive or psychotic symptoms and 
negative symptoms, characterize schizophrenia. Positive symptoms are associated 
with the presence of dysfunctions or abnormalities and include disturbances of 
perception and inferential thinking, such as hallucinations and delusions, 
disorganized thinking and speech. Patients with schizophrenia may hear voices that 
other people do not hear, may think that someone else is controlling their thoughts or 
reading their minds or even believe they are victims of a plot with the intention to 
harm them. They often have a hard time organizing their thoughts or speaking in a 
logical, coherent manner. These symptoms usually become apparent at the early 
stages of the disease, in adolescence or early adulthood and are usually mitigated 
with the use of anti-psychotic treatment, although recurrent relapses and remissions 
commonly go on throughout the patient’s life.  
Negative symptoms generally succeed this florid psychotic phase and are mostly 
linked to a lack of motivation and emotional responsiveness, a loss of interest in 
oneself, social isolation and withdrawal. Current anti-psychotic medication does not 
seem to treat negative symptoms, which tend to persist for longer than positive 
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symptoms and are generally associated with a poorer outcome (Hunter & Barry 
2012). Disturbances in cognitive functions form another cluster of signs and 
symptoms of schizophrenia, although they are not widely considered as distinct a 
dimension of the disorder as positive and negative symptoms. Impairments in 
executive functions, working memory and attention are generally signs that might 
precede the florid psychotic stage of the disorder and might be apparent in the 
prodrome to overt psychosis, and usually persist or even deteriorate during the course 
of the disease.  
No single symptom can be considered pathognomonic for schizophrenia and patients 
usually present with different constellations of symptoms. Symptom heterogeneity 
across patients can be described in the context of distinct clinical subtypes that are 
captured in the previous DSM-IV and the ICD-10, and include among others: 
paranoid, disorganized, catatonic and undifferentiated schizophrenia. Clinical 
presentation of patients is not, however, limited to only one subtype, nor this subtype 
remains stable throughout the course of the illness, thus rendering the subtyping of 
schizophrenia diagnostically unstable and possibly unreliable (Tandon et al. 2009). 
As a result, descriptions of subtypes have been removed in the most recent DSM-5 
(Tandon et al. 2013). 
Comorbidity with other psychiatric disorders such as depression or comorbid 
substance-use disorders is common among schizophrenia patients. Depressive 
symptoms might be present at any point during the illness, with the majority of 
patients suffering from them in the pre-morbid (pre-psychotic) phase of the disorder 
or during acute psychotic exacerbations, and usually as an adverse side effect of anti-
psychotic medication. Substance abuse, such as nicotine, alcohol or cannabis is 
highly prevalent among schizophrenia patients and is linked to poorer outcome, 
including increased psychotic symptoms and poorer adherence to treatment (Dixon 
1999, Winklbauer et al. 2006).  
 6 





Table 1.2 ICD-10 Diagnostic criteria for schizophrenia 
Criterion A. 
Two (or more of the following), each present for a significant period of time during a 1-month 




3. Disorganised speech 
4. Grossly disorganized or catatonic behaviour 
5. Negative symptoms, e.g. avolition, alogia, diminished emotional expression 
 
Criterion B. 
Social/ Occupational Dysfunction 
 
Criterion C. 
Duration of at least six months, with at least one month of active symptoms. 
 
Either at least one of the syndromes, symptoms, and signs listed under (1) below, or at least two of the 
symptoms and signs listed under (2) should be present for most of the time during an episode of 
psychotic illness lasting for at least 1 month (or at some time during most of the days). 
 
(1)  At least one of the following must be present: 
 (a)  thought echo, thought insertion or withdrawal, or thought broadcasting; 
(b)  delusions of control, influence, or passivity, clearly referred to body or limb movements 
or specific thoughts, actions, or sensations; delusional perception; 
(c)  hallucinatory voices giving a running commentary on the patient’s behavior, or 
discussing the patient among themselves, or other types of hallucinatory voices coming 
from some part of the body; 
(d)  persistent delusions of other kinds that are culturally inappropriate and completely 
impossible (e.g., being able to control the weather, or being in communication with aliens 
from another world). 
 
(2)  Or at least two of the following: 
(a)  persistent hallucinations in any modality, when occurring every day for at least 1 
month, when accompanied by delusions (which may be fleeting or half-formed) 
without clear  
affective content, or when accompanied by persistent overvalued ideas; 
(b)  neologisms, breaks, or interpolations in the train of thought, resulting in 
incoherence or irrelevant speech; 
(c)  catatonic behavior, such as excitement, posturing or waxy flexibility, negativism, 
mutism, and stupor; 
(d) negative symptoms, such as marked apathy, paucity of speech, and blunting or 
incongruity of emotional responses (it must be clear that these are not due to 




1.4 Epidemiology of schizophrenia 
 
Schizophrenia is one of the most severe and devastating mental disorders, ranked by 
the World Health Organization as one of the top ten illnesses contributing to global 
burden of disease (Jablensky 1997). Epidemiological studies provide a useful tool in 
the understanding of the disorder by studying and describing the distribution pattern 
of schizophrenia in populations and across cultures and identifying factors that 
convey risk for the development of psychosis. 
Based on epidemiological studies conducted over the last century, the prevalence of 
schizophrenia (i.e. the number of cases at any time point) in the general population is 
approximately 1% (Jablensky et al. 1992). Based on the only global study that 
directly generated incidence data (WHO-10 nation study, Jablensky et al. 1992), the 
annual incidence of schizophrenia (i.e. the number of new cases) was estimated to 
range from 16-40/100,000 per year using broad diagnostic criteria (ICD-9, WHO-
1978) and 7-14/100,000 using narrow criteria (CATEGO class S+, Wing et al. 1974). 
Since incidence is a measure of the number of new cases with a disease over the 
number of cases who are at-risk for developing the illness over a specified period of 
time, this measure is highly dependent on the diagnostic criteria used, and thus 
incidence rates exhibit some variation across sites. A recent meta-analysis of all 
published studies from 1965 to 2001 reported a median incidence rate of 15.2 per 
100,000 per year with 80% confidence interval rates (10th to 90th decile) ranging 
from 8-43 per 100,000 per year (McGrath et al. 2004). The notion that the incidence 
rates of schizophrenia vary across sites has also been supported by another meta-
analysis of the same research group (McGrath et al.2008), which further reported that 
sex, urbanicity and migration (Cantor-Graae & Selten 2005) are associated with a 
higher risk for developing schizophrenia.  
Gender differences in schizophrenia have been widely reported by a host of studies, 
showing differences in disease onset, course and outcome (Leung & Chue 2000). A 
recent meta-analysis reported higher incidence of schizophrenia in men versus 
women (Aleman et al. 2003). A recent review quantified a median male to female 
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rate ratio of 1.4: 1 (McGrath et al. 2004, McGrath et al. 2008). Differences in age of 
onset have been widely reported, with men having an earlier disease onset than 
women (Leung & Chue 2000, Castle et al. 1998, Goldstein et al. 1989, Gureje 1991), 
although this finding is not universally replicated (Folnegovic 1994, Addigton et al. 
1996, Murthy et al. 1998). In addition, earlier studies reported a worse course of 
illness in male patients, who tend to exhibit more severe negative symptoms (Castle 
& Murray 1991, Gur et al. 1996, Riecher-Rossler & Hafner 2000) and have worse 
outcome resulting in higher rates of relapses and institutionalizations (Haro et al. 
2006).  
Women with schizophrenia usually have better social functioning, fewer admissions 
to hospitals (Morgan et al. 2008) and better response to treatment (Goldstein et al. 
2002, Usall et al. 2007). A possible explanation for the better level of functioning 
might be the later age onset of schizophrenia in women that enables them to attain a 
certain level of social functioning by the time they develop full-blown symptoms and 
are first admitted to clinical services, thus contributing to a better clinical outcome. 
The effect of oestrogen in women has also been suggested as a protective factor in 
the development of schizophrenia (Hafner 2000). 
 
 
1.4.1 Premorbid phase and onset 
 
The typical onset is between the ages of 16 and 30, with rare cases developing 
schizophrenia by the age of 12 (childhood-onset schizophrenia) (Russel 1994) or 
after the age of 45 (late-onset schizophrenia) (Folsom et al. 2006). The onset of 
schizophrenia is often preceded by a premorbid phase where subtle and non-specific 
abnormalities in motor, cognitive and social functioning are observed (Figure 1.1; 
Schenkel & Silverstein 2004). The premorbid phase is usually followed by a 
prodromal phase that can last from several months or even years and it is 
characterised by non-specific changes in the person's behaviour and a noticeable 
decline in functioning. At this stage, academic, work and/or social functioning might 
show signs of impairment; the individual might report increased anxiety, 
 9 
suspiciousness or a non-specific feeling that the world seems different. The 
individual is considered at-risk for developing psychosis and often presents with 
attenuated or transient psychotic symptoms; however these are not severe or frequent 
enough to warrant a diagnosis of schizophrenia or any other psychotic-related 
disorder. Onset of schizophrenia is usually accompanied by prolonged and/or acute 
episodes of psychosis that lead individuals to their first hospital admission and 
possibly the first administration of anti-psychotic treatment. There is often significant 
delay from the index individual and his family in seeking clinical management and 
treatment that can last up to 1-2 years (McGlashan 1999). Negative symptoms tend 




Figure 1.1 The stages of schizophrenia. Figure adjusted from Tandon et al. 2009. 
 
 
The course of schizophrenia varies substantially across patients. After the first 
psychotic episode, the majority of individuals have one or more relapses in the 
course of illness that may lead to hospitalization. The first ten years of schizophrenia 
are usually characterized by repeated relapses of psychotic episodes of variable 
extent and severity, followed by varied periods of symptoms’ remission (Ciompi 
1980, Andreasen et al. 2005) and accompanied by a decline in cognitive functioning 
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over the course of illness. Over the long-term of the illness, positive symptoms seem 
to subside and become less devastating, partly on account of the anti-psychotic 





Despite advances in treatment, the outcomes for most schizophrenia patients remain 
poor. Only a small fraction of patients achieve full recovery. The majority of 
patients, after a long course of relapses and remissions, reach a stable phase in the 
illness trajectory where social isolation, impaired social and cognitive functioning 
remain. Most patients have trouble finding or keeping a job and being active in the 
community. Individuals with schizophrenia have higher risk of attempting and/or 
committing suicide (Hawton et al. 2005), increased incidence of comorbid medical or 
psychiatric illnesses (Leucht et al. 2007, Carney et al. 2006) and lower quality of life 
(Eack & Newhill 2007) than the general population.   
The outcome of schizophrenia is influenced by several factors, including premorbid 
functioning, the characteristics of the illness symptomatology and course, and social 
variables. A favourable outcome in schizophrenia has been linked with an acute 
onset of the illness, a later age of onset, the female gender and absence of substance 
abuse. On the contrary, insidious disease onset, early age of onset, the presence of 
negative symptoms and poor compliance to treatment are factors linked to poor 
prognosis. 
The outcome of schizophrenia is also influenced by socioeconomic variables. In the 
multinational World Health Organization study, patients in developing countries had 








1.5 Aetiology of schizophrenia 
 
1.5.1 The neurodevelopmental model                
 
The neurodevelopmental hypothesis of schizophrenia has been one of the 
predominant models in schizophrenia research over the past two decades. This model 
postulates that schizophrenia is the result of aberrative neurodevelopmental processes 
that commence long before the onset of clinical symptoms (Weinberger 1987, 
Murray & Lewis 1987) and are caused by genetic and environmental factors 
(presented in more detail in the following subsections) or a combination of both. 
Converging evidence from a wide range of research studies supports the 
neurodevelopmental model. Patients affected with schizophrenia are more likely to 
have experienced pre- and/or perinatal adverse events (such as hypoxia during their 
birth or exposure to maternal virus when in utero) than healthy controls (Geddes & 
Lawrie 1995, Keshavan et al. 2006, Gilmore & Murray 2006, Byrne et al. 2007). 
Additionally, schizophrenia patients often exhibit increased rates of minor physical 
anomalies (Compton and Walker 2009, Ismail et al. 1998) and motor, cognitive and 
behavioural impairments (Weinberger 1996) long before illness onset (even present 
in childhood), thus further supporting the neurodevelopmental hypothesis. Subtle 
brain structural abnormalities have also been found in patients prior to illness onset 
(Lawrie et al. 2001b, Pantelis et al. 2003, Pantelis et al. 2005; to be discussed in more 
detail in Chapter 2). 
To explain the gap between the early developmental insults and the onset of 
schizophrenia in adolescence or early adulthood, researchers have postulated that 
these early developmental abnormalities are likely linked to aberrant brain 
maturational processes (such as excessive synaptic pruning), possibly in synergy 
with some stressor, that ultimately lead to the development of psychotic symptoms 
and schizophrenia.  
The controversy between a neurodevelopmental and neurodegenerative origin of 
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schizophrenia goes back to the years of Kraepelin and is still a matter of debate 
(Lieberman 1999, Woods 1998). However, the idea that these are not mutually 
exclusive and may both characterize the development and course of schizophrenia 






Genetic predisposition appears to be a major risk factor for the development of 
schizophrenia. A plethora of family, twin and adoption studies have examined the 
contribution of genetic factors to the development of schizophrenia. As already 
mentioned above, the lifetime risk for the development of schizophrenia is estimated 
around 1% in the general population, while having an affected family member 
substantially increases the risk for the disorder (McGuffin et al. 1995, Tandon et al. 
2008). It is estimated that having a second or third degree relative increases the risk 
of developing schizophrenia to 2-6% (Gottesman et al. 1987), while a first-degree 
relative (e.g. sibling, parent) can increase the risk up to 15% (Tandon et al. 2008). A 
useful approach for elucidating the genetic underpinnings of vulnerability to 
schizophrenia is the study of monozygotic and dizygotic twin pairs who are 
discordant for schizophrenia (Sullivan et al. 2003). Dizygotic twins share on average 
50% of their genes, so if one twin is affected, the other has 10-15% risk of 
developing schizophrenia while monozygotic twins discordant for schizophrenia, 
who share almost 100% of their genetic material have 40-50% risk of schizophrenia 
(Gottesman et al. 1987, Sullivan et al. 2003). 
Despite the fact that the role of genetic risk is undisputed, it remains unclear which 
genes or genetic variations confer this risk for schizophrenia from one generation to 
the next. Converging evidence suggests that no single gene is sufficient or necessary 
for the development of schizophrenia but instead many, even thousands of genes 
might act in additive or interactive ways to mediate risk for the disorder (Walker et 
al. 2010). Findings from genome-wide association studies (GWAS) have implicated 
a large number of putative risk genes and susceptibility loci that may be linked to 
 13 
abnormal neurodevelopmental processes associated with schizophrenia. Failure to 
replicate findings in genetic association studies has, however, seriously impeded the 
definite consideration of genes for their involvement in developing schizophrenia 
(Tandon et al. 2008). In one of the largest molecular genetic studies of schizophrenia 
that combined numerous GWAS genotypes into a single analysis, the authors found 
108 independent genomic loci, some of which were not previously reported, that 
increase the risk for the development of schizophrenia (Ripke et al. 2014).  
 
1.5.3 Environmental factors 
 
A series of environmental factors have been postulated to convey an added risk for 
schizophrenia. Maternal virus infections, nutritional deficiencies during pregnancy 
and complications during birth delivery have been linked to an increased liability to 
schizophrenia (Maki et al. 2005, Tandon et al. 2008). Birth during winter or early-
spring months (Torrey et al. 1997) and older paternal age have also been associated 
with a greater probability for developing schizophrenia (Malaspina et al. 2001).  
There is also evidence suggesting that urbanization and migration are significant risk 
factors for the development of schizophrenia (Boydell & Murray 2003, Hickling et 
al. 1999). Finally cannabis abuse during adolescence has been consistently linked to 
an increased risk for schizophrenia (Moore et al. 2007) that was estimated to be 2-
times higher than the relative risk for schizophrenia on an individual level 
(Arseneault et al. 2004). Although a direct causational relationship between cannabis 
use and schizophrenia has not yet been found, it is postulated that cannabis can 
precipitate schizophrenia in vulnerable (or at-risk) individuals (Barnes et al. 2006). 
For a detailed review of the risk factors in schizophrenia, the interested reader is 
referred to Lawrie et al. 2011.  
In general, it is highly likely that a combination of genetic and environmental factors 
interact to cause schizophrenia. It remains, however, elusive exactly which and how 





1.6 High-risk paradigms  
 
As explained above, the onset of schizophrenia is usually preceded by a prodromal 
phase characterized by mild, sub-threshold positive symptoms and functional 
decline. Research into the early phases of psychosis may provide important clues to 
the pathophysiological mechanisms underlying transition to psychosis, without the 
confounding effects of anti-psychotic medication. Early intervention strategies 
during this prodromal stage are of great interest because they have been shown to 
provide better outcome and ameliorate the burden of psychosis (Marshall & 
Lockwood 2006). 
Two research paradigms have been employed in order to explore vulnerability 
markers to psychosis. Utilising a clinical high-risk (HR) paradigm, individuals 
presenting with prodromal signs of psychosis are considered at an imminent, 
increased risk of making a transition to full psychosis (also often described as at an 
‘at-risk mental state’ or ARMS) (Fusar-Poli et al. 2013a, Cornblatt et al. 2002, 
Phillips et al. 2000). In general individuals at clinical HR most often present with 
attenuated positive symptoms, brief limited intermittent psychotic symptoms 
(Riecher-Rossler et al. 2007, Yung et al. 2004), mild cognitive deficits (Brewer et al. 
2006, Lencz et al. 2006, Riecher-Rossler et al. 2009) and/or might have a family 
history of psychosis with an accompanying reduction in functioning.  
In familial HR paradigms, individuals are characterised on the basis of having at 
least one affected first or second-degree relative (Lawrie et al. 2001b, Cannon & 
Mednick 1993, Erlenmeyer-Kimling et al. 1997, van Haren et al. 2004). 
Schizophrenia is known to have a heritable component (Harrison & Weinberger 
2005). Thus by examining individuals from multiply affected families diagnosed 
with schizophrenia, it is possible to evaluate whether and to what extent brain, 
clinical and cognitive abnormalities are mediated by a genetic risk to the disorder.  
It should be noted, however, that this delineation of HR subjects is not 
straightforward as many individuals at familial HR often exhibit pre-psychotic 
symptoms and clinical HR subjects might also have a family history of the disorder. 
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A recent systematic review of clinical and familial HR cohorts reported overlapping 
brain changes in the frontal, temporal and cingulate regions (Smieskova et al. 2013). 
In addition, individuals in both HR paradigms also share a higher probability of 
developing schizophrenia than a healthy population, suggesting that several aspects 




1.7 Aims and outline of the present thesis  
 
The overriding aim of the present thesis was to apply machine learning in order to 
identify predictors of transition to schizophrenia in subjects at high risk for 
developing the illness. Initially, data from the Edinburgh High Risk Study (EHRS), 
which were immediately available, were used with the intention of identifying 
neuroanatomical-based markers of transition and also replicating earlier findings in 
the EHRS literature (Johnstone et al. 2005). The second aim was to examine if our 
classification technique could generalize to other high risk cohorts and especially to 
high-risk individuals that were identified on the basis of having prodromal symptoms 
(clinical HR cohorts). To this aim, baseline neuroanatomical data from the FePsy 
(Fruherkennung von Psychosen) study (Riecher-Rossler et al. 2007) were obtained. 
Finally, the prognostic performance of our classifier was tested by pooling data from 
the EHRS and the FePsy datasets. 
Overall the thesis spans two main areas of study; neuroimaging and machine 
learning. Therefore, relevant concepts from the fields of neuroimaging and machine 
learning are presented in Chapters 2 and 3, respectively. Chapter 2 gives an 
introduction to Magnetic Resonance Imaging (MRI), including an overview of the 
pre-processing steps and standard univariate methods of analysis. A review of MRI 
findings in schizophrenia is additionally presented. Chapter 3 provides an 
introduction to machine learning approaches and the steps of a machine learning-
based classification pipeline. In addition, a literature review of machine learning 
studies in schizophrenia is presented. Chapter 4 presents the subject material in the 
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present thesis and describes the methodology used. Subsequent chapters constitute 
the main experimental sections of the present thesis. Chapter 5 addresses the first aim 
of the thesis and presents the results of applying our classification technique in 
distinguishing at baseline those high-risk subjects that later developed schizophrenia 
from those who did not, yet had psychotic symptoms. Chapter 6 addresses the second 
aim and presents results pertaining to applying the classifier to baseline data from the 
FePsy study. Chapter 7 addresses the final aim of the thesis and examines the 
performance of the classifier on the pooled dataset. Finally, Chapter 8 comprises an 
overall summary of the main findings presented in this thesis and a general 


















































2.1 Introduction  
 
Recent advances in neuroimaging have enabled scientists to visualize and study the 
human brain in vivo and develop methods to understand its anatomy and function. 
Commonly used neuroimaging modalities include X-ray computed tomography 
(CT), positron emission tomography (PET) and magnetic resonance imaging (MRI). 
The work presented in this thesis will focus on MRI, which is described in the 





The human brain is broadly divided into three parts: the cerebrum, the cerebellum 
and the brain stem. The cerebrum is the largest part of the brain and is composed of 
the cerebral cortex and several subcortical structures, such as the hippocampus and 
basal ganglia. The cerebrum is divided into two hemispheres, left and right, which 
are connected together by a flat bundle of neural fibers, the corpus callosum. 
Outermost to the cerebrum lies the cerebral cortex, which is divided into four lobes: 
frontal, parietal, occipital and temporal (Figure 2.1).  
In general, each lobe in the cerebral cortex specializes in different functions. The 
frontal lobe, which lies at the front of the brain and behind the forehead, is 
responsible for reasoning and planning. It also plays an important role in long-term 
memory. Posterior or caudal (behind) to the frontal lobe, and dorsal (superior) to the 
occipital lobe is the parietal lobe, which is primarily responsible for visuo-spatial 
processing, recognition and navigation. Ventral (inferior) to the parietal lobe is the 
temporal lobe, which is mainly responsible for auditory processing and is associated 
with memory and speech. Finally, the occipital lobe, which lies at the back of the 




At the back of the brain, underlying the occipital and temporal lobes is the 
cerebellum, also known as 'the little brain', which is responsible for movement 
coordination and balance.  
 
 
(a)                                   (b)                                          (c) 
 
Figure 2.1 The human brain and anatomical planes and directions. (a) A sagittal 
view of the human showing the four lobes and cerebellum. (b) An axial slice of a 
structural MRI scan highlighting the grey matter, white matter and the ventricles (c) 




The cerebral cortex has a typical grey color due to grey matter (GM), which is also 
distributed at the depths of the cerebrum (e.g. thalamus, hypothamalus etc.), the 
cerebellum and the spinal cord. The grey matter consists mainly of neuronal cell 
bodies that are responsible for neural processing and several functions. In contrast, 
white matter (WM) consists mostly of glial cells and myelinated axon tracts that 
transmit information (i.e. signals) from one part of the brain to the other and act 
supportively to the function of neurons (e.g. by providing nutrients to the neurons 
etc.). At the center of the brain are the ventricles, which are filled with cerebrospinal 
fluid (CSF) that facilitates the transmission of several substances across brain regions 
and acts like a 'cushion' to the cortex, by protecting it and absorbing pressure.  
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2.1.2 Magnetic resonance imaging 
 
Magnetic resonance imaging (MRI) utilizes the phenomenon of nuclear magnetic 
resonance (NMR) of the hydrogen atom in order to produce high-quality, detailed 
images of internal body structures and any other tissue.  
In order to obtain a structural MRI, the patient is placed inside a MRI scanner. A 
MRI scanner is a cylinder-shaped magnet that generates a powerful static magnetic 
field. The strength of the magnetic field determines to a great degree the quality of 
the produced images. Scanners currently used can generate magnetic fields that range 
from 1T to 4T.  
MRI exploits the spin of the hydrogen nuclei. In the presence of a static magnetic 
field Bo, protons of the hydrogen nuclei tend to align parallel or anti-parallel to the 
direction of the magnetic field and rotate along the axis. A slightly larger number of 
protons spin (or precess) in the direction that is parallel to the field and have less 
energy than those that are anti-parallel, thus creating a net longitudinal magnetic field 
in the z-direction (Figure 2.2a). 
When a radiofrequency (RF) pulse is introduced and emitted at the precession 
frequency of the hydrogen atom, lower-energy protons are excited and jump to a 
higher-energy state, where they align anti-parallel to the field and precess in phase. A 
new transversal magnetic field is thus created in the (x,y)-plane (Figure 2.2). When 
the RF pulse is then switched off, the excited protons gradually release their 
previously absorbed energy and return to the initial lower-energy state in their 
parallel orientation (relaxation phase). This results in a gradual increase in the 
longitudinal magnetic field, which is characterized by the longitudinal T1 relaxation 
time. In addition, in the absence of the RF pulse, protons begin to precess again in 
different phases. This causes a gradual decline in the net transversal magnetic field, 
which is characterized by the T2* relaxation time.  




 (a)                       (b)                          (c)                        (d) 
 
Figure 2.2 Behavior of hydrogen atom after an RF pulse. (a) The system of 
conventional axes: z–axis is defined by the line that connects toe to head of the 
subject. The xy–plane is parallel to the z–axis. (b) The net longitudinal magnetic 
field in the +z direction, before the introduction of the RF signal. (c) The application 
of an RF pulse flips some protons to the –z direction and this reduces the longitudinal 
magnetic field. (d) Application of RF pulse makes protons rotate in phase, creating a 
transversal (in xy–plane) magnetic field. 
 
 
The construction of contrast images is based on the differing T1 and T2* relaxation 
properties of various brain tissues. In most structural MRI studies, a T1 contrast is 
used to obtain the images, while a T2* contrast is used for functional MRI.  
Two imaging parameters are of great importance in MRI: the time to repeat (TR) and 
the time to echo (TE). TR represents the time interval between two consecutive 
applications of the RF pulse and TE the time lapse from the moment the RF pulse is 
applied and the moment when the signal is measured. For a more thorough 




2.1.3 Functional MRI 
 
Functional MRI (fMRI) is used to visualize brain activation in response to an 
external stimulus or a certain task. Functional MRI builds on the same technology as 
MRI, with the difference that it exploits the ratio of oxygenated to deoxygenated 
blood instead of the hydrogen atom. It is considered an indirect measure of brain 
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activity, since fMRI does not capture neural activity per se but the hemodynamic 
response instead (Huettel et al. 2004, Lazar 2008). 
When a brain region becomes active, oxygenated haemoglobin flows to that area in 
order to increase blood concentration. What is measured in an fMRI task is the 
difference of oxygenated to deoxygenated haemoglobin. Deoxygenated haemoglobin 
is more paramagnetic than oxygenated haemoglobin (the atoms of a paramagnetic 
material tend to align themselves in the presence of an external magnetic field, thus 
increasing the field strength). This difference induces change in the local magnetic 
field and thus affects the MR signal through the Blood Oxygenation Level 
Dependent (BOLD) contrast (Ogawa et al., 1990). The BOLD signal gives an 
indication of neuronal activity. 
 
 
2.2 Image Processing 
 
The present work is based on the analysis of brain imaging data that were acquired 
using MRI. Each MRI brain scan consists of volume units called voxels, in which an 
aspect of a specific function or structure is recorded.  
In order to achieve spatial correspondence of voxels between subjects, normalization 
of brain scans to a common standard space is required. In addition, a certain number 
of pre-processing steps are usually performed before analysing the data and making 
inferences for specific effects. The scientific question to be investigated and the type 
of task at hand generally determine the processing procedures to be followed. 
In this work, structural MRI data were pre-processed by employing voxel-based 
morphometry. A general overview to the voxel-based morphometry theory and 
methodology is given below. More details about specific steps (and parameters) 
followed in the pre-processing of the MRI scans in this thesis can be found in 




2.2.1 Voxel-based Morphometry  
 
The aim of voxel-based morphometry (VBM) is to identify differences in the local 
concentration of brain tissue (usually GM), after correcting for large-scale 
differences in gross anatomy and position (Ashburner & Friston, 2000, Mechelli et 
al. 2005). VBM involves spatially normalizing all the structural images to the same 
stereotactic space, extracting GM and WM from the normalized images, smoothing 
the normalized GM and WM segments and finally performing voxel-wise statistical 
comparisons to make inferences about group differences (Figure 2.3). 
One important aspect of VBM is that it is not restricted to a specific brain region, like 
a region-of-interest (ROI) analysis that requires a priori assumptions, but examines 
the whole brain in an unbiased and objective manner.  
 





2.2.1.1 Spatial Normalization 
Spatial normalization involves the registration of all images to the same template 
image, by minimizing the residual sum of squared differences. The first step in 
spatially aligning each brain image involves matching the image by estimating the 
optimum 12-parameter affine transformations (Ashburner & Friston 1997). The 
second step accounts for global non-linear shape differences, which are modeled by a 
linear combination of smooth spatial basis functions. This step involves estimating 
the coefficients of the basis functions that minimize the residual squared difference 
between the image and the template, while simultaneously maximizing the 
smoothness of the deformations. Spatial normalization does not aim to match every 
cortical feature exactly but merely correct for global brain differences. 
 
2.2.1.2 Segmentation 
The spatially normalized brain images are then segmented into grey matter, white 
matter and cerebrospinal fluid. Segmentation employs a mixture model cluster 
analysis to identify voxel intensities matching particular tissue types combined with 
an a priori knowledge of the spatial distribution of these tissues in normal subjects, 
derived from tissue probability maps. The segmentation step also incorporates an 
image intensity non-uniformity correction (Ashburner & Friston, 2000) to address 
image intensity variations caused by different positions of cranial structures within 
the MRI head coil. 
A unified segmentation approach has also been adopted in currently used pre-
processing streams (Ashburner & Friston 2005). Unified segmentation is a 
probabilistic framework in which image registration, tissue classification and 
intensity non-uniformity (bias) correction are all combined in the same generative 
model. In this way, the inherent circularity found in standard VBM approaches, 
where image registration requires an initial tissue classification and in turn tissue 






The normalized, segmented images are then smoothed using an isotropic Gaussian 
kernel. The intensity in each voxel of the smoothed data is a locally weighted 
average of grey matter  (or white matter) density from a region of surrounding 
voxels, the size of the region being defined by the size of the smoothing kernel 
(Ashburner & Friston, 2000). Smoothing also renders the data more normally 
distributed, thus increasing the validity of the following parametric statistical tests. 
Additional pre-processing steps can be included in the standard VBM processing 
pipeline. Creation of GM and WM study specific templates and skull extraction can 
be performed prior to the initial normalization step so that errors pertaining to 
misclassification of tissue can be avoided.  
In the optimized protocol suggested by Good et al. 2001, study-specific templates for 
GM and WM are created by averaging the smoothed normalized GM and WM 
images from all subjects in the study. Then an iterative procedure of normalization 
and segmentation steps is followed. First, the original structural MRI images in 
native space are segmented. The resulting GM and WM images are then spatially 
normalized using the GM/WM study-specific templates to derive the optimized 
normalization parameters. These parameters are then applied to the original, whole-
brain structural images in native space before a second segmentation step takes place.  
Details for the creation of study-specific priors and the exact steps of the pre-
processing pipeline that were followed in this work can be found in Chapter 4 of 
Materials & Methods. 
Following the pre-processing of structural MRI data, voxel-wise statistical analysis 





2.2.2 Univariate methods of analysis 
 
In univariate methods of analysis, each voxel is treated independently in order to 
examine an effect of interest. Parametric statistical models are assumed at each 
voxel, using the General Linear Model (GLM) in order to describe the data as a 
linear combination of experimental effects, potentially confounding variables and 
some error (Friston et al. 1995). Classical statistical inference is then used to test 
hypotheses that are expressed in terms of GLM parameters. Inferences in 
neuroimaging settings may be about structural differences when comparing one 
group of subjects to another (e.g. voxel-based morphometry- Ashburner & Friston 
2000), or neurophysiological indices of brain function (fMRI- Friston et al. 1994).  
 
 
2.2.2.1 Statistical Parametric Mapping 
Statistical Parametric Mapping is the most prevalent approach to characterizing 
effects pertaining to structural and functional anatomy. Two steps are involved in the 
characterization of regionally specific effects: i) modelling the data, i.e. estimating 
parameters using a GLM and ii) making inferences via t- or F-statistics.  
 
 
Figure 2.4 General Linear Model. The General Linear Model assumes that the 
acquired signal intensities in Y are the combination of three components: the design 
matrix X that contains the actual data for the two groups of interest along with 
confounds that model some source of noise. A weight assigned to each component of 
interest (β1) or confound (β2) and some error e.  Source: SPM-Zurich course notes. 
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A GLM model that describes the signal intensities in voxel Y can be expressed in 
terms of some experimental parameters B and some residual variability (error) E. For 
characterising group differences in this voxel, this can be expressed as: Y = XB + e, 
where X is the design matrix that contains the data for the two groups (Figure 2.4). 
Parameters in B are determined for each voxel either using students t-Test or analysis 
of variance (ANOVA). Following the estimation of parameters, t- or F-scores are 
constructed from contrasts, which basically define the hypothesis (i.e. the scientific 
question) to be investigated. Statistical scores are then compared to the expected 
distribution under the null hypothesis, allowing the computation of a p-value for each 
voxel. P-values should be corrected for multiple comparisons to ensure that voxels 
did not reach statistical significance levels by chance on account of the large number 
of voxels that are treated independently. Standard Bonferroni correction could be 
used to control for multiple comparisons. However, given that it requires all tests to 
be independent, this adjustment is too harsh and possibly inappropriate in 
neuroimaging settings where voxels are highly correlated. In contrast, Random Field 
Theory (RFT) takes into account that contiguous voxels are not independent (Brett et 
al. 2003, Worsley et al. 1996, Worsley et al. 2004) and provides a more 
parisimonious approach to controlling for type I errors.  
Type I errors occur when the null hypothesis is rejected when in fact it is true (also 
known as false positive error). For example, a brain region (or voxel) is shown to be 
activated during a particular task when it is actually not or a difference in 
experimental conditions is detected but such a difference does not truly exist.  On the 
other hand, a type II error (or false negative error) occurs when the null hypothesis 
(e.g. no difference between two experimental groups or no voxel activation during a 
task) is accepted when it is actually false. While controlling for type I errors is a 
widely accepted practice in neuroimaging studies (through Bonferroni correction or 
RFT), type II errors are more rarely considered (Bennett et al. 2009). Although, the 
focus on controlling for type I errors is clearly necessary in that it ensures that most 
observed effects represent true differences, it could, also, result in a number of 
negative consequences, such as an increase in type II errors and deficient meta-
analyses (Lieberman and Cunningham 2009). The key in neuroimaging studies is to 
 28 
find a balance between the two types of error; a tricky endeavour in which one must 
consider the desired power and the purpose or nature of the study. This balance could 
be achieved by increasing the sample size in single neuroimaging studies, which is 
not always cost-effective and easy to perform, or by considering studies in the 
aggregate through systematic meta-analyses that can compensate for the low 
statistical power. Increasing sample size will result in less conservative thresholds 
being needed to control for false positives and provide more statistical power to 
detect the more subtle differences and as a result this will reduce false negative errors 
as well. Another possible solution would be to restrict the amount of multiple 
corrections to be performed by either focusing on specific regions of interest or by 




Figure 2.5 Example of an unthresholded T-map. Axial, coronal and sagittal views of 
T-map overlaid over a single subject anatomical image. 
 
 
Finally, the results of statistical parametric analyses can be illustrated in 3D maps, 
often called SPM maps, where statistically significant differences in brain voxels can 
be highlighted (Figure 2.5). 
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In terms of neuroimaging packages, SPM software is currently the most prevalent 
one for the pre-processing and analysis of brain imaging data. It was first made 
available to the neuroimaging community in 1991 (Friston et al. 1991) and has been 
available ever since from the Wellcome Trust Centre for Neuroimaging at University 
College London (http://www.fil.ion.ucl.ac.uk/spm), along with detailed 
documentation and related publications. The latest version of SPM released is the 
SPM12. However, in this work I have mainly used SPM5 because I found this 
version to be relatively more stable to work with than the other SPM versions. 
 
2.3 MRI findings in schizophrenia 
 
Since the time of Kraepelin and Bleuler, it was strongly believed that schizophrenia 
was an organic brain disorder. Since then, brain imaging studies have attempted to 
unravel the pathophysiology of schizophrenia and reported a host of structural and 
functional brain abnormalities associated with the disorder.  
 
 
2.3.1 Neuroanatomical abnormalities in established and first-episode 
schizophrenia  
 
The first CT study of schizophrenia (Johnstone et al. 1976) reported abnormally 
enlarged lateral ventricles in patients with schizophrenia; a finding that has been 
highly replicated in most subsequent MRI studies (Shenton et al. 2001). Early MRI 
studies have also reported significant reductions in total brain volume in 
schizophrenia patients compared to healthy individuals (Shenton et al. 1997). In 
Lawrie & Abukmeil 1998, the authors reported about 3% global brain volume 
reduction in patients, mainly attributed to grey matter volume loss (of about 4%).  In 
an extensive meta-analysis of regional brain volume studies in schizophrenia, Wright 
et al. 2000 reported that the mean cerebral volume of patients was 2% smaller than 
the mean volume for healthy controls in 58 studies that involved 1,588 schizophrenia 
patients.  
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Temporal and frontal lobe volume reductions have also been consistently reported in 
studies comparing schizophrenia patients and healthy controls that employed either 
ROI or VBM (Lawrie & Abukmeil 1998, Wright et al. 2000, Shenton et al. 2001, 
Zakzanis et al. 2000, Honea et al. 2005, Haijma et al. 2013). Medial temporal lobe 
structures, particularly the hippocampus (Velakoulis et al. 2006), amygdala (Lawrie 
& Abukmeil 1998, Nelson et al. 1998) and superior temporal gyrus (Honea et al. 
2005, Sun et al. 2009b), were found to be greatly reduced among patients. In a recent 
meta-analysis conducted by Honea et al. 2005, 50% of the studies included reported 
grey matter deficits in schizophrenia in the left superior temporal, parahippocampal 
and inferior frontal gyrus. Findings in the parietal and occipital lobes have been less 
consistently replicated in schizophrenia research. Moderate evidence for 
abnormalities in the parietal lobe (in 60% of studies reviewed) has been reported in a 
review conducted by Shenton et al. 2001. A certain number of VBM studies and 
meta-analyses have reported volumetric reductions in parts of the parietal or occipital 
lobes (Honea et al. 2005, Ellison-Wright et al. 2008, Hulshoff Pol et. al 2001). 
Divergent evidence has been reported for findings concerning the cerebellum and the 
anterior cingulate. Two recent meta-analyses have reported decreased volume in the 
anterior cingulate in schizophrenia patients (Baiano et al. 2007, Fornito et al. 2009), 
whereas other studies reported increased volume in that region (Kopelman et al. 
2005, McCormick et al. 2005). Similarly, some studies have reported volumetric 
deficits in the cerebellum in schizophrenia patients as compared to healthy 
individuals (Honea et al. 2005, Ellison-Wright et al. 2008), while others have 
reported grey matter increase in the area (Wilke et al. 2001, Suzuki et al. 2002). 
Diversity in findings in schizophrenia studies might be partly attributed to 
methodological differences in the implementation of the pre-processing approaches 
selected and the choice of parameters in the VBM pipeline. Specifically it has been 
suggested that the smoothing kernel and the choice of statistical analysis (either 
voxel-level or cluster-level significance) can significantly impact results (Honea et 
al. 2005). 
Differences in patient groups can be another possible explanation for the 
controversies in the structural abnormalities reported. Patient groups may vary with 
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respect to age, anti-psychotic treatment and/or treatment duration, symptom severity, 
presence of comorbidity and substance use.  
Traditional meta-analyses, that pool together statistical findings from individual 
research studies are invaluable in summarizing the effect size of research findings 
and also identifying and explaining the heterogeneity in findings across different 
studies that may be due to the plethora and diversity of the participating cohorts. A 
recent meta-analysis conducted by Bora et al. 2011 reported that GM abnormalities 
in the bilateral insula, superior temporal and anterior cingulate gyrus and the 
thalamus were more widespread in studies consisting of more males than females or 
where more chronic cases of schizophrenia, with more severe negative symptoms 
were included.  
Prospective meta-analysis efforts, such as those performed by the Enhancing 
NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium (Thompson 
et al. 2014) have the added benefit of standardizing the analyses across individual 
sites and thus promoting their consistency rather than the ad hoc aggregation of 
statistical results. The ENIGMA is one of the largest consortia to date that aims to 
integrate and meta-analyze data sets across the world in order to delineate the 
neurobiological, clinical and genetic underpinnings of various psychiatric disorders. 
In schizophrenia, the ENIGMA-Schizophrenia Working Group provides a 
framework that ranks brain measures based on their effect sizes for the comparisons 
between patients and healthy controls.  In a recent meta-analysis of data from 2,028 
patients and 2,540 controls, the ENIGMA-Schizophrenia Working Group found that 
deficits in hippocampal volume had the largest effect size in differentiating between 
patient and controls (van Erp et al. 2015), followed by deficits in the amygdala, 
thalamus and accumbens. Significant positive associations were also found between 
duration of illness and also age, with putamen and pallidum volume increases in 
schizophrenia patients. 
 
Other studies tried to link the structural brain alterations to distinct clinical 
syndromes in schizophrenia, in an effort to delineate the neurobiological 
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underpinnings of clinical heterogeneity in schizophrenia. It was suggested that 
schizophrenia syndromes can be broadly subdivided into three different nosological 
profiles, each of which highlight the prevalence of either positive, negative or 
disorganized symptoms (Buchanan & Carpenter 1994, Andreasen et al. 1995, Grube 
et al. 1998). A significant number of studies have employed either ROI (Flaum et al. 
1998, Gur et al. 2000, Crespo-Facorro et al. 2004) or VBM (Sigmundsson et al. 
2001, Koutsouleris et al. 2008, Nenadic et al. 2010) approaches in order to evaluate 
whether these three symptom domains engage different patterns of structural 
abnormalities, thus linking symptoms to different neural surrogates. Specifically, 
Koutsouleris et al. 2008 reported that the three clinically defined schizophrenia 
subgroups possibly share common structural abnormalities compared to healthy 
controls in prefrontal and perisylvian structures but specific and extended GM 
density reductions affecting the medial prefrontal, limbic and temporal cortices 
bilaterally were observed in the disorganized symptom dimension. Positive 
symptoms were associated with pronounced alterations in perisylvian regions of the 
left hemisphere and extended GM density reductions in the thalamus while negative 
symptoms were mostly linked to extended alterations within orbitofrontal, medial 
prefrontal, lateral prefrontal and temporal cortices as well as limbic and subcortical 
structures (Koutsouleris et al.  2008). A more recent study employing an advanced 
morphometric analysis method that provides superior sensitivity and specificity 
compared to VBM approaches by accounting for the interrelatedness of spatial 
information, confirmed the prefronto-perisylvian grey matter reduction pattern found 
in the schizophrenia group as a whole, but also revealed marked brain volume 
changes within the three subgroups, including pronounced reductions in the 
cerebellum in the negative symptom dimension, marked GM volume losses in the 
ventro-medial prefrontal and occipitotemporal cortex associated with positive 
symptoms (Zhang et al. 2015). The disorganized symptom dimension presented a 




Similar structural abnormalities to those described above in schizophrenia patients 
have also been identified in groups of patients in the first episode (FE) of the disorder 
(Kubicki et al. 2002, Steen et al. 2006). First-episode refers to individuals who have 
experienced their first psychotic episode, and are thus in the early phase of 
schizophrenia, and is operationally defined as the first psychiatric hospitalization 
(Lawrie et al. 2001b, DeLisi et al. 1991, Chua et al. 2003) or first contact with 
psychiatric services or even the first administration of anti-psychotic treatment (Cahn 
et al. 2002, Zipursky et al. 1998). In general most MRI studies corroborated a similar 
network of regions being affected in FE as in the chronic schizophrenia (Shenton et 
al. 2001). Specifically, MRI-based studies reported deficits in total brain volume 
(Vita et al. 2006, Steen et al. 2006), GM volume reductions in temporal and 
prefrontal areas including the anterior cingulate gyrus (Kubicki et al. 2002) and the 
thalamus (Meisenzahl et al. 2008a, Watson et al. 2012), volumetric deficits in the 
hippocampus (Velakoulis et al. 2006, Vita et al. 2006, Meisenzahl et al. 2008a, 
Watson et al. 2012, Steen et al. 2006) and an enlargement of the lateral ventricles in 
FE patients compared to healthy controls (Steen et al. 2006, Vita et al. 2006). 
These structural abnormalities are however less pronounced in FE compared to the 
established state, possibly suggesting active disease processes around the time of 
onset, although genetic factors, substance misuse, antipsychotic drug treatment and 
other factors may be partly responsible (Meisenzahl et al. 2008a, Olabi et al. 2011). 
Additionally, the fact that more extended brain alterations are observed in chronic 
schizophrenia compared to FE suggests that additional cortical and sub-cortical brain 
regions become involved in the disease process in the advanced stages of 
schizophrenia (Meisenzahl et al. 2008a).  
However, there is no consensus in findings in FE schizophrenia studies with regards 
to the brain regions involved. Kubicki et al. 2002 did not report any reductions in 
medial temporal lobe structures and interestingly enough, a meta-analysis by Vita et 
al. (2006) did not confirm volumetric reductions in the temporal lobe and amygdala 
in FE patients.  
Despite any controversies in structural findings, the study of FE schizophrenia is 
useful because it allows the detection of regional effects of the disease at the time of 
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onset and represents a useful tool in assessing hypotheses about progressive brain 
changes in the longitudinal course of schizophrenia. 
Converging evidence reveals that ongoing brain volume changes in schizophrenia 
might not be limited to the early, first-episode phase of the disorder but progress over 
the course of the illness. Longitudinal studies of schizophrenia have suggested 
continuous progressive lateral ventricle increases (Van Haren et al. 2008a, DeLisi et 
al. 2004, Hulshoff & Kahn 2008, Olabi et al. 2011), progressive whole-brain volume 
loss (Van Haren et al. 2008a) and brain tissue volume decreases, especially in frontal 
(DeLisi et al. 2004) and temporal GM volume (Hulshoff & Kahn 2008) in chronic 
patients with schizophrenia compared to healthy individuals. Ongoing volume 
reductions in the right caudate and thalamus have also been reported (Van Haren et 
al. 2007). No progressive volumetric changes in chronically ill schizophrenia patients 
in the hippocampus were found (Wood et al. 2001). More widespread and 
pronounced alterations in brain tissue were found to be associated with poor 
outcome, severe negative symptoms and more pronounced neuropsychological 
impairment (Hulshoff & Kahn 2008). Specifically, progressive ventricular 
enlargement was found to be associated with poorer outcome (Lieberman et al. 2001, 
Ho et al. 2003), greater frontal and temporal volume reductions were correlated with 
less improvement in negative symptoms (Gur et al. 1998, Mathalon et al 2001, Kasai 
et al. 2003) and poorer neurocognitive and executive functioning was associated with 
more pronounced frontal and parietal GM volume reductions (Lieberman et al. 2005, 
Hoet al. 2003) as patients progressed from their first episode to the chronic state.   
The ascertainment of progressive brain changes is of fundamental importance as to 
whether schizophrenia is a neurodevelopmental or neurodegenerative disorder. The 
fact that ongoing brain alterations continue over the course of the illness in chronic 
patients suggests that one or more active pathophysiological processes take place 
during the illness. Identification of those pathophysiological processes is of high 
clinical relevance as it could advise strategies to stop or reverse the disease process 
and possibly provide better outcome. In this direction, longitudinal studies of healthy 
controls are highly relevant in order to distinguish normal brain changes, possibly 
associated to age, gender or other factor, from aberrant alterations associated with 
 35 
schizophrenia. 
A potential confounding factor in most schizophrenia studies is the effect of anti-
psychotic medication since it is very difficult to establish whether (progressive) brain 
volume changes are a result of anti-psychotic treatment (or not) and to what extent 
(Van Haren et al. 2008b). Volume increases in the basal ganglia, and specifically the 
caudate nucleus, have been consistently linked to antipsychotic treatment (Chakos et 
al. 1994, DeLisi et al. 2006, Keshavan et al. 1994). Cumulative dose of anti-
psychotic drug treatment was linked to progressive cerebral GM volume deficits, 
particularly in the superior medial frontal gyrus (Cahn et al. 2002) and also 
progressive decreases in frontal lobe volumes (Madsen et al. 1999). Another study 
compared the effect of typical (haloperidol) and atypical (olanzapine) anti-psychotic 
medication and reported progressive whole-brain GM volume loss in both first-
episode and chronically ill patients receiving haloperidol compared to olanzapine, 
where no such effect was found (Lieberman et al. 2005). Administration of typical 
and atypical anti-psychotic medication seems to affect the basal ganglia volume 
differently as well, as volume decreases were reported when changing to atypical 
antipsychotic treatment (Chakos et al. 1995, Scheepers et al. 2001). 
 
 
2.3.2 Neuroanatomical abnormalities in high-risk individuals 
 
In order to minimize the confounding effect of anti-psychotic medication and shed 
light to the nature and extent of pathophysiological processes underlying 
schizophrenia researchers have begun to study anti-psychotic naive individuals at 
imminent risk of developing the disorder either due to sub-threshold clinical 
symptoms (clinical HR paradigms- Fusar-Poli et al. 2013) and/or increased genetic 
liability (genetic HR) (Cannon et al. 2005).  A detailed presentation of the two HR 
paradigms can be found in Chapter 1.  
Converging evidence suggests that baseline structural abnormalities, qualitatively 
similar to the established state, are already evident before the onset of schizophrenia 
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albeit to a lesser extent. The identification of neuroanatomical abnormalities already 
present in HR cohorts would allow the evaluation of correlates of vulnerability to 
psychosis, possibly reflective of its neurodevelopmental origin, and serve as a basis 
for the further distinction of markers of transition to psychosis (Bois et al. 2015, 
Borgwardt et al. 2011). Clinical high-risk studies employing VBM methodology 
have reported structural abnormalities in frontal, lateral temporal, medial temporal 
and limbic regions already present in HR subjects compared to healthy individuals 
(Borgwardt et al. 2007a, Borgwardt et al. 2007b, Borgwardt et al. 2008, Meisenzahl 
et al. 2008b, Mechelli et al. 2011, Dazzan et al. 2012). In Job et al. 2003, the authors 
found GM density reductions in the anterior cingulate (bilaterally) and left 
parahippocampal gyrus in individuals at HR for familial reasons against healthy 
controls. 
 A recent voxel-based meta-analysis concluded that individuals at HR, for both 
clinical and familial reasons, showed reduced GM volume in the right superior 
temporal gyrus, left precuneus, left medial frontal gyrus, right middle frontal gyrus, 
bilateral parahippocampal, hippocampal regions and bilateral anterior cingulate 
(Fusar-Poli  et al. 2011) compared to healthy control subjects. Another meta-analysis 
of whole-brain VBM studies employing familial HR cohorts found GM reductions in 
the right superior frontal gyrus, left insula, thalamus and putamen but surprisingly 
increased GM volumes in the left medial frontal gyrus (Cooper et al. 2014).  
 
A plethora of studies have also examined the high risk individuals, who go on to 
develop psychosis (HR-T) against individuals that do not make a transition (HR-NT) 
with the aim of identifying the neuroanatomical markers associated with transition to 
schizophrenia, and other related psychoses. Neuroanatomical deficits in HR subjects 
who later developed psychosis were found in clusters of brain regions spanning the 
frontal, orbito-frontal, temporal and medial temporal lobe structures, the cerebellum 
and the cingulate gyri (Borgwardt et al. 2007a, Borgwardt et al. 2007b, Borgwardt et 
al. 2008, Pantelis et al. 2003, Koutsouleris et al. 2009a, Mechelli et al. 2011, Dazzan 
et al. 2012). The meta-analysis conducted by Fusar-Poli and colleagues (2011) 
concluded that HR-T individuals showed GM volume reductions in the right inferior 
 37 
frontal and the right superior temporal gyrus at baseline, compared to HR-NT 
subjects. Another meta-analysis reported subtle GM volume decreases in the 
cingulate, insular and prefrontal cortex and the cerebellum (Smieskova et al. 2010) 
occurring in HR-T subjects.  
Longitudinal studies have also focused on the progressive changes underlying the 
onset of psychosis. In a study conducted by Pantelis et al. (2003), the authors 
reported continuous GM volume reductions in the left parahippocampal, fusiform, 
orbitofrontal and cerebellar cortices and the cingulate gyrus in HR-T individuals 
compared to HR-NT. Another study found longitudinal volume reductions in the 
superior frontal, orbitofrontal, inferior temporal medial and superior parietal cortex 
and in the cerebellum (Borgwardt et al. 2008). In the only genetic HR study, the 
authors reported progressive GM density reductions in the left inferior temporal 
gyrus, uncus and the right cerebellum (Job et al. 2005).  
 
 
2.4 Functional MRI findings in schizophrenia 
 
Functional MRI studies in schizophrenia have focused on identifying a network of 
brain regions that are responsible for abnormal functioning in the disorder. The goal 
behind these studies is to demonstrate how failure to activate a network of brain 
regions (and/or an over-activation of another network) leads to behavioural and 
cognitive deficits related to the illness. Functional MRI tasks in schizophrenia 
include motor, working memory, verbal learning and memory, emotion processing, 
and decision-making tasks. Several studies have examined the fronto-temporal 
connectivity, a circuitry that is considered to play an essential role in executive 
functioning, learning and memory and reported abnormal activation in a network of 
brain regions, particularly implicating the prefrontal cortex (Meyer-Lindenberg 2010, 




The majority of fMRI studies have demonstrated a reduced connectivity in patients 
in all subgroups of schizophrenia (chronic schizophrenia and first-episode patients, 
high-risk individuals) relative to healthy control subjects (Petterson et al. 2011) and 
an involvement of frontal brain regions with thalamic and cerebellar regions 
(Whalley et al. 2005) or temporal regions (Lawrie et al. 2002). A reduced activation 
in the prefrontal cortex and in the anterior cingulate was observed in schizophrenia 
patients compared to healthy controls in a meta-analysis of 41 executive fMRI tasks 
(Minzenberg et al. 2009) and in a working memory task (Glahn et al. 2005).  
A recent meta-analysis by Fusar-Poli and colleagues (2007) found that 
neurophysiological abnormalities in the prefrontal cortex, particularly involving the 
dorsolateral, ventrolateral and anterior prefrontal cortex, are present in HR subjects. 
Similar functional dysfunctions are also found in first-episode patients to a greater 
extent (Fusar-Poli et al. 2007). Another meta-analysis focusing on genetic HR 
cohorts, reported increased activation in the right posterior superior temporal gyrus 
and hypo-activation of the left thalamus and cerebellum in HR subjects compared to 
controls (Cooper et al. 2014). 
In a cross-sectional study of familial HR individuals, increased activation in the left 
parietal lobe and decreased activation in the anterior cingulate cortex was observed 
in HR subjects that subsequently developed schizophrenia relative to healthy controls 
(Whalley et al. 2006). Compared to HR-NT, HR-T individuals demonstrated smaller 
increases in activation with increasing task difficulty in the right lingual gyrus and 










The advent of MRI has provided promising leads towards the identification of the 
neurobiological processes underlying schizophrenia. In general, it appears that 
neuroanatomical and neurophysiological abnormalities occur at different stages of 
the disorder and progress as patients transit to a more chronic state of the illness. 
Active neurobiological alterations might also take place before the onset of 
schizophrenia; some of which may be specifically linked to a later onset of 
psychosis, as opposed to an increased vulnerability. The identification of markers of 
transition to psychosis is of high clinical relevance because early intervention 
strategies could provide a significant effect on clinical outcome. 
However, the identification of neuroanatomical and neurophysiological markers in 
schizophrenia warrants some degree of concensus in imaging finding. As it has been 
presented and discussed in the previous sections of this chapter, this has not always 
been the case. Contrasting findings in the imaging literature on schizophrenia may 
reflect either differences in the clinical populations or methodological issues. Clinical 
populations often differ in the number of subjects included in the analysis which 
significantly influences results and statistical power of the analyses (Salmond et al. 
2002). Additionally, clinical cohorts may differ with respect to age, duration of 
illness and symptom severity scales, the use and type of antipsychotic medication 
(typical or atypical), substance abuse and the existence of comorbid illnesses (such as 
depression). These factors have been shown to have modulatory effects on 
neuroimaging findings (Bora et al. 2011, Fusar-Poli et al. 2011, Haijma et al. 2013, 
Van Erp et al. 2015) and may partly account for the existing variability. 
From a technical point of view, variation in the preprocessing and the image analysis 
methodology applied (Fusar-Poli et al. 2010), such as the size of the smoothing 
kernel, the method used for correcting for multiple comparisons or the significance 
and thresholding scheme, are likely to have influenced imaging findings (Fusar-Poli 
et al. 2011). Differences in image acquisition parameters and the quality of the 
acquired images (with respect to the signal to noise ratio) could significantly impact 
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on segmentation procedures, which is in turn a potential cause of varied brain 
measures and findings (Abdulkadir et al. 2011, Fusar-Poli et al. 2011). Such 
variation in image findings leads to an urgent need for replication studies and also 
meta-analyses that could estimate the effect sizes of those findings across individual 
studies and account for the confounding effect of clinical- and technical-related 
factors. 
Another important anchor in the identification of biomarkers in schizophrenia is their 
potential for clinical translation which requires a shift away from considering 
differences at the group-level and towards making inferences at the individual level. 
Mass-univariate methods of analysing imaging data are, however, limited to making 
inferences at the group level.  Moreover, region-of-interest (ROI) methods require a 
priori assumptions to be made about regionally specific effects and are thus confined 
to predefined brain regions. Voxel-based morphometry and other approaches to 
computational morphometry on the other hand, provide an unbiased, whole-brain 
approach to studying brain abnormalities but require brain averaging and can neither 
determine subtle and diffuse networks of neuroanatomical and neurophysiological 
abnormality across the brain nor capture individual deviations from the norm 
(Davatzikos 2004). To address these limitations, the neuroimaging community has 
turned to machine learning methods in an effort to detect the MRI correlates of 
clinical relevance and utility both because of their ability to examine voxels jointly 
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biomarkers in schizophrenia, using multivariate pattern classification at a single-
subject level. Neuroimage Clin. 2013;3:279-289.  
 
 
3.1 Introduction  
 
In this chapter, I present the application of machine learning in the analysis of 
structural and functional MRI data in diagnosing schizophrenia, particularly for 
making an early prediction in people at high-risk of developing the disorder. Firstly, 
a brief overview of machine learning theory is given along with a description of the 
most common processing steps in the image analysis pipelines. Then, I present and 
discuss the studies that have employed machine learning in schizophrenia research 
and finally, I analyze the main practical challenges and limitations that machine 
learning methods suffer from, in the context of their potential integration into routine 
clinical practice, before concluding with future research directions.  
 
 
3.2 Overview of machine Learning 
 
Machine learning (ML) is a term used to describe a set of methods for detecting 
patterns in data that would enable reliable future predictions. There are two major 
methodological approaches: supervised and unsupervised machine learning 
techniques. In supervised learning, the goal is to find a mapping from the data 
instances xi to a set of desired outputs yi, given a set of labeled input-output pairs 
D={xi, yi}, for i=1..N instances. Here, D is the training set, consisting of feature 
vectors xi and their corresponding labels drawn from label set yi and N is the number 
of the training instances. If yi is a categorical or nominal variable drawn from a finite 
set, for instance yi = {1, 2 ,....C}, then the problem is known as a classification 
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problem. In its simplest form where C = 2 (and thus yi = {-1, 1}) this is a binary 
classification problem, whereas if C > 2, then there is a multi-class classification 
problem. On the other hand, if yi is a real-valued (continuous) variable, the problem 
is known as regression. In unsupervised learning, on the other hand, the goal is to 
identify an inherent structure in the data in order to classify given data instances D= 




3.2.1 Classification pipeline  
 
The following steps in the image analysis pipeline are common to most machine 
learning methods: 
 
Preparation of the training set. The first step in an ML analysis is the creation of the 
training set. This procedure involves two main processes: i) feature extraction and ii) 
feature selection. Feature extraction involves the transformation of the original data 
set into a form that would be meaningful for the classifier to process. In the context 
of neuroimaging, this procedure entails the extraction of feature vectors 
corresponding to intensity values of voxels from each subject's scan. Feature 
selection involves a procedure for selecting those feature vectors that are better at 
discriminating between the classes and thus could facilitate and speed up the 
classification process. Feature selection can be performed either with a 
dimensionality reduction technique (such as Principal Component Analysis) or by 
constraining the research to specific brain areas for which the research team 
possesses prior knowledge about their likely involvement in the condition under 
investigation. Feature extraction is an obligatory step in the classification pipeline, 
but feature selection approaches are optional. 
 
Model training and testing. In the model training step of the pipeline, the chosen 
algorithm has to learn the relationship between the training set and the labels 
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associated with it, while trying to optimize the algorithm's parameters in order to 
maximally discriminate between the groups. In the testing phase, the algorithm tries 
to predict the class label (in the case of classification) or the continuous variable (in 
the case of regression) of previously unseen data instances. It is very important that 
the algorithm generalizes well to new instances. That is, the testing set should not 
include instances of the training set to avoid circularity or data overfitting. Cross-
validation techniques are a popular way to ensure this. In k-fold cross validation, the 
original data set is split into k non-overlapping sets and then the algorithm is trained 
using k-1 subsets and the left-out set is used in the testing phase. The procedure is 
repeated k times, so that every subgroup is used in the testing phase. 
 
Performance evaluation. The final step is the evaluation of classification 
performance of the method. This usually includes measures such as sensitivity, 
specificity and accuracy. Sensitivity refers to the proportion of actual positive cases 
correctly identified (e.g the number of schizophrenia patients identified as in the ill 
group or class) while specificity refers to the proportion of the negatives cases 
correctly classified (e.g healthy controls correctly identified as being healthy). 




3.3 Machine learning in psychiatry 
 
Machine learning methods have already been applied in the analysis and 
interpretation of functional and structural MRI data (Pereira et al. 2009, LaConte et 
al. 2005, Lemm et al. 2011), in 'mind reading' paradigms (Cox & Savoy 2003, 
Haynes & Rees 2006), the classification of cognitive states (Mitchell et al. 2004, 
Mourao-Miranda et al. 2005), and in lie detection approaches (Davatzikos et al. 
2005a). More recently, classification algorithms have been applied to diagnose 
neurological and psychiatric disorders (Kloppel et al. 2011, Orru et al. 2012, Bray et 
al. 2009), such as dementia (Kloppel et al. 2008a, Kloppel et al. 2008b, Davatzikos et 
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al. 2011), depression (Fu et al. 2008, Mourao-Miranda et al. 2011) and schizophrenia 
(Fan et al. 2008a, Davatzikos et al. 2005b, Koutsouleris et al. 2009b, Koutsouleris et 
al. 2012a). Multivariate pattern recognition techniques provide the possibility of 
making inferences about a subject's health status at an individual level and, thus, are 




3.3.1 Machine learning in schizophrenia  
 
In the past few years, an increasing number of studies have employed machine 
learning to investigate the neuroanatomical and neurophysiological correlates of 
schizophrenia. These studies can be divided into three main categories: (i) studies 
that examine the diagnostic power of machine learning in distinguishing between 
healthy controls (HC) and schizophrenia patients (SCHZ), (ii) studies which examine 
the potential of machine learning to make an early diagnosis of schizophrenia 
(prediction) by comparing scans at baseline of people at high risk (either for familial 
or clinical reasons) of making a transition to the disorder and (iii) studies which 
examine the performance of machine learning in predicting progression of the 
disease and response to treatment, usually by examining the baseline scans of first-
episode (FE) patients with a later known clinical outcome or treatment response.  
 
 
3.3.1.1 Diagnostic Studies of Schizophrenia 
The first study to apply a sMRI-based classification method was conducted by 
Davatzikos et al. (2005b), who tested the performance of Support Vector Machine 
(SVM) in classifying 69 schizophrenia patients (46 men, 23 women) and 79 matched 
healthy controls (41 men, 38 women), reaching a 81% classification accuracy via 
leave-one-out cross-validation. The authors also tested individual men and women 
classifiers and observed similar classification results (85% accuracy for the male and 
82% for the female classifier), possibly implying good generalisability of the MRI-
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based diagnostic system. In another study by the same group, Fan et al. 2007 
achieved an impressive 91.8% and 90.8% accuracy in distinguishing between the 
same 23 female SCHZ patients and 38 female HC and 46 male SCHZ patients and 41 
male HC respectively. Here, the development of an adaptive regional feature 
extraction method, that automatically grouped morphological traits of similar 
classification power, along with a SVM-Recursive Feature Elimination method, that 
selected features with the highest discriminatory power, may possibly account for 
what still remains one of the best diagnostic performances observed in chronic 
schizophrenia diagnostic studies published to date. The researchers achieved this 
diagnostic performance by using just 39 features for the female and 44 features for 
the male individual classifiers. This diagnostic result was, however, obtained from a 
feature set that might be specific to this sample group and the result may well not 
generalize to other data samples. In the context of examining family members of 
schizophrenia, only one study has up to date investigated the role of genetic factors 
in the disorder, using MRI-based machine learning (Fan et al. 2008a). Fan et al. 
2008a observed that unaffected family members share similar phenotypic patterns to 
their affected schizophrenia relatives. Although these initial results are encouraging, 
longitudinal studies are, however, essential in determining whether this 
endophenotypic pattern is present before disease onset and how it relates (if so) to 
transition to psychosis in unaffected relatives. 
Evaluating a classifier on a totally independent cohort is of course the ideal way of 
examining the generalizability and robustness of the classifier (Nieuwenhuis et al. 
2012, Schnack et al. 2014). Unfortunately, the consequent need for large data sets 
makes this endeavor very difficult. In an impressive two-stage study, Kawasaki et al. 
2007 observed a 80% classification accuracy using a partial least squares model that 
was trained on 30 male HC and 30 male SCHZ patients and tested on a new, 
independent cohort of 16 male controls and 16 SCHZ patients. In a particularly large 
classification study employing an independent test set, diagnostic accuracy was 
however only about 70% (Nieuwenhuis et al. 2012), when testing a SVM classifier 
developed on 239 participants (128 SCHZ) on a completely independent sample of 
277 subjects (155 SCHZ). The use of a larger validation set may partly account for 
the lower diagnostic accuracy, if one takes into account the possible inclusion of 
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Table 3.1 Studies employing machine learning and structural MRI to distinguish 
patients with schizophrenia from healthy controls. 
 
Author Sample (N, diagnostic 
classification) 






















HC1 vs SCH1= 91.8 
HC2 VS SCH2=90.8 
Kawasaki et al. 
(2007) 
Train set: HC=30 
SCHZ=30 (males) 




DA & MLM 
1.5T 
80 

















al. (2011)  
HC=47, ROS=28 
 

























Abbreviations: ARMS-T, at-risk mental state with transition to sch izophrenia; COS, child-
onset schizophrenia; DA, discriminant analysis; DSM-IV, Diagnostic and Statistical Manual 
of Mental Disorder Fourth Edition; DSM-IIIR,  Diagnostic and Statistical Manual of Mental 
Disorder Third Edition Revised ; FE, first-episode schizophrenia patients; HC, healthy 
controls; ICD-10, the International Statistical Classification of Disease and Related Health 
Problems; LDA, linear discriminant analysis; MLDA, Maximum-uncertainty linear 
discrimination analysis; MLM, multivariate linear model; PCA, principal components 
analysis; RF, random forests; ROS, recent-onset schizophrenia; SCHZ, schizophrenia 
patients; SCID-I, Structural Clinical Interview; SMLR, sparse multinomial logistic 
regression; SVM, Support Vector Machine; SVR, Support Vector Regression; SVM-RFE, 





Several studies have, alternatively, employed fMRI in an attempt to establish the 
diagnosis in groups of people with schizophrenia and controls (Table 3.2). These 
studies have included various cognitive tasks (Costafreda et al. 2011, Yoon et al. 
2012) or resting-state fMRI (Calhoun et al. 2006, Shen et al. 2010, Venkataraman et 
Nieuwenhuis et 
al. (2012) 
Train set: HC=111 
SCHZ=128 














HC vs FE =73.4 








HC vs FE=86.7 
HC vs ARMS-T=80.7 
FE vs ARMS-T= 80 
Schnack et al. 
(2014) 
Train set: HC=66, 
SCHZ=66  
 





1.5 T: train set 
3T: independent test 
set 





t test set:76  
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al. 2012), in which the subject is simply instructed to remain still during scanning, 
not to think of anything in particular and not fall asleep. In recent fMRI studies, 
resting-state paradigms are often preferred to task-related approaches, as they are 
free from task-related confounds and easier for patient populations to perform, 
although they do have limitations (Morcom & Fletcher 2007). The diagnostic 
accuracy of resting-state fMRI-based classification methods ranged from 75% (Jafri 
& Calhoun 2006, Venkataraman et al. 2012) to 92% (Costafreda et al. 2011, Shen et 
al. 2010), suggesting that resting-state fMRI has the potential to be useful in clinical 
practice. Results should, however, be interpreted with caution since the sample sizes 
in most cases (Shen et al. 2010, Anderson et al. 2010) were very small, potentially 
introducing a bias to the classification (Demrici & Calhoun 2009). 
A recent meta-analysis of 38 multivariate pattern recognition studies, including a 
total of 1602 schizophrenia patients and 1637 healthy controls and both structural 
and functional MRI studies, concluded that neuroimaging-based phenotypes can 
differentiate patients from controls with an overall sensitivity and specificity of 80%, 
with age and disease stage having significant effects on sensitivity and antipsychotic 
medication significantly impacting on specificity levels (Kambeitz et al. 2015).  
Sample size is, also, an important consideration in neuroimaging-based studies and 
might also affect classification performance. Although counterintuitive, based on the 
studies presented here (see Tables 3.1, 3.2 and 3.3), classifiers using small sample 
sizes seem to have favored diagnostic performance (Fan et al. 2007, Kawasaki et al. 
2007, Yoon et al. 2007, Sun et al. 2009b, Anderson et al. 2010, Yang et al. 2010) 
whereas in studies that emloyed larger participating cohorts, the classification 
accuracy was lower (Greenstein et al. 2012, Zanetti et al. 2013, Nieuwenhuis et al. 
2012), possibly due to the fact that the latter studies have included more variable 
patient and/or control cohorts, exhibiting a wider range of phenotypic manifestations. 
However, despite this observation, it should be particularly noted that large sample 
sizes are needed for building (and testing) reliable and robust models as well as 
encompassing the range of clinical profiles of schizophrenia patients presented in 
routine clinical practice.  
 Differences in the image analysis and classification pipelines might, also, partly 
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explain such variation in findings. The introduction of refined feature selection 
methods can boost classifiers' performance, as it was observed in Fan et al. 2007, 
compared to a previous study of the same group (Davatzikos et al. 2005b). The 
choice of the machine learning method is another crucial factor in the performance of 
the diagnostic model as well. Notably, SVM's tend to provide better classification 
results (Pereira et al. 2009) (Table 3.1) than other pattern recognition methods, 
although, a direct comparison between the machine learning methods used in the 
presented studies and classification performance cannot be performed due to other 
differences in the imaging and clinical characteristics of the samples used.  
The clinical characteristics of patients may play a significant role in the observed 
fluctuations in accuracy across diagnostic studies (Greenstein et al. 2012, Zanetti et 
al. 2013). Machine learning in FE schizophrenia studies seem to deliver worse 
diagnostic performance (Kasparek et al. 2011, Zanetti et al. 2013, Yoon et al. 2012) 
than studies of established schizophrenia (see Tables 3.1 and 3.2), possibly due to the 
less pronounced brain alterations in the former group (Kambeitz et al. 2015), 
although diagnostic accuracies can be as high as 92% (see Table 3.1). As was 
previously mentioned, the first-episode stage of schizophrenia is characterized by 
less marked brain changes than in chronic schizophrenia, and this could partly 
account for the accuracy fluctuations observed. In addition, comorbid disorders and 
patient recruitment procedures may, also, have an effect on the sensitivity of the 
classifier in detecting disease-specific patterns. For instance, Zanetti et al. (2013) 
recruited a population-based sample of FE patients with comorbid substance use 
disorders, using epidemiological methods in order to ensure representativeness of 
'real-world' individual cases, and observed just 73.4% accuracy in classifying them 
against HCs. In childhood-onset schizophrenia (COS), only one study examined the 
neuroanatomical correlates in 98 COS subjects (all below the age of 13) versus 99 
HCs (Greenstein et al. 2012) and observed moderate diagnostic accuracy (73.7%), 
possibly due to the young age of their patients and the fact that their unconsolidated 
brain structure may hinder the detection of clear, concrete brain patterns that would 
facilitate classification. Factors associated with the use of anti-psychotic drug 
treatment are, also, a serious consideration because medication may have an effect on 
brain structure (Pantelis et al. 2003, Navari & Dazzan 2009) possibly even up to a 
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point that the sensitivity of the classifier to detect morphological abnormalities 
specifically associated with schizophrenia diagnosis is compromised.  
A possible way to control for the confounding effect of anti-psychotic medication 
would be to remove from any analyses those brain regions that are known to be 
affected by anti-psychotic medication, as seen in the study conducted by 
Nieuwenhuis et al. 2012 where the authors masked out the stratium and tested the 
diagnostic accuracy of a SVM-based classifier by excluding (and including) this 
brain region. However, given the contrasting findings on the effects of anti-psychotic 
medication on brain structure (Smieskova et al. 2009), and especially gray matter 
(Shepherd et al. 2012), it would be challenging to decide which brain regions should 
be left out.  
Another analysis-based solution to controlling for any type of counfounding variable 
would be to stratify the participating cohorts into corresponding sub-groups (for 
instances users and non-users of anti-psychotic medication, or typical and atypical 
anti-psychotics users), estimate the effect on the aggregated data and on each stratum 
and then calculate the pooled estimate across strata (Tripepi et al. 2010). This 
stratification technique is a very informative strategy as it describes how the effect of 
the explanatory variable on the outcome of interest varies across subgroups of 
subjects with different characteristics.  
 
 
3.3.1.2 Early Diagnostic Studies of Schizophrenia 
Several recent neuroimaging studies have shown structural and functional 
abnormalities in subjects at high-risk of developing schizophrenia compared to 
healthy controls as well as compared to established patients (Lawrie et al. 2008, 
Smieskova et al. 2010, Mechelli et al. 2011). To date, there are no biological markers 
for the identification of emerging psychosis, which is currently identified by clinical 
symptomatology. The early identification of those high-risk individuals who are most 
likely to develop psychosis is of high potential clinical value, as early intervention 
and treatment planning could alleviate symptoms burden or even prevent disease 
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onset (Marshall & Lockwood 2006, Riecher-Rossler et al. 2006). Job et al. 2005 
were the first to assess the predictive value of grey matter reductions in genetic high-
risk subjects regarding the possible transition to schizophrenia but as previously 
discussed, they used univariate analysis methods, with their known limitations. More 
recently, machine learning has been applied in the context of making an early 
diagnosis of schizophrenia and even to predict disease transition at individual level 
(Table 3.3), by identifying the neuroanatomical correlates of vulnerability to 





Table 3.2 Studies employing machine learning methods and functional MRI in 
diagnosing schizophrenia. 
Author Sample (N, diagnostic 
classification, fMRI 
paradigm) 










ICA & NN 
3T 
76 








SCHZ vs N-SCHZ: 
sensitivity=92 
specificity=98 
HC vs N-HC: 
sensitivity=95 
specificity=88 































ICA & Composite 
kernels with RFE 
3T 
 95 





Verbal fluency task 
SVM 
1.5T 
SCHZ vs HC: 92 
 
 




ICA & SVM 
1.5T 
85.5 









Yoon et al. (2012)  HC=51, FE=51 
 
DSM-IV 




Abbreviations: AOD, auditory oddball discrimination; BD, bipolar disorder; DSM-IV, 
Diagnostic and Statistical Manual of Mental Disorder Fourth Edition; FE, first-episode 
schizophrenia patients; HC, healthy controls; ICA, independent component analysis; LDA, 
linear discriminant analysis; NN, neural networks; N-BD, non-bipolar subjects; N-HC, non-
healthy controls; N-SCHZ, non- schizophrenia subjects; RF, random forests; SCHZ, 
schizophrenia patients; SVM, Support Vector Machine;  
 
 
Koutsouleris et al. (2009b) were the first to apply multivariate pattern recognition to 
evaluate individual vulnerability to psychosis and predict disease onset. In their 
work, a SVM classifier was built upon structural MRI data of individuals in early 
(ARMS-E, n=20) and late at-risk mental state of psychosis (ARMS-L, n=25) and a 
group of matched healthy controls (HC1, n=25). The performance of the classifier 
was validated by distinguishing sMRI data derived from baseline scans of individuals 
with subsequent transition to schizophrenia (ARMS-T, n=15), those who did not 
make the transition (ARMS-NT, n=18) and matched healthy controls (HC2, n=17). 
Three group and pairwise classifiers were constructed, all achieving classification 
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performance above 80% (with the exception for the binary classifier HC1 vs ARMS-
L =78%). In the most critical in terms of clinical utility, the ARMS-T vs ARMS-NT 
pairwise classifier achieved an accuracy of 82%, suggesting the potential of a MRI-
based system in predicting transition to schizophrenia. In a follow-up study, 
Koutsouleris and colleageus (2012a) emphasized the predictive potential of SVMs in 
classifying an independent cohort of 22 HC, 16 ARMS-T and 21 ARMS-NT 
subjects. The authors, here, constructed a robust classification method, based on 
SVM ensemble classifiers that performed feature selection, model learning and 
predictive ensemble learning wrapped in a nested cross-validation framework. The 
critical ARMS-T vs ARMS-NT pairwise classifier showed slightly improved 
classification results compared to their previous work (Koutsouleris et al. 2009b), 
whereas diagnostic performance was lower in the pairwise HC vs ARMS-NT 
classifier (66.9% accuracy as opposed to 86% in Koutsouleris et al. 2009b), possibly 
due to greater heterogeneity in the control sample.  
In an effort to identify neuroanatomical markers of transition to psychosis across 
clinically defined high-risk populations, Koutsouleris et al. (2015b) extended their 
previous single-site investigations (Koutsouleris et al. 2009b, Koutsouleris et al. 
2012a) by pooling two independent cohorts of subjects with ARMS recruited at two 
different early recognition centres. In this study, the authors constructed an ensemble 
SVM classifier by using baseline structural MRI data from a pooled data set of 33 
ARMS-T and 33 ARMS-NT subjects while an independent group of 7 ARMS-NT 
subjects was used to further validate the classification. The classifier’s performance 
was evaluated by cross-validation and classification of the independent test set (see 
Table 3.3) and achieved a balanced accuracy of 80.3% in the pooled data set 
(sensitivity=75.8%, specificity=84.8%) and 80.4% (sensitivity=75.8%, 
specificity=85%) in the entire dataset (N=73), suggesting the existence of a 
neuroanatomical signature across research centres, irrespective of between-site 
differences. Additional Kaplan-Meier survival analyses, also, enabled the prediction 
of time to transition, thus facilitating an individualized risk staging that has added 
benefits for clinical management.  
Despite the fact that these studies have delivered very encouraging results in the 
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context of prediction of disease transition, it should be borne in mind that the at-risk 
mental state sample in those studies involved symptomatic, help-seeking individuals 
(Koutsouleris et al. 2012a) and it is therefore unclear if these classification results 
could generalize to asymptomatic high-risk groups as well. 
 
 
3.3.1.3 Predicting disease progression and treatment response   
Prediction of disease progression is also of interest and potential clinical utility in 
established cases of schizophrenia, with a view to establishing the prognostic context 
and/or therapeutic responsivity of psychosis. Based on neuroanatomical pattern 
classification methods, studies reported poor to modest diagnostic performance 
(Table 3.3) in predicting the outcome of psychosis in FE schizophrenia patients at 
baseline. In this context, Mourao-Miranda et al. (2012a) used a linear SVM to predict 
clinical outcome from baseline sMRI scans of 100 FE psychosis individuals, who at 
6-year follow-up were classified as having a continuous, episodic or intermediate 
course and a group of 91 matched HCs. Although classification accuracy was less 
than 75% in all contrasts, (see Table 3.3), this result serves as a promising starting 
point in predicting subsequent course type at the individual level. In another study, 
Zanetti et al. 2013 failed to predict 1-year outcome of FE schizophrenia patients. 
Despite the fact that the authors presented a robust method for feature generation and 
feature selection, their SVM classifier (based on the method proposed in Fan et al. 
2007), achieved 58.3% accuracy in predicting clinical outcome of 15 FE patients 
with a subsequent remitting course versus 21 first-episodes with a subsequent non-
remitting course. Differences in data samples (and/or data sample selection 
procedures) and in the duration of follow-up might partly explain the accuracy 
discrepancies observed between the two studies. 
A key determinant of prognosis in psychosis is diagnosis, both because 
schizophrenia tends to have a worse outcome than bipolar disorder, and because 
these conditions tend to respond differently to treatments. Early studies have shown 
the possibility of distinguishing group activation patterns on fMRI in schizophrenia 
and bipolar disorder (McIntosh et al. 2008), but little SVM work has thus far been 
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done in this vein, especially at first presentation when it might be most valuable.  
In the context of predicting response to treatment in schizophrenia, only one study 
that I am aware of has thus far employed machine learning to do so. Khodayari-
Rostamabad et al. (2010) used kernel partial least squares regression in order to 
predict response to clozapine in chronic schizophrenia subjects, based on pre-
treatment electroencephalography (EEG) data, providing 85% accuracy in 
identifying responders and non-responders to the medicine.  
 
 
Table 3.3 Studies using machine learning to predict transition, progression and 
treatment response in schizophrenia. 





















HC1 vs ARMS-E vs 
ARMS-L = 81 
 
HC2 vs ARMS-T vs 
ARMS-NT = 82 
Khodayari-
Romastabad et 
al. (2010)  
Train set: SCHZ=23 
R=12, NR=11 
Test set: SCHZ=14 
 








R vs  NR= 85 
Koutsouleris et 





at inclusion: DSM-IV 





HC vs ARMS: r = 0.83  
HC vs ARMS-T vs 
ARMS-NT: r= 0.83 
Koutsouleris et HC=22, ARMS-T=16, Structural MRI HC vs ARMS-T= 92.3 
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al. (2012a)  ARMS-NT=21 
 
at inclusion: APS, BLIPS 
at follow-up: classification 




HC vs ARMS-NT= 66.9 
ARMS-T vs ARMS-NT 
= 84.2 
Mourao-





at inclusion: ICD-10 







EP-PS vs CON-PS= 70 
CON-PS vs HC=67 
EP-PS vs HC= 54 
 




at inclusion: DSM-IV 
(SCID) 





R-FE vs NRsub-FE=58.3 




Train set: ARMS-T=33, 
ARMS-NT=33 











iii) Overall BAC: 
80 
Abbreviations: ARMS, at-risk mental state; ARMS-E, at-risk mental state early; ARMS-L, 
at-risk mental state late; ARMS-T, at-risk mental state with Transition to schizophrenia; 
ARMS-NT, at-risk mental state without transition to schizophrenia; APS, Attenuated 
Psychotic Symptoms; BAC, Balanced accuracy; BLIPS, brief limited intermittent psychotic 
symptoms; CON-PS, continuous psychotic; DSM-IV, Diagnostic and Statistical Manual of 
Mental Disorder Fourth Edition; EP-PS, episodic psychotic; HC, healthy controls; ICD-10, 
the International Statistical Classification of Disease and Related Health Problems; INT-PS, 
intermediate psychotic; NR, non-responders; NRsub-FE, subgroup of non-remittent first-
episodes; partial least squares regression; PANSS, positive and negative syndrome scale; 
PSLR, partial least squares regression; R, responders; R-FE, remittent fist-episodes; SCHZ, 
schizophrenia patients; SCID, Structured Clinical Interview; SVM, Support Vector Machine; 







Studies published so far demonstrate promising leads for the development of 
neuroimaging machine learning-based tools that could assist in establishing the 
diagnosis and prognosis of schizophrenia and therefore be useful in clinical practice. 
Machine learning methods are advantageous compared to standard univariate 
statistical methods, in that they have the potential to make inferences about effects of 
interest at a single-subject level and can detect subtle and widespread 
neuroanatomical and functional differences that span over large networks of brain 
regions, by virtue of their multivariate nature.  
The development of a MRI-based machine learning system could well aid in the 
identification of objective biological markers for schizophrenia, and could thus help 
overcome the subjectivity in traditional clinical assessments. There are, however, 
significant hurdles to be overcome before their integration of machine learning into 
clinical practice is possible. The classifiers' performance is a key element for the 
potential integration of machine learning into clinical decision-making. As a general 
observation, diagnostic classification performance in psychiatry may not supersede 
clinical expertise in the foreseeable future, no matter the techniques employed, since 
training a classifier requires prior knowledge of a subject's clinical status (Orru et al. 
2012). Where imaging and machine learning could still provide added clinical value 
is where early diagnosis, prognosis of long-term outcome and treatment response are 
difficult to predict. For example, the identification of high-risk individuals, likely to 
convert to schizophrenia is of high clinical value as a means to inform early 
treatment strategies that could result in better outcomes for the patients. It is, 
however, evident from the early diagnosis studies thus far (see Tables 3.1-3.3) that 
classification accuracy in the early detection of schizophrenia and predicting clinical 
course is not as high as in diagnostic schemes. This is probably explained by the fact 
that in the diagnosis of established groups of patients from controls, neuroanatomical 
and functional patterns of differentiation are more clearly and strongly established 
than in same group subjects who do or do not go on to show an outcome of interest 
and therefore present a more difficult classification problem.  
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It should be borne in mind that a classifier with high sensitivity and high specificity 
is desirable, and that overall accuracy is important, but the relative value of high and 
low sensitivity and specificity could have different implications in patients' clinical 
management, in different clinical scenarios, depending on the availability of 
treatment and the seriousness and frequency of adverse effects. Moreover, for an 
individualized patient high positive/negative predictive power is the most critical 
consideration (Lawrie et al. 2011). Furthermore, classification performance is 
primarily affected by the sample size. The limited number and nature of patient 
populations in SVM neuroimaging-based studies means that these encouraging early 
results may not generalize well to other patient groups. Recruiting patients for 
research studies can be difficult and patients with co-morbid conditions are often 
excluded, resulting in a limited representation of the various phenotypes across the 
spectrum of schizophrenia. Despite the fact that several machine learning methods 
can deal effectively with small sample size (Pereira et al. 2009), a limited number of 
data samples can cause model overfitting, resulting in poor generalization of the 
method to independent data sets. In such cases, cross-validation frameworks are 
often employed, to partition the original data set. However, cross-validation schemes 
should be performed with caution, as in many cases data samples in the validation (or 
training) set are also present in the testing set, seriously biasing the classifier's 
performance as a result. As a general rule, the greater the complexity of a method, 
the higher is the risk for overfitting the data (Mourao-Miranda et al. 2012a). Ideally, 
data for validation and training should be derived from completely independent 
cohorts, thus eliminating the need for performing cross-validation and the ensuing 
danger of poorly conducting one, and ensuring the robustness and reliability of the 
classification methodology (Kawasaki et al. 2007, van Haren et al.  2012).  
The need for large data sets could be addressed with pooling data from multiple 
research centres (Mechelli et al. 2011). The existence of a well-validated training 
dataset to be shared between neuroimaging centres is likely to be of importance for 
standardizing classification accuracy across laboratories. In addition, future multi-
site studies could provide the possibility for encompassing more heterogeneous 
clinical populations, demonstrating a range of clinical manifestations of a disorder 
(Borgwardt et al. 2012), for example subjects with various transition rates to 
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psychosis or subjects of lower diagnostic certainty, which could thus provide a more 
realistic mirroring of everyday psychiatric practice. Multi-site projects for the 
development of biomarkers for the Alzheimer’s disease already exist (Alzheimer’s 
Disease Neuroimage Initiative - Mueller et al.  2005) while only recently, multi-
centre projects have launched for the early diagnosis and management of early 
psychosis; the PSYSCAN (http://psyscan.eu) and PRONIA projects 
(http://www.pronia.eu). Data sharing among research centres faces, however, its own 
difficulties. Different scanners, imaging parameters and protocols result in varying 
image intensity and susceptibility profiles that will require careful consideration and 
compatibility solutions. One promising approach is however to generate metrics from 
individual scans that can then be compared to reference data sets (Tijms et al. 2012). 
Equally important, future studies should test the efficacy of machine learning in 
making a diagnosis of psychiatric disorders apart from schizophrenia, such as bipolar 
disorder, borderline personality disorder, depression, autism etc. Initial studies have 
already used machine learning to differentiate schizophrenia from bipolar disorder 
(and HC subjects) both by employing structural (Schnack et al. 2014) or functional 
MRI data (Costafreda et al. 2011, Cahloun et al. 2008) and delivering very 
encouraging diagnostic results. In the same context, another recent study has 
employed a neuroanatomical-based pattern classification technique to make a 
differential diagnosis of schizophrenia and mood disorders, namely major depression 
and bipolar disorder (Koutsouleris et al. 2015a). In order to explore the hypothesis 
that major depression, bipolar disorder and schizophrenia might represent different 
stages along the same neurobiological continuum (Lin et al. 2013), the authors first 
examined whether schizophrenia patients (n=158) could be distinguished from major 
depression patients (n=104) at the single-subject level and then quantified differential 
diagnostic decision values in order to characterize independent cohorts of clinically-
defined HR and FE individuals (n=112 in total) and patients with bipolar disorder 
(n=35). A cross-validation scheme delivered an 76% balanced accuracy in the 
schizophrenia versus major depression classification task, whereas the trained model 
assigned 74% of bipolar patients to the major depression group, possibly suggesting 
that major depression and bipolar disorder share similar neuroanatomical signatures 
that are differentiated from schizophrenia (Koutsouleris et al. 2015a). However, 
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replication of these early findings in studies that include larger samples and more 
cases across a putative psychosis spectrum is necessary in order to identify patterns 
that differentiate between these psychiatric disorders. 
From a methodological point of view, novel methods for feature selection and 
decision making of the classifiers could be introduced in order to improve diagnostic 
power in schizophrenia studies. For example, ensemble-learning methods could be 
introduced in order to improve the generalization ability of a classifier. Ensemble 
classifiers can achieve better predictive performance than single classifiers, by 
combining multiple weak learning models that decide upon the classification of a 
new instance through majority voting (Polikar 2006). Some well-known ensemble 
learning methods, such as bagging and random subspace methods have already been 
used in neuroimaging settings to identify biological markers for prodromal 
Alzheimer’s disease (Fan et al. 2008b, Liu et al. 2012), reporting excellent diagnostic 
results. Ensemble learning could be a useful approach in data fusion studies as well, 
where a single classifier could be built and trained for each imaging modality and/or 
clinical measures (such as neurocognitive measures) separately and outputs from 
each classifier could be combined to classify new instances. An example of this 
approach is the study of Yang et al. (2010), who developed SVM-based ensemble 
classifiers of genetic and fMRI data and combined them to a single module that 
decided upon classification of testing samples via majority voting, achieving better 
diagnostic accuracy than either SVM ensembles alone (87% for the combined 
module, 74% for the genetic data classifier and 83% for the fMRI classifier). Future 
studies could, also, possibly address the problem of 'tuning' a machine learning 
method to fit into neuroimaging settings. Refinements in the SVM method, for 
example, already exist. The SVM-Recursive Feature Elimination (SVM-RFE), a very 
popular method that performs feature selection during training and recursively 
removes data instances, and has already been successfully employed in cancer 
classification (Guyon et al. 2002), and SVM-Sequential Minimal Optimization 
(SVM-SMO) which facilitates and speeds up the classifier's training, are methods yet 






The application of machine learning methods for the purposes of diagnosing or 
making a prediction of psychosis onset has already demonstrated very encouraging 
results. The main advantage of machine learning methods, over standard univariate 
ways of analysing and interpreting neuroimaging data, is that they allow inferences 
to be made at subject-level; a key-feature in clinical practice. There are however, 
important difficulties yet to be fully considered and overcome, before their 
translation into routine clinical practice. The optimal means of multi-centre analyses, 
fusing imaging modalities and integrating various sources of information are critical 
considerations. Finally, once suitable techniques have been developed, they will 
ideally need to be tested, preferably in randomized control trials to ensure that they 































































In the previous chapters, the concepts of neuroimaging and machine learning were 
presented along with a critical review of the application of machine learning in 
schizophrenia. As has been described in Chapter 1, the overriding aim of the present 
thesis is to apply machine learning in order to identify predictors of transition to 
schizophrenia in subjects at high risk for developing the illness. Initially, data from 
the Edinburgh High Risk Study (EHRS), which were immediately available, were 
used in order to examine the capability of SVM in identifying neuroanatomical 
markers that predict schizophrenia onset, and then data from the FePsy 
(Fruherkennung von Psychosen) study, which comprised clinical high-risk subjets, 
were put to the test with the intention of replicating earlier findings and examining 
the generalizability of the method in distinguishing clinical high-risk cohorts.  
In this chapter, the subject material of the EHRS and the FePsy studies is presented 
and the pre-processing and classification methodology is extensively described. To 
help the reader in the understanding and comparing the EHRS and FePsy study, 
Tables 4.1 and 4.2 provide a summary of the main cohort information and the main 





4.2.1 Edinburgh High Risk Study 
 
The Edinburgh High Risk Study (EHRS) was a prospective, longitudinal study in 
which young people from multiply affected families with schizophrenia and matched 
groups of controls without family history were recruited. Comprehensive details of 
the recruitment process can be found in previous papers (Hodges et al. 1999, 
Johnstone et al. 2000). The original idea for this study was conceived by Professor 
Johnstone. The purpose of the EHRS was to determine the features that distinguish 
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high risk individuals who go on to develop schizophrenia from those who do not, and 
to compare relevant variables in affected and unaffected members of the high-risk 
sample with matched controls. 
The study took place between 1994 and 2004. High-risk subjects were selected on 
the basis of having two or more first or second-degree relatives with a confirmed 
diagnosis of schizophrenia using the OPCRIT (Operational Criteria Checklist) 
computer program (McGuffin et al. 1991). Potential high-risk participants were 
identified by examining case-notes of patients with schizophrenia. Upon completion 
of recruitment, a total of 229 high-risk individuals were identified throughout 
Scotland, from which 156 participants provided complete data at baseline. Ten to 
fifteen percent of the high-risk group was predicted to develop schizophrenia by the 
age of 30 on the basis of the known frequency of the disease in individuals with this 
degree of heredity, and the actual occurrence of schizophrenia by this age (Johnstone 
et al. 2002a). Based on this, comparable groups of control subjects were determined 
and recruited: 36 healthy control subjects and 37 individuals in their first episode of 
the illness, both with no known family history of schizophrenia. All study 
participants were given written information about the study and time to consider 
before formally consenting taking part in the study. They were, also, aware that they 
could withdraw at any time. The study was approved by the Lothian Research Ethics 
Committee for Psychiatry and Pathology. 
The high risk participants recruited had an age range between 16-24 years at baseline 
in order to ensure that the period of maximum risk of onset of schizophrenia would 
be covered. High-risk participants were followed up for up to 10 years during which 
they underwent a series of clinical, neuropsychological and neuroimaging 






Table 4.1 Outline of the EHRS and the FePsy study. 
 EHRS FePsy 
Cohort Familial High Risk Clinical High Risk 
Inclusion criteria 2 or more 1rst  or 2nd degree 
relatives with schizophrenia 
1. Basel Screening 
Instrument for psychosis 
(BSIP) 
2. PACE criteria: 
   - attenuated psychotic    
symptoms (APS) 
 
   - brief limited intermittent 
psychotic symptoms (BLIPS) 
 
   - genetic risk plus 2 risk 
factors 
 




assessments every 18-24 months 
Up to 4-years; 
Monthly during 1rst year, 
months interval (2nd and 3rd 
year),  
annually thereafter 
Psychopathology Present State Examination (PSE); 
five-score psychopathological 
scale 
Brief Psychiatric rating Scale 
(BPRS); 
Scale for the Assessment of 
Negative Symptoms (SANS) 
Transition Criteria PSE, score 4. 
Further validated using the ICD-
10. 
As defined in PACE criteria; 
further validated by ICD-10. 
Converters and non-
converters numbers 
- 17 converters (with complete 
clinical assessments and at least 1 
MRI scan) 
Non-converters: 
   -57 HR[symp]  
   -57 HR[well]  
- 16 converters 
- 19 non-converters 





All anti-psychotic naïve. 30 subjects, some time prior 
to study inclusion. 
HR[symp]: High risk individuals that did not develop schizophrenia but yet exhibit psychotic 
or partially-held psychotic symptoms; HR[well]: High risk subjects that did not develop 




Psychopathology was assessed at entry and follow-up by the Present State 
Examination (PSE, Wing et al. 1974), which involved a structured interview with a 
psychiatrist in order to identify any psychotic symptoms. The PSE is a very detailed 
instrument giving a standardised assessment of a wide range of symptomatology and 
therefore would be helpful in evaluating the extent of any psychopathology shown by 
the high-risk participants and controls. Based on the PSE profiles, a five-score 
psychopathological scale system (Johnstone et al. 2000, Johnstone et al. 2002a) was 
administered by three experienced clinicians (Professor Johnstone, Professor Owens 
and Professor Lawrie). A score of 4 was assigned for definite schizophrenia based on 
the PSE, and was further validated by the ICD-10 (World Health Organization, 
1993). A score of 3 was assigned for any fully-rated psychotic symptom; PSE items 
55-92 (including thought reading, echo broadcast auditory, visual or other 
hallucinations, delusions of control, misinterpretation, reference, persecution, 
grandiosity influence or other) or PSE behavioural items 128, 129 and 135-137 
(including blunted affect, incongruous affect, neologisms or idiosyncratic use of 
words, incoherence of speech, flight of ideas). A score of 2 was assigned if any of the 
features in 3 were partially held or present to a mild degree plus symptoms 49-54 
(perceptual disorders other than hallucinations), and behavioural items 108, 109, 118, 
125, 126 (self-neglect, bizarre appearance, behaves as if hallucinated, suspicious, 
perplexed) fully rated and items 133 (muteness) partially or fully rated. A score of 1 
was assigned in cases where none of the above features existed but any other fully 
rated PSE item (such as tension, depression, anxiety, instability, obsessions etc.).  






3= fully rated psychotic symptoms 
2=partially rated psychotic symptoms 
1= fully or partially rated non-psychotic symptoms 
0= no symptoms 
Subjects were further categorized according to the presence or absence of psychotic 
symptoms as individuals with fully or partially held psychotic symptoms (HR[symp], 
scores 2 and 3 combined), individuals without psychotic symptoms (HR[well], 
scores 0 and 1 combined) and individuals with schizophrenia (HR[ill], score 4).  
All subjects were antipsychotic-naive at study-entry and at follow-up or until they 
were clinically diagnosed with schizophrenia. From those HR subjects who provided 
complete clinical assessments and had a MRI scan, 17 were diagnosed at follow-up 
with schizophrenia (after an average of 929 days, SD=138) based on the ICD-10. 
Once diagnosis of schizophrenia has been established, these subjects did not undergo 
any further assessments. However, clinical management of those patients ensured 
that their diagnoses remained unchanged until the end of the study and no other 
psychotic diagnoses were recorded.  
Among the rest, 57 subjects experienced psychotic or possibly psychotic symptoms 
but were never ill enough to be given formal diagnosis of schizophrenia, up until the 
end of the 10-year follow-up period. However, these symptoms were too transient or 
mild to satisfy operational definition for schizophrenia or any related psychotic 
illness. The rest of the HR subjects remained well, with no symptoms. A summary of 








4.2.1.2 Main findings in the EHRS 
In terms of demographic details, there were no significant differences between high-
risk individuals and healthy controls with respect to age, sex, parental social class, 
alcohol and cannabis use at baseline (Johnstone et al. 2000). However, the high-risk 
group showed poorer educational and employment attainment than the control group 
(Johnstone et al. 2000).  
Early studies in the ERHS have reported differences in clinical, psychopathological, 
neuropsychological and neurological indices between the high-risk group and the 
control groups (Johnstone et al. 2000, Cosway et al. 2000, Johnstone et al. 2002a, 
Owens et al. 2006 Lawrie et al. 2001a, Miller et al. 2002a, Miller et al. 2002b, Byrne 
et al. 2003, Byrne et al. 1999). Additionally the performance of high-risk participants 
on some neuropsychological tests remained poor over time but did not deteriorate 
relative to controls, which may provide evidence of a stable trait deficit and a 
possible cognitive marker for schizophrenia. In terms of psychopathology, high risk 
individuals showed more symptomatology than controls, mostly including partial and 
definite psychotic and non-psychotic symptoms (Johnstone et al. 2002a, Johnstone et 
al. 2002b). These findings might indicate that what is inherited by high risk 
individuals due to genetic liability is not the disorder itself, but a state of 
vulnerability manifested by fairly widespread neuropsychological impairments.  
 
Significant predictors of schizophrenia have, also, been identified from a battery of 
behavioural and neuropsychological tests administered to high-risk individuals at 
baseline (Johnstone et al. 2005). Baseline memory and learning, as tested using the 
Rey Auditory Verbal Learning Test (RAVLT, Rey 1964) was significantly worse in 
high risk than control subjects (Byrne et al. 1999, Byrne et al. 2003) and particularly 
poor in those who developed the disorder (Whyte et al. 2006). Notably, over-time 
performance in the RAVLT was significantly improved across all HR and HC 
individuals and those HR that developed schizophrenia but also remained 
significantly different between the groups, possibly reflecting a familiarity with the 
test procedures at repeated assessments (Whyte et al. 2006). Previous studies have 
shown that the Rust Inventory of Schizotypal Cognitions (RISC, Rust 1998) and the 
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Structured Interview for Schizotypy (SIS, Kendler et al. 1989) were able to 
discriminate between schizophrenia patients and healthy controls. In the EHRS, 
baseline assessments of the SIS (total score, Miller et al. 2002a), RISC (Miller et al. 
2002b) and the RAVLT (Byrne et al. 2003) were able to distinguish at baseline those 
high-risk subjects that will go on to develop schizophrenia from the high-risk 
subjects who do and do not develop psychotic symptoms (Johnstone et al. 2005). 
Specifically, those individuals that developed schizophrenia differed those who did 
not on social anxiety and withdrawal, verbal learning and memory and other 
schizotypal features (Johnstone et al. 2005). In relation to studies that included high-
risk populations on the basis of symptomatic criteria or a combination of familial risk 
and symptomatic criteria, the EHRS cohort comprised non-help seeking individuals 
that presented much lower transition rates to schizophrenia. Most of these high-risk 
subjects were asymptomatic and functioned at a similar level to controls in terms of 
employment or further education. It can, also, be concluded that transient or partially-
held psychotic symptoms in this familial cohort occurred in many more individuals 
that might be anticipated to develop schizophrenia. In contrast, in clinical high-risk 
studies the presence of sub-threshold psychotic symptoms was associated with later 
development of psychosis. 
 
A significant number of studies have also reported a plethora of neuroimaging 
abnormalities within the groups of the EHRS (Lawrie et al. 2001b, Lawrie et al. 
2008, Owens et al. 2006). Significant reductions in the amygdalo-hippocampal 
complex and the volume of the thalamus were reported in high-risk subjects against 
controls (Lawrie et al. 1999). A previous VBM study showed significant grey matter 
reductions in the anterior cingulate and medial prefrontal lobes in high-risk versus 
healthy controls with more marked changes shown in first episode patients (Job et al. 
2002, Job et al. 2003). Job et al. 2005 found reductions in the concentration of grey 
matter in the temporal and prefrontal lobes in the high-risk group compared to the 
healthy controls but these were more pronounced in those subjects with a liability to 
develop psychotic symptoms. However these findings do not establish whether brain 
structure changes as a result of psychotic symptoms, or whether symptoms and 
changes in brain structure occur in unison. Additional grey matter density reductions 
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were presented in the left para-hippocampal uncus, fusiform gyrus and right 
cerebellar cortex in those that made a transition to schizophrenia against those who 
did not but had psychotic symptoms (Job et al. 2005). Progressive reductions over 
two successive MRI time-points (18-months apart) in the three previously specified 
regions showed significant diagnostic properties in predicting transition to 
schizophrenia, reporting positive predictive values as high as 60% and thus possibly 
suggesting their use as part of a positive predictive test for schizophrenia (Job et al. 
2006). These findings could be clinically relevant as part of a predictive test for 
schizophrenia in people at enhanced risk for familial reasons, for positive predictive 
power and in combination with other neurocognitive and behavioural predictive 
measures that were shown to have strong negative predictive power (Johnstone et al. 
2005). It should be noted, however, that while this might be the case, the values of 
sensitivity and specificity are not high enough for diagnosis of schizophrenia. 
Finally, in the context of associating brain structure with schizotypal measures, as 
assessed by the RISC and SIS, and verbal and learning memory RAVLT assessment, 
significant associations between grey matter density in the left superior temporal 
gyrus and the RISC measure was found for those high-risk subjects that made a 
transition to schizophrenia while the RAVLT was significantly correlated with grey 
matter density reductions in the right parahippocampal gyrus in high risk subjects 
that exhibited transient, isolated or partial symptoms (Lymer et al. 2006). 
Overall, the findings from the EHRS literature presented above have many strengths 
including the unprecendently large number of familial high risk individuals, all of 
whom were unmedicated at study-entry and at follow-up or until they met 
operational criteria for schizophrenia. However, as seen in all studies that involved 
high-risk subjects that later developed schizophrenia, the sample size was small and 
therefore findings require replication. Moreover, studies presented in this section 
only include findings from VBM analysis and are thus restricted to limitations 
inherent to this technique. It is widely recognised that VBM is sensitive to systematic 
shape differences, so the choice of the parameters in spatial normalization and the 
template used for that purpose can have an impact on the resulting brain measures 
(Job et al. 2003). The choice of kernel in the smoothing step can also obscure 
differences of lesser spatial extent and affect results. Finally, the use of small volume 
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corrections (SVC) and the size of resels along with the inclusion and exclusion of 
specific confounding variables such as age, sex and total intracranial brain volume in 
the modelling stage of VBM could partly explain the heterogeneity with previous 




4.2.2 The FePsy study 
 
The FePsy (Fruherkennung von Psychosen) study is a prospective, longitudinal study 
that aims to identify and investigate individuals considered to be at high risk of 
psychosis and matched groups of individuals at their first psychotic episode. Subjects 
were recruited through a specialized clinic for the early detection of psychosis at the 
Psychiatric Outpatient Department, University Hospital in Basel, Switzerland. The 
FePsy study started in March 2000 and inclusion of high risk participants was 
completed by February 2004.  
The study was approved by the local ethics committee of the University of Basel and 
written informed consent was obtained for each participant. 
 
 
4.2.2.1 Screening and psychopathology 
For screening purposes, subjects were assessed using the Basel Screening Instrument 
for Psychosis (BSIP, Riecher-Rossler et al. 2008). The BSIP is a 46-item checklist 
based on variables which have been reported as risk factors or predictors of 
psychosis (Riecher et al. 1990, Riecher-Rossler et al. 2006, Riecher-Rossler et al. 
2007), such as DSM-III-R-‘prodromal’ symptoms, social decline, drug abuse, 
previous psychiatric disorders or genetic liability for psychosis. The BSIP checklist 
was used in combination with the Brief Psychiatric Rating Scale (BPRS expanded 
version; Lykoff et al. 1986, Ventura et al. 1993) in order to evaluate the severity of 
pre-psychotic signs. All assessments were conducted by experienced psychiatrists 
 73 
who underwent regular training.  
Subjects were identified as high-risk or an at-risk mental state (ARMS) if they met 
(one or more of) the following inclusion criteria that corresponded to the Personal 
Assessment and Crisis Evaluation (PACE) criteria (Yung et al. 1998), which have 
been already employed in other studies using individuals with an at-risk mental state 
(Phillips et al. 2002, Pantelis et al. 2003): 
i) Attenuated psychotic-like symptoms 
ii) Brief limited intermittent psychotic symptoms (BLIPS) 
iii) genetic risk: a first or second-degree relative with a psychotic disorder 
plus at least 2 further risk factors for or indicators of beginning 
psychosis according to the BSIP screening instrument. 
Inclusion because of attenuated psychotic symptoms required that change in mental 
state had to be present at least several times a week and for more than 1 week’s 
duration (a score of 2 or 3 on the BPRS hallucination item or 3 or 4 on BPRS items 
for unusual thought content or suspiciousness). 
Inclusion because of BLIPS required scores of 4 or above on the hallucination item 
or 5 or above on the unusual thought content, suspiciousness, or conceptual 
disorganization items of the BPRS, with each symptom lasting less than 1 week 
before resolving spontaneously. A more detailed description of these ARMS criteria 
can be found in Riecher-Rossler et al. 2007.  
Additionally, negative symptoms were assessed using the Scale for the Assessment 
of Negative Symptoms (SANS; Andreasen 1989), which was used in combination 
with the BSIP. The SANS assessment is a well-recognised rating scale for the 
assessment of negative symptoms in schizophrenia and consists of 19 items, which 
are grouped into five domains or factors (affective flattening, alogia, avolition-
apathy, anhedonia-asociality, and inattention). Further assessments to elicit 
neuropsychological and psychopathological indices were performed. However, their 
description is outside the scope of the present thesis, and additional information can 
 74 
be sought in previous papers of the FePsy study (Gschwandtner et al. 2003, Riecher-
Rossler et al. 2009).  
 Exclusion criteria were age below 18 years, insufficient knowledge of German, IQ 
<70, previous episodes of schizophrenic psychosis (treated with major tranquillizers 
for more than 3 weeks), a clearly diagnosed brain disease or substance dependency 
(except for cannabis dependency), or psychotic symptoms within a clearly diagnosed 
depression or borderline personality disorder.  
In total, 37 ARMS individuals were recruited. Thirty of the 37 ARMS individuals 
never received antipsychotic medication. Seven participants had been administered 
low doses of antipsychotic medication for behavioural control by the referring 
psychiatrist or general practitioner (2 participants on olanzapine, 2 Chlorprothixene 
and 3 risperidone) at some time prior to study inclusion. 
Matched groups of healthy controls and first-episode patients were recruited as well. 
In short, 22 healthy controls (HC) with no personal or family history of any 
psychiatric disorder were recruited from the same geographical area as the ARMS 
group through local advertisements and were matched to the ARMS sample group-
wise for age, gender, handedness, and education level. The first-episode group (FE) 
consisted of 25 individuals who met operational criteria for first episode psychosis as 
described in Yung et al. 1998. More details regarding inclusion and operational 
criteria for the HC and FE group can be found in Riecher-Rossler et al. 2007. 
Transition to psychosis was monitored by means of the transition criteria defined in 
Yung et al. (1998) and based on the BPRS scale; that is BPRS scores of 4 or above 
on the hallucination item or scores of 5 or above on the unusual thought content, 
suspiciousness, or conceptual disorganization items; symptoms had to occur daily 
and persist for more than 1 week to be deemed a conversion to frank psychosis. In 
subjects who met these criteria the diagnosis was determined by an interview using 
ICD-10 research criteria at the time of transition, corroborated by a subsequent 
assessment at least one year post transition using the Operational Criteria for 
schizophrenia/schizoaffective disorder (OPCRIT) checklist for psychotic and 
affective illness (McGuffin et al. 1991). Based on these, the ARMS group was 
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subsequently divided into 16 ARMS subjects that made a transition to psychosis 
(ARMS-T) and 19 ARMS individuals that did not convert (ARMS-NT) (no follow-
up information was available for two ARMS subjects). See Table 4.1 for an outline 
of the FePSY study compared to the EHRS. 
 
Table 4.2 The main structural imaging findings in the EHRS and FePsy literature. 
 EHRS FePsy 
 
 
HR vs. HC  
 
↓   anterior cingulate (R+L) 
      medial frontal lobe (R) 
      middle temporal gyrus (L) 
      postcentral gyrus (L) 
      limbic lobe (L) 
     parahippocampal gyrus(R+L) 
      thalamus (R+L) 
 
↓   insula (L) 
     superior temporal gyrus (R+L)  
      hippocampus (R) 
      amygdala (R) 
      posterior cingulate gyrus 
      precuneus 
 
 
HR-T vs. HR-NT 
 
↓   cerebellum (R) 
     inferior temporal gyrus (L) 








↓  insula (R) 
    inferior frontal gyrus 
    superior temporal gyrus (R) 
    anterior cingulate (R+L) 
 
 
↑  parahippocampal gyrus (R+L) 
     fusiform gyrus (R+L) 
     medial occipital gyrus (R+L)  
     thalamus(R+L) 
     supramarginal gyrus (R) 
R: right; L: left. 
 
 
4.2.2.2 Main Findings in the FePsy study 
In the FePsy study, individuals with an ARMS did not differ significantly from 
healthy controls with respect to age, sex, ethnicity, educational level and total brain 
volume. The ARMS subjects that later developed psychosis showed at baseline more 
pre-psychotic symptoms than ARMS subjects who did not, but less severe symptoms 
than the FE group, namely in all four BPRS subgroups (see Appendix IV, Figure 1) 
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but also for the BPRS global score measuring general psychopathology (Riecher-
Rossler et al. 2007). In the negative symptomatology scale as measured by the 
SANS, the anhedonia/ asociality scale was significantly different in those ARMS that 
developed psychosis versus those who did not (Riecher-Rossler et al. 2007).  It was, 
also, shown that a stronger weighting of clinical and cognitive variables in an 
intergrated model could predict transition to psychosis in the ARMS population 
(Riecher-Rossler et al. 2009). Specifically, suspiciousness (attenutated psychotic 
symptom/ BPRS subscale; see Appendix IV, Table 1), anhedonia/asociality (negative 
symptoms, SANS subscale) and reduced speed in information processing task (Test 
for Attentional Performance; TAP Go/NoGo false alarms; Zimmermann and Fimm 
1993) could achieve an overall predictive accuracy of 80.9%, with a sensitivity of 
83.3% and a specificity of 79.3% (Riecher-Rossler et al. 2009). 
At as structural level, ARMS individuals showed significant volumetric deficits in a 
cluster of regions that included the left insula, superior temporal gyrus, cingulate 
gyrus and precuneus against control groups of healthy individuals and first-episode 
patients (Borgwardt et al. 2007b). Within the ARMS group, those individuals that 
later made transition to psychosis demonstrated grey matter volume deficits in the 
right insula, inferior frontal and superior temporal gyrus compared to the AMRS 
individuals that did not develop psychosis (Borgwardt et al. 2007b), suggesting that 
transition to psychosis is associated with alterations in regional grey matter volume, 
particularly in the inferior frontal and medial temporal cortex as seen in the EHRS 
(Job et al. 2005). In addition, ARMS-T individuals showed relatively greater grey 
matter volume in the parahippocampal gyrus, the parietal and posterior temporal 
cortex, and the thalamus contrary to their initial hypotheses. The finding of larger 
parahippocampal gyri is of particular interest as in the EHRS literature transition to 
psychosis was associated with a progressive reduction in medial temporal volume in 
high risk individuals due to familial reasons (Job et al. 2005). 
Another study compared only the ARMS-T group against healthy controls and found 
grey matter volume reductions in the posterior cingulate gyrus, the precuneus, 
paracentral lobule bilaterally and in the left superior parietal lobule while compared 
to first-episodes, ARMS-T individuals showed greater volume in the temporal gyrus 
bilaterally, possibly suggesting that temporal lobe abnormalities seem to occur later 
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in the course of illness (Borgwardt et al. 2007a). 
Table 4.2 provides a summary of the main MRI findings in the EHRS and FePsy 
study. 
4.3 Preprocessing of the MRI scans 
 
Preprocessing of the MRI scans was based on the VBM methodology, as described 
in Ashburner & Friston (2000) and Good et al. 2001, and was performed using the 
SPM5 toolbox (http://www.fil.ion.ucl.ac.uk/spm/software/spm5), running in Matlab 
version 7 (The MathWorks, Natick, MA) on a linux machine operating GNOME 
version 2.2.8.2. The same preprocessing pipeline was followed for both the EHRS 
and the FePsy dataset. Study-specific templates and study-specific brain tissue a-
priori maps were constructed for each dataset separately, as described below. 
 
 
4.3.1 EHRS study-specific templates and priors 
 
A study-specific template was constructed from all 146 HR and 36 control 
structurally normal MRI scans. Since this group contained scans from subjects of 
mixed outcome (i.e., those without psychotic symptoms (HR[well]), those with 
isolated or partial psychotic symptoms (HR[symp]) and those who were later 
diagnosed with schizophrenia (HR[ill]), it was believed to represent the entire study 
population and therefore minimised bias for spatial normalisation. The scans were 
normalised to the generic SPM T1 template using 12-point linear affine 
transformation to minimise the residual sum of squares differences between the 
images and the template. A study-specific T1 template was created from the mean 
image calculated from all the normalised T1 images and smoothed at 8-mm full-
width at half maximum (FWHM). 
To generate study-specific brain tissue a priori maps, the normalised images were 
segmented into grey matter (GM), white matter (WM) and cerebrospinal fluid (CSF)  
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using an SPM cluster analysis with a modified mixture model and the SPM-derived 
GM, WM and CSF a-priori probability maps. A brain tissue mask was produced 
using the “Xtract brain” function. This removes the extra-cerebral voxels from both 
the GM and WM segmented images using a series of dilation functions and adds 
together the segments forming a binary image of extracted brain tissue. 
Multiplication of this image with the original segmented images removes the extra-
cerebral voxels. Mean images were calculated and extracted GM and WM segments 




4.3.2 FePsy study-specific templates and priors 
 
Study-specific templates and customized prior probability maps were constructed 
based on all 82 subjects (i.e. 35 ARMS, 22 HC and 25 FE). Again, scans were 
normalised to the generic SPM T1 template using 12-point linear affine 
transformation to minimise the residual sum of squares differences between the 
images and the template. A study-specific T1 template was created from the mean 
image calculated from all the normalised T1 images and smoothed at 8-mm full-
width at half maximum (FWHM). 
The normalised images were, then, segmented into GM, WM and CSF using the 
generative segmentation approach in SPM5 that involves image registration, bias 
correction and tissue classification all combined in the same probabilistic model 
(Ashburner & Friston, 2005; for more details see chapter 2). To generate study-
specific brain tissue a priori maps, mean images for the normalized GM, WM and 






4.3.3 Image acquisition 
 
Details of the scanning protocols are given in relevant subsections of Chapters 5 and 
6. 
 
4.3.4 Image processing pipeline 
 
Before any pre-processing, I manually set the origin of the images to the anterior 
commissure using the ‘Display’ function in SPM.  The pre-processing stages for both 
datasets were identical and were as follows. Firstly, T1 brain scans were segmented 
(using the unified segmentation approach in SPM5) in native space into GM, WM 
and CSF using study-specific images for GM, WM and CSF, after which the SPM 
brain extraction function returned a tissue mask for each scan. These masks were, 
then, applied to the original T1 images in order to remove non-brain tissue. T1 brain 
images were, then, spatially normalized to the study-specific T1 template using a 12-
parameter linear affine transformation. Bilinear interpolation was used to resample 
the normalized images and write MNI-normalized images into the stereotactic space 
at a 1x1x1mm voxel resolution. These normalized images were again segmented 
using the study-specific a priori templates and spatially normalized segments for 
GM, WM and CFS were returned. Finally, the spatially normalized, segmented 
images were smoothed with an 8mm full-width at maximum (FWHM) isotropic 




4.4 Pattern Classification Analysis 
 
4.4.1 Support Vector Machine 
 
This section gives a brief introduction to Support Vector Machine (SVM). Despite 
the fact that one cannot claim that SVM is universally the best classification method 
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to date, it has, however, been widely used in neuroimaging-based studies of various 
psychiatric disorders (Kloppel et al. 2008a, Kloppel et al. 2008b, Mourao-Miranda et 
al. 2011, Fu et al. 2008, Davatzikos et al. 2011) including schizophrenia (Fan et al. 
2007, Fan et al. 2008a, Davatzikos et al. 2005b, Koutsouleris et al. 2009b, 
Koutsouleris et al. 2012a, Nieuwenhuis et al. 2012, Mourao-Miranda et al. 2012a,  
Zanetti et al. 2013, Schnack et al. 2014, Zhang et al. 2015, Koutsouleris et al. 2015a) 
and has thus far delivered rather satisfactory classification results. For a critical 
review on the application of SVM in psychiatric disorders, see Orru et al. 2012. 
Therefore, the reason for selecting this classification method lies, on the one hand, on 
its wide use by the neuroimaging community and, on the other hand, on the fact that 
it can deal effectively with high dimensional data and deliver good classification 
performance. The diagnostic and prognostic accuracy of the SVM models 
implemented in schizophrenia studies has ranged from 70% (Mourao-Miranda et al. 
2012a, Nieuwenhuis et al. 2012) to over 90% (Fan et al. 2007, Yoon et al. 2007, 
Costafreda et al. 2011, Koutsouleris et al. 2012b), which is very impressive 
considering the high-dimensionality of the brain imaging data, with thousands of 
voxels being used as input in the classifiers. For a detailed description and discussion 
of the variability in the performance of the SVM models in schizophrenia research, 
one can go back to Chapter 3, section 3.3.1. The rest of this section comprises of a 
description of the rationale and the mathematical background of SVM models. 
 
The SVM methodology is based on statistical learning theory as originally proposed 
by Vapnik and Chervonenkis (1971). In the original implementation described in 
Vapnik (1995) SVM was a linear classifier but other modifications exist that describe 
the classification for non-linear cases (Boser et al. 1992).  
The main goal of SVM is to construct a decision boundary that would allow the 
classification of individual observations into two (or more) distinct classes, while 
simultaneously trying to maximise the margin between those classes (training stage). 
A hypothetical example of a binary SVM classifier is illustrated in Figure 4.1. The 
optimal separating hyperplane is determined by maximising the distance between the 
nearest data instances of opposite classes (i.e. the support vectors; Figure4.1b). Once 
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determined, the optimal hyperplane can be used to classify new, previously unseen 






(a)             (b) 
  
 
Figure 4.1 Representation of a linear, binary SVM classifier. (a) Illustration of the classification 
problem between two groups (i.e. circles represent patients, squares represent healthy controls) for the 
simplified case of two voxels. The dashed lines represent a subset of possible separating hyperplanes, 
described by a weight vector w and an offset b. (b) The optimal separating hyperplane is the one with 
the largest margin of separation between the two groups and is described as a function of f(x)= w*x+b, 
where w is a weight vector that is normal to the hyperplane, b is an offset and b/ ||w|| is the distance 
from the hyperplane to the origin. Points in the dashed lines represent the support vectors. During the 
training phase, the SVM classifier computes the optimal decision function f(x) and in the testing phase, 
this decision boundary is applied to new data instances. 
 
    
Here, a linear support vector machine (SVM) classifier was used for the classification task.  
    
4.4.1.1 Linear Support Vector Machines  
A linear binary SVM implies that data instances of two classes can be separated by 
either a line (in case of two dimensions) or a hyperplane (in case of more than two 
dimensions). Each data instance is represented by an n-dimensional vector of 
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features and each instance belongs to only one of the two classes (i.e. +1 for the 
positive class; patients and -1 for the negative class, i.e. control subjects).  
 
Now, let's assume that we have l  training instances, where each data instance ix has 
n  attributes, and belongs to one of the two possible classes iy = {-1, +1}.  This set of 
instance-label pairs is called training set and is of the form:  
            ( )ii y,x   where i = 1.... l , ( )li +y 11,−∈   and  nRx∈    (1) 
 
 
In the training phase of the SVM, the classifier computes a decision function 
(hyperplane) that maximises the distance between the opposite classes. This linear 
decision function is based on the linear discriminant function of the form: 
( ) b+xw=xf ii





  is the distance from the hyperplane to the origin (Figure 4.1). As it is 
observed in Figure 4.1, the margin between the classes is equal to
w
1 , however 
maximising this quantity is equivalent to minimising 2
2
1 w .  
For each class (y=+1, y=-1), one needs to solve: 
1+≥⋅ b+xw i

  when iy = +1            (2) 
1−≤⋅ b+xw i

  when iy = -1                                          (3) 
Equations (2) and (3) can be combined to:     1)( ≥⋅ b+xwy ii
  
This problem now becomes a primal optimisation one and we therefore need to: 
 
          2
2
1 wmin     subject to   ( ) iii b+wxy ∀≥−⋅ 01

    (4)
  
 
The above is an optimization problem with a convex quadratic objective and only 
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linear contraints and its solution gives the optimal margin classifier. The constraint in 
this formulation ensures that this maximum-margin SVM classifies data instances 
correctly and no data points of the one class lie on the opposite class. In practice, 
however, data are not often 'exactly' linearly separable. A greater margin can, thus, 
be achieved by allowing some misclassification. To allow some errors in the data 











1     s.t.     ( ) iiiii ξξb+wxy ∀≥−≥⋅ 0,1

   (5) 
 
 
where 0>C is a regularisation parameter of the error term (or else a penalty 
parameter that controls the trade-off between having no training errors and allowing 
some misclassification) and iξ  is a positive slack variable that allows 
misclassification of points.  
If 10 ≤≤ iξ , then the corresponding data point lies in the margin, while if 1≥iξ the 
data point is misclassified. This formulation is called soft-margin SVM. 
 
In order to solve ths constrained optimization problem one can, also, use the 
Lagrangian multipliers a  and thus obtain the dual formulation of the optimization 
problem expressed as: 
 



















i∑          (6) 
 
 
This is also a convex quadratic optimization problem but with N variables ( ia , i=1,.., 
L) where L is the number of samples. The dual formulation leads to the expression of 






. The dual 
formulation is computationally more efficient as the decision function is only 
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computed by a subset of the training data for which: Cai ≤ ≤ 0 , and additionally 
there is no need to access the original data but only dot products. Data instances from 
this subset are called support vectors and are data points that lie upon the separating 
hyperplane (see Figure 4.1).  For a complete description of the derivation of the dual 
formulation please see Appendix II. 
 
Additionally, the dual formulation problem lends itself to the kernel trick (Aizerman 
et al. 1964), where instead of computing the ordinary dot product between data 
instances; one can only compute the kernel function: 
 





















i∑      (7) 
 
The use of kernels is highly efficient in order to get optimal margin classifiers in 
high-dimensional space and especially in cases where the data are not linearly 
seperable. However, the mathematical description of non-lineal SVM models is 
outside the scope of this chapter.  
 
Having computed the decision function, each new previously unseen data instance 
'x  can be classified to one of the two classes by computing the decision function





There are a wide range of SVM toolboxes available. We used LIBSVM library for 
the implementation of the linear SVM classifier (Chang & Lin 2011), running in 
Matlab version 7. This toolbox requires that each data instance is represented as a 
vector of real numbers, so transformation of the original data set into LIBSVM 
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format was necessary before running the method (Hsu et al. 2010). In addition, 
scaling to [0, 1] range was performed in order to ensure that attributes in greater 
numeric ranges would not dominate those in smaller ranges.  
A ‘grid-search’ on the C parameter using cross-validation was also performed. 
Various C values were tried and the one that gave the best cross-validation accuracy 
was picked. More details on the C parameter can be found in the following results 
chapters of this thesis. 
   
 
 
4.4.2 Feature Extraction 
As described in Chapter 3, feature extraction is a fundamental and obligatory step in 
every pattern recognition image analysis pipeline. 
Prior to using the SVM, all smoothed and normalized GM maps were mapped to the 
Automated Anatomical Labeling (AAL) brain atlas (Tzourio-Mazoyer et al. 2002). 
The AAL template is an atlas that provides a parcellation of the human brain in 116 
brain regions and serves as a basis for the correspondence between sets of co-
ordinates and their anatomical labels (Figure 4.2). For its construction, the AAL atlas 
was based on the spatially normalized MNI single-subject MRI brain template, 
which was obtained by repeatedly scanning a young man (27 times) and averaging 
each MRI acquisition to produce the final MRI brain template. For a detailed 
description of the delineation and parcellation process, one can see the Tzourio-









    a)                                        b)                                             c) 
              




A script in C programming language (Kernighan & Ritchie 1978) was implemented 
in order to extract the GM density volumes corresponding to the 116 pre-defined 
brain regions of the AAL template from each smoothed and normalized GM map in 
the EHRS and the FePsy datasets. Specifically, each subject’s smoothed and 
normalized GM image was mapped to the AAL-atlas template, where in each AAL-
specified region the intensity values of the voxels that comprised the brain region 
were summed up and their mean intensity was derived. These (mean) GM density 
values were, then, used as input features into the SVM classifier.   
For reasons of disc memory and speed efficiency, it was decided to use a ROI-based 
approach instead of a voxel-based one. The C code for mapping and extracting mean 
intensity values was already available in the lab. There are a number of advantages to 
choosing such an approach, which include a faster calculation of the separating SVM 
hyperplane, since the number of features in the ROI-based classification is 
significantly lower than in the voxel-based case, a faster and more efficient feature 
selection and interpretation of the involved brain regions. On the other hand, because 
the signal intensity is averaged in the AAL-defined ROI, this could possibly lead to 
loss of information since there is no way one could detect differences or significant 





4.4.3 Feature selection 
 
In machine learning, feature selection is an important step in the analysis pipeline for 
a number of reasons: meeting computational and time constraints, facilitating the 
interpretation and visualization of results and enhancing the generalization 
performance (Guyon & Elisseeff 2003). A variety of feature selection methods exist. 
Filters are the simplest and most computationally efficient feature selection methods, 
in which features are ranked and eliminated based on a selection criterion during the 
pre-processing stage and just before the data enter the classifier. Filter methods are, 
therefore, independent of the classifier. The main disadvantage of filters is that these 
methods do not examine features jointly with respect to how significant they are in 
the classification task (as a group) but rather rank them independently of one another. 
Thus, filter methods are not well suited for situations where apart from removing 
redundancy, one is also interested in increasing classification performance because a 
group of features might be able to provide better accuracy than another and filter 
methods cannot examine this in any way. To this end, embedded methods are better 
suited because they aim to find a combination or a subset of features that would 
provide maximum classification accuracy. To do that, embedded methods utilize the 
classifier to exmamine the quality of the features by incorporating variable selection 
as part of the training process of the classifier and by implementing a ranking 
criterion that is bound to the cross-validation performance.  
In the present work, a series of feature selection methods was tried out. Initially filter 
methods, such as the F-score (Chen and Lin, 2006) and the Pearson Correlation 
coefficient, which is closely related to the t-Test criterion (Guyon & Elisseeff 2003), 
were examined. A detailed descrition of these filter methods can be found in 
Appendix III. However, both of these methods failed to increase the classification 
accuracy (both when tried with linear and nonlinear SVM classifiers), which was one 
of the reasons for applying feature selection in the first place, apart form removing 
redundancy.   
An embedded feature selection method, called Recursive Feature Elimination (RFE), 
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was then put to the test. It was observed that the classification performance was 
significantly improved after implementing the Recursive Feature Elimination, as 
opposed to not incorporating it in to the SVM classifier. However, for the sake of 
consistency, the performance of the SVM classifier with and without RFE will be 
given in the following results chapters. A detailed descrition of the RFE 
methodology is given below. 
 
 
4.4.3.1 Recursive Feature Elimination 
Recursive Feature Elimination (RFE) is one of the most effective feature selection 
methods, proposed and originally implemented by Guyon et al. (2002) for gene 
selection in cancer classification. It is a backward sequential feature elimination 
approach, embedded in an SVM classifier that selects features based on their 
influence on the determination of the maximum margin hyperplane. 
The algorithm starts with all feature variables in the training set and gradually 
removes one feature at a time (or for speed reasons, more than one feature could be 
eliminated). At each step, a linear SVM classifier is trained using a subset of the 
original feature set and the coefficients of the w vector are used to compute a feature 
ranking score. For the linear case, the feature ranking criteria is the: ( )2ii w=c , for all 
features i. Based on this ranking criteria, the feature with the smallest ranking score 
is eliminated from the feature set and the method iterates in the same way until a 
specified number of features have been eliminated or until the classifier reaches its 
best classification performance (see Panel 1). However, in this implementation, the 
RFE method continued until all features were eliminated from the feature set while at 
each elimination step the performance on the validation step was recorded so that the 
(smaller) subset of features that achieved the highest performance on the validation 
set was determined and retrieved. Feature elimination based on this ranking criterion 
corresponds to eliminating that feature whose removal changes the objective function 
the least, thus, having the least contribution on the margin definition. Recall from the 
previous section, the objective function is 2
2
1 w=J , which justifies the use of ( )2iw
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as the ranking criterion. This approach is based on linear SVM, although other 











4.4.4 Classification performance 
 
Measures of classification performance are needed in order to assess the 
generalizability of the classifier to independent testing cases. The most widely used 
metric is the accuracy, which measures the proportion of correctly predicted data to 
the total number of the test data. 
In the following subsections I present the performance metrics employed in this 
study and also describe the technique of cross-validation, which was used in order to 
assess the classifier’s performance. 
 
   
  1. Start:  training examples [ ]Tlk2 x,x,x,x=X .....10  
      class labels [ ]Tlk2 y,y,y,y=y ....1  
      ranked feature subset R=[],  
      surviving feature subset S=[1,2,.., n] 
  2. Repeat until S=[] 
       a) train a linear SVM with features in set S 
      b) compute the weight coefficients 
      c) compute the ranking score ( )2ii w=c for each feature in S 
      d) find the feature with the smallest ranking score ( )icargmin=f  
      e) Update the R=[f, R] and S=S-[f]. 
  3. Output: Ranked feature list R 
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4.4.4.1 Performance metrics 
The performance of a classification method can be visualised using a confusion 
matrix (Table 4.1), which contains information about the actual and predicted 
instances classified by the chosen classifier (Kohavi & Provost, 1998). The correctly 
labelled instances are located on the diagonal and consist of the true positives (TP) 
that refer to correctly classified patients and the true negatives (TN) that represent the 
correctly labelled controls. Instances that are incorrectly labelled are divided in false 
positives (FP) and false negatives (FN) that describe the proportion of control 
subjects incorrectly labelled as patients and the number of patients incorrectly 
identified as controls respectively. 
 
                  
Table 4.1 Confusion matrix of a binary classifier. The confusion matrix aims to 
classify positive cases (i.e. patients) and negative examples (i.e. control subjects).  
 
The accuracy is the proportion of the total number of correct classifications and is 
given by the formula: 
 
 








In cases where the two classes are unbalanced, the accuracy is not a very reliable 
measure of the classification performance. It is, thus, important to report other 
performance metrics. 
Sensitivity refers to the proportion of the actual cases in the positive class correctly 
classified and is given by: 
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Specificity refers to the proportion of actual cases in the negative class correctly 
classified and is computed by: 
 






Positive predictive value (PPV) gives the probability that a person identified by the 




TP=PPV  % 
 
Negative predictive value (NPV) refers to the probability that a person identified as 
free of a disease truly does not have it and is given by the:  
100×
FN+TN






In cases where the data set is large enough, one would be advised to split the set into 
a training set and a holdout set that would serve for evaluating the classifier’s 
performance (test set). However, it is not always ‘affordable’ to set aside a portion of 
the original data set for testing purposes, especially when this data set consists of 
limited cases; as is often the case in neuroimaging studies. To this end, cross-
validation is usually performed (Kohavi 1995).  
Here, a leave-one-out (LOO) cross-validation (CV) approach was employed. Leave-
one-out CV can effectively deal with over-fitting and provide an almost unbiased 
estimate of the generalisation error. It involves a repeating procedure, where in each 
trial data from all but one subject (k-1 of k subjects) are used for training and the left-
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out subject is used for testing the classifier's performance. This procedure is repeated 
k times, until all data instances have been used in the test set and then classification 




4.4.5 Permutation Testing 
 
Permutation testing was used to evaluate the probability of obtaining accuracy levels 
higher than the ones obtained during the cross-validation procedure. An illustration 
of how permutation tests work is given in Figure 4.3. This test is used to derive a p-
value that gives an estimate of the statistical significance of the classifier and 
determines whether classification accuracy exceeded chance levels (50%). After 
having completed the RFE procedure, and using the final set of selected features, I 
permuted the class labels 1000 times, by randomly assigning patient and control 
labels to the training subjects. I then counted the number of times the permuted 
accuracy exceeded the one obtained for the true labels and by dividing this number 





Figure 4.3 Permutation testing. The significance of a classifier’s performance is assessed 
using permutations tests. The ‘true’ labels are randomly permuted to obtain “baseline” model 
performances. The “true” model performance is then compared to the baseline level obtained 
from the permutations. Typically, a model performance is significant if the performance 
obtained by chance does not exceed or is equal to the true model performance more than 5% 
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5.1 Introduction 
    
As seen in previous chapters, schizophrenia is associated with a number of brain 
abnormalities. However, it remains unclear whether these brain abnormalities occur 
prior to disease onset, or in high-risk individuals coming from multiply affected 
families or only those high-risk subjects that go on to develop schizophrenia. The 
EHRS was conceptualized with the aim of shedding light to those questions and 
identify predictors of vulnerability and transition to schizophrenia. Findings from 
previous EHRS studies using univariate methods of data analysis have been 
discussed in previous chapters. 
The scope of this chapter is to investigate the utility of baseline structural MRI data 
in predicting transition to schizophrenia in high-risk subjects, who took part in the 
EHRS and were identified at a heightened risk for developing psychosis for familial 
reasons, using a Support Vector Machine (SVM) approach. Additionally, the 
diagnostic performance of the classifier was examined by combining baseline 
neuroanatomical information with baseline schizotypal and neurocognitive variables 
that were previously reported as good predictors for the development of 
schizophrenia. It was hypothesized high risk subjects who later go on to develop 
schizophrenia could be distinguished at baseline from HR subjects who do not and 
that a combination of structural brain imaging, schizotypal and neurocognitive data 
would enhance predictive performance compared to either individual measures alone. 
 
 
5.2 Background   
 
Psychiatric research interest has recently shifted from studying schizophrenia to 
attempting an early detection of the disorder before diagnosis of full-blown psychosis 
can be established. Making an early diagnosis of schizophrenia and other psychoses 
is, however, quite challenging mainly because of the underlying difficulty of 
identifying an 'at-risk' state for the disorder (Riecher-Rossler et al. 2006). 
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As seen in previous chapters, a plethora of risk factors for psychosis have been 
identified; the most predominant of which include the existence of subclinical 
psychotic symptoms and genetic risk. Individuals conceptualised as at clinical HR 
(or as having an ‘at-risk mental state’- ARMS) present with early signs of psychosis 
such as attenuated positive symptoms or brief limited intermittent psychotic 
symptoms (Fusar-Poli et al. 2013a, Phillips et al. 2000). In familial HR paradigms, 
individuals are characterised on the basis of having at least one affected first or 
second-degree relative (Cannon & Mednick 1993, Erlenmeyer-Kimling et al. 1997, 
Mirsky et al. 1995). Several aspects of the familial and clinical HR paradigms, 
however, overlap as many individuals at familial HR often exhibit pre-psychotic 
symptoms and clinical HR subjects might also have a family history of the disorder.  
Nevertheless, both HR paradigms are associated with an increased risk for 
development of psychosis and share various neurocognitive and neuroanatomical 
alterations (Smieskova et al. 2013), some of which might even be predictive of future 
disease transition (Lawrie et al. 2001b, Brewer et al. 2006, Smieskova et al. 2013). 
Neurocognitive dysfunctions are cardinal to schizophrenia (Heinrichs & Zakzanis 
1998) and some of them can even be detected early in the course of the disease 
(Fusar-Poli et al. 2012a, Seidman et al. 2006). Previous studies reported significant 
neurocognitive impairments in the domains of attention, working memory, executive 
function, verbal learning/fluency and memory in HR compared to healthy control 
(HC) subjects (Seidman et al. 2006, O’Connor et al. 2009, Brewer et al. 2005, Pukrop 
et al. 2006, Byrne et al. 2003, Gschwandtner et al. 2003, Wood et al. 2003). Reduced 
baseline performance in verbal fluency and memory was also found to distinguish 
HR subjects who later converted to psychosis from those who did not, both in 
clinical (Fusar-Poli et al. 2012a, Pukrop et al. 2007, Lencz et al. 2006) and familial 
HR paradigms (Johnstone et al. 2005, Erlenmeyer-Kimling et al. 2000, Whyte et al. 
2006). Furthermore, prediction performance of multivariate models was shown to 
improve, up to 80% accuracy (Lencz et al. 2006), when neurocognitive functioning 
and symptom severity scores were integrated in a stepwise risk assessment (Riecher-
Rossler et al. 2009, Lencz et al. 2006). Studies employing prognostic index, in a 
multilevel context that combines individualized risk estimation and stratification, 
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have also reported remarkable results in predicting transition to psychosis. The 
combination of data from different domains such as neuropsychological data and 
clinical HR criteria (Ruhrmann et al. 2010) or neurophysiology measures with 
premorbid adjustment (Nieman et al. 2014), has resulted in positive predictive value 
of up to 83% (Ruhrmann et al. 2010) and as a second step enabled an individualized 
risk classification in terms of magnitude and time to transition, that has an added 
benefit for informing targeted prevention strategies.  
As seen in previous chapters, VBM studies have shown that schizophrenia is 
associated with grey matter (GM) volume reductions in frontal, superior temporal 
and anterior cingulate gyri and medial temporal lobe structures (Bora et al. 2011). 
Subtle GM reductions in prefrontal, medial temporal, limbic and temporo-parietal 
regions were also found across the whole HR population (Smieskova et al. 2010, 
Borgwardt et al. 2011, Meisenzahl et al. 2008b, Job et al. 2003, Pantelis et al. 2003) 
suggesting that they might be correlates of vulnerability to psychosis (Fusar-Poli et al. 
2011). Transition to schizophrenia was found to be associated with further GM 
volume reductions in temporal, cingulate and cerebellar regions in clinical HR 
samples (Borgwardt et al. 2006, Koutsouleris et al. 2009a, Pantelis et al. 2003). In 
our own EHRS, progressive GM reductions in the inferior temporal gyrus, uncus and 
right cerebellum were reported in those HR subjects that later transited to 
schizophrenia versus those who did not (Job et al. 2006).  
What is more needed in clinical practice, however, is moving from a characterisation 
of group differences to models that could simultaneously capture individual 
variations from the norm while making inferences at a single-subject level. To this 
end, pattern classification techniques, including the Support Vector Machine (SVM), 
have emerged as powerful brain image analysis tools and have already been applied 
in diagnosing various neurological and psychiatric disorders (Kloppel et al. 2012, 
Orru et al. 2012, Davatzikos et al. 2005b, Kloppel et al. 2008a, Mourão-Miranda et al. 
2011). As seen in the literature review in Chapter 3, SVM has achieved high 
diagnostic accuracy, ranging from 77% (Koutsouleris et al. 2012b) to 84% 
(Koutsouleris et al. 2012a) in predicting future transition to psychosis in ARMS 
subjects, either using neurocognitive (Koutsouleris et al. 2012b) or neuroanatomical 
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data (Koutsouleris et al. 2012a, Koutsouleris et al. 2009b). 
However, these studies have only focussed on using a single type of data at a time. A 
limited number of studies have examined the diagnostic performance of combined 
data in distinguishing schizophrenia or first episode patients (Pettersson-Yeo et al. 
2013) against HC, mostly by combining genetic data with either functional or 
structural MRI (Yang et al. 2010) or clinical information (Struyf et al. 2008), and 
have produced quite encouraging results (Sui et al. 2012).  To our knowledge, only 
one study has combined structural MRI with neurocognitive data (Karageorgiou et al. 
2011), reporting good classification performance (89% sensitivity and 93% 








The subject material was gathered as part of the Edinburgh High Risk Study (EHRS). 
A detailed description of the EHRS recruitment and assessment procedures was 
given in Chapter 4, section 4.2.1, and can also be found in previous papers (Hodges 
et al. 1999, Johnstone et al. 2000).  
Briefly, 160 individuals aged 16-25 years, with no previous history of psychiatric 
problems, were drawn throughout Scotland and were identified as HR on the basis of 
having two or more relatives affected with schizophrenia. Subjects were followed up 
for up to 10 years during which they underwent a series of clinical, behavioural and 
neuroimaging assessments every 18 months.  
Psychopathology was assessed at entry and follow-up by the Present State 
Examination (PSE; Wing et al. 1974) and allowed the classification of subjects into 
five categories: 0, no symptoms; 1, non-psychotic symptoms; 2, partially held 
psychotic symptoms; 3, definite but isolated and/or transient psychotic symptoms 
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and 4, diagnosis of schizophrenia, which was further validated by the ICD-10.  
All subjects were antipsychotic-naive at study-entry and at follow-up or until they 
were clinically diagnosed with schizophrenia. From those HR subjects who provided 
complete data and had a MRI scan, 17 were diagnosed at follow-up with 
schizophrenia (after an average of 929 days, SD=138). Among the rest, 57 subjects 
experienced psychotic or possibly psychotic symptoms (points 2 and 3 combined) 
but these were too transient or mild to satisfy operational definition for schizophrenia 
or any related psychotic illness (Johnstone et al. 2000). The rest of the HR subjects 
remained well, with no symptoms.  
In this study, the aim was to contrast the two groups who exhibited psychotic 
symptoms and were the most difficult to discriminate against on any basis: the one 
group of subjects that surpassed the clinical threshold for schizophrenia (HR[ill]) and 
the other remaining below the threshold for clinical diagnosis (HR[symp]) but yet 
exhibited psychotic symptoms. In that way, our study groups could indirectly relate 
to other studies in this area, which study ARMS individuals who typically present 
psychotic symptoms, although these were identified based on different assessment 
criteria than the present study.  
To build the classifier, 17 of the 57 HR[symp] subjects were randomly selected to 
contrast with the 17 HR[ill] subjects (Table 5.1), a practice seen in other studies in 
this area (Koutsouleris et al. 2015b, Mourao-Miranda et al. 2012a, Koutsouleris et al. 
2010, Koutsouleris et al. 2009b), primarily in order to alleviate class imbalance 
issues that can result in a classification bias towards the majority class (Japkowicz 
2000, Akbani et al. 2004, Weiss 2004). The data of the remaining 40 subjects were 
used to further validate the classification (Table 5.2- HR[symp]test), after training and 
cross-validation. A more detailed discussion on the reasons for choosing this 






5.3.2 Schizotypal and Neurocognitive Measures 
 
We aimed to include in our analysis those variables that constituted the best 
predictors of schizophrenia in the EHRS literature (Johnstone et al. 2005), namely 
the Rust Inventory of Schizotypal Cognitions (RISC) questionnaire (Miller et al. 
2002b) and the Rey Auditory Verbal Learning Test (RAVLT). 
Briefly, the RISC is a self-completed, 26-item questionnaire that evaluates 
schizotypy and schizotypal cognitions, rather than overt psychotic symptoms, 
primarily associated with the positive symptoms of schizophrenia (Rust 1988). The 
areas tapped include ritualistic thinking, psychotic symptoms such as delusions of 
grandeur, schizophrenic symptoms such as auditory hallucinations and defense 
mechanisms such as reaction to disturbing ideas. A few indicative examples of the 
cognitions measured in the RISC are: ‘I never use a lucky charm’ and ‘sometimes I 
get a weird feeling that I am not really here’. Here, a uni-dimensional test score was 
calculated for each participant at study-entry through the cumulative summation of 
the item scales.  
The RAVLT instrument evaluates verbal memory and learning, by repeatedly (5 
times) presenting the individual with a list of words and asking to recall as many as 
he/she can (Byrne et al. 2003). The final test score produced is equal to the total 
number of words recalled across all five trials. Previously, an equal mis-classification 
costs cut-off on the RISC score showed 94% negative and 50% positive predictive 
power while the same approach to the RAVLT trials 1-5 total score showed figures 
of 85% and 11%  respectively (optimal cut-off points: 39.5 and 48.5 respectively; 






5.3.3 Image Acquisition and Preprocessing 
 
In the present thesis, only baseline neuroimaging scans were considered. In the 
EHRS study, all baseline scanning was performed on a 1.0 T Siemens Magnetom 
scanner (Erlangen, Germany). After localisation and a double spin-echo sequence to 
identify any gross brain abnormalities, T1-weighted MRI scans were acquired using 
a three-dimensional Magnetization Prepared Rapid Acquisition Gradient Echo 
(MPRAGE) sequence with the following parameters: TR=10 ms, TE=4 ms, TI=200 
ms, relaxation delay time=500 ms, flip angle= 12o, FOV= 250mm x 250mm, 
resulting in 128 contiguous, 1.88-mm thick “slices”. To correct for inhomogeneity of 
the RF coil and any scanner changes over time, an oil phantom was scanned 
immediately after each subject, using the same coil and in the same orientation as the 
subject’s head (Job et al. 2002). An example of a typical structural MRI scan of a 
high-risk individual in the EHRS is given in Figure 5.1.  
 
 
                       Figure 5.1 A typical MRI scan in the EHRS dataset. 
 
A detailed description of the steps in the preprocessing pipeline can be found in 
Chapter 4, section 4.2. 
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 Number of participants 17 17 
  Mean age at baseline (SD) 20.07(2.37) 20.03(2.6) nsa 
 Male (%) 11(64.7) 11(64.7) nsb 
 Mean RISC score (SD) 39.88(10.6) 25.23(11.75) <0.01a 
 Mean RAVLT, trials 1-5 (SD) 47.64(7.49) 53.41(7.45) nsa ** 




         Right 16 15 
          Left 0 1 
          Mixed 1 1 
  Social Class of origin 
  
nsb 
         I and II 2 3 
          III and IV 13 10 
         V and VI 2 3 
        unclassifiable 0 1 
  Cannabis use at baseline 
  
nsb 
         None 8 12 
          Occasional 5 4 
          Frequent 4 1 
 Smoking cigarettes 
  
nsb 
         None 7 9 
          <10 6 4 
         10-20 3 2 
          >20 1 2 
  Symptoms severity (PSE rating)  
  
nsb 
        No psychotic symptoms 2 7 
         Neurotic symptoms only 4 3 
         Partially held psychotic symptoms 9 6 
         Isolated and/or transient psychotic 
symptoms 2 1 
   
HR[ill]: individuals at high familial risk who developed schizophrenia during follow-up 
period; HR[symp]: individuals at high familial risk who remained well but developed 
psychotic symptoms during follow-up period; IQ, Intelligence Quotient; RISC, Rust 
Inventory of Schizotypal Cognitions; RAVLT,  Rey Auditory Verbal Learning Test; WAIS-
R, Wechsler Adult Intelligence Scale- Revised. Social class of origin was based on the 
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father's occupation at the time of the subject's birth using the Occupational Classification of 
the Registrar General (HMSO 19991). a Student’s T-test.  b Fisher’s exact test.  **effect size 
was r=0.54 
 









 Number of participants 17 40 
  Mean age at baseline (SD) 20.03(2.6) 21.07(4.59) nsa 
 Male (%) 11(64.7) 14(35) nsb 
 Mean RISC score (SD) 25.23(11.75) 33.45(13.39) nsa 
 Mean RAVLT, trials 1-5 (SD) 53.41(7.45) 51.15(11.59) nsa 




         Right 15 34 
          Left 1 4 
          Mixed 1 2 
  Social Class of origin 
  
nsb 
         I and II 3 7 
          III and IV 10 22 
         V and VI 3 10 
        unclassifiable 1 1 
  Cannabis use at baseline 
  
nsb 
         None 12 26 
          Occasional 4 10 
          Frequent 1 4 
 Smoking cigarettes 
  
nsb 
         None 9 21 
          <10 4 12 
         10-20 2 4 
          >20 2 3 
  Symptoms severity (PSE rating)  
  
nsb 
        No psychotic symptoms 7 13 
         Neurotic symptoms only 3 13 
         Partially held psychotic 
symptoms 6 13 
         Isolated and/or transient 
psychotic symptoms 1 1 
 Note: please see legend of Table 5.1 
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5.3.4 Multivariate Pattern Classification Analysis 
 
A detailed description of the pattern classification analysis pipeline can be found in 
Chapter 4, section 4.3. 
 
5.3.4.1 Support Vector Machine 
A linear Support Vector Machine (SVM) was used for the classification task. A 
detailed description of the linear SVM classifier can be found in Chapter 4, section 
4.3.1.1. Briefly, a binary SVM classifier works by finding an optimal decision 
function that separates the two classes. The classification procedure consists of two 
phases: training and testing. During the training phase, the classifier is trained by 
providing examples of the form (xi, yi), where xi represent a spatial patter (e.g. grey 
matter map) and yi represent class labels (here, HR[ill] and HR[symp]) in order to 
determine a hyperplane that optimally separates the two groups. Once the decision 
function is learned, it can be used to predict the class of a new test example. 
As described before in chapter 4, the linear SVM has a slack variable that controls 
for the desired amount of misclassifications. Here, a ‘grid-search’ on the C parameter 
was performed, as recommended by Hsu et al. 2010, in order to identify the optimal 
value for the parameter (that is the value that produced the highest accuracy in the 
cross-validation). However, the grid search was only performed in the inner cross-
validation loop of the nested cross-validation scheme (described in more detail 
below), whereas in the outer cross-validation loop the default C value was used (i.e. 
C=1). 
Apart from the linear SVM, non-linear SVM classifiers were also tried out. Briefly, 
when the relationship between the class labels and the features is nonlinear, one can 
choose to map the original data into a higher dimensional space where the data 
samples are linearly separable. To do that, the kernel trick is employed (recall from 
section 4.4.1.1); the most widely used nonlinear kernel is the Radial Basis Function 
(RBF). In the following Results’ section, the results pertaining to the use of the 
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nonlinear RBF SVM will be briefly presented.  
 
 
5.3.4.2 Feature Extraction 
As previously described, prior to using the SVM, all smoothed and normalized GM 
maps were mapped to the Automated Anatomical Labeling (AAL) brain atlas 
(Tzourio-Mazoyer et al. 2002) and GM density volumes corresponding to the 116 
brain regions of the template were returned. The 116-length vector of GM density 
values was then concatenated with the baseline RISC and RAVLT scores and was 
used as input to the classifier. To ensure commensurability of the different data types, 
the features were scaled to [0 1] in the training set and then the same scaling was 
applied to the testing set. 
 
5.3.4.3 Feature Selection 
To identify the most significant features in the classification task, recursive feature 
elimination (RFE; Guyon et al. 2002) was applied. As previously described, RFE is a 
backward feature selection technique, that recursively removes features from the 
original dataset with the aim of removing the most redundant features, while keeping 
the most significant. During RFE, a linear SVM classifier is trained and the method 
removes one (or more) features based on a feature-ranking criterion that is computed 
as the square of each weight vector coefficient (wi2). 
Here, apart from removing the least significant features, I was also interested in 
improving diagnostic performance. A nested leave-one-out cross-validation (LOO-
CV) framework was, thus, employed (Mourão-Miranda et al. 2012, DeMartino et al. 
2008) in which one subject was removed from the original data set to comprise the 
test set and then a second split where the remaining subjects were again repeatedly 
repartitioned to form a validation and a training set was performed (Figure 5.2). The 
nested LOO-CV provided an unbiased estimate of the expected diagnostic accuracy 
on new cases. 
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The testing points had no involvement whatsoever in the RFE and the training 
process. The feature set that produced the maximal accuracy on the validation set 
was selected and applied to the testing set. The final accuracy was calculated as the 
mean accuracy over all test subjects. 
The feature set that contained the most significant features in the classification 
process and produced maximal accuracy was returned. Each feature is associated 
with a weight vector wi that gives an indication of the relative importance of each 
feature in predicting one class over the other. Given the labels +1 and -1 for the 
HR[ill] and HR[symp] groups respectively, a positive weight vector implies a  higher 
importance of this feature in classifying the HR[ill] group whereas a negative value 
means this feature is more important in classifying HR[symp] individuals over HR[ill] 
ones. Figure 5.3 presents an illustration of the most discriminating regions based on 
their weight vectors (Figure 5.3). 
 
Finally, it should be noted that the implementation of the RFE methodology for 
nonlinear SVM classifiers was fairly complicated and was not attempted; therefore 
results pertaining to the nonlinear SVM classifier (and specifically RBF SVM) 
include a single leave-one-out cross-validation loop. The lower predictive accuracy 
of the RBF-SVM classifiers and the entailed difficulty in implementing the RFE 
method were the main reasons for opting out of the nonlinear SVM and continuing 


















Figure 5.2 Pattern classification analysis pipeline. (1) Feature extraction: after 
standard scan preprocessing, GM segments were mapped to the AAL atlas and 
transformed into feature vectors containing GM volume information. In the second 
analysis, baseline clinical variables were concatenated to form the SVM input 
vectors. (2) Nested LOO-CV SMV-RFE. A nested LOO-CV was employed where I 
repeatedly excluded one subject from our data set to comprise the test set and the 
remaining subjects (33) were again repeatedly repartitioned in an internal validation 
loop where one subject was left out for validation and the rest (32) formed the 
training group. In this loop, RFE was repeatedly performed and the mean accuracy 
on the validation group at each elimination level was recorded until all features were 
removed. The feature set that produced the maximum accuracy on the validation set 
was selected and applied to the testing set of the outer testing loop. (3) Mean 





5.3.4.4 Permutation testing 
Permutation testing was performed in order to determine whether our classifier has 
produced these accuracy levels simply by chance. The rationale and implementation 





Demographic details for the two study groups are presented in Table 5.1. Student’s 
T-tests were performed on the continuous variables (i.e. age, RISC, RAVLT and IQ 
measures) and Fisher’s exact tests were performed on the rest, categorical variables. 
There were no significant differences in age, handedness, socio-economic 
background of origin, IQ, smoking, cannabis use and symptom severity at study-
entry between the study groups (Table 5.1), except for the baseline RISC score which 
differed between the HR[ill] and HR[symp] group (p<0.01).  
Additionally, I compared the 17 HR[symp] subjects against the 40 HR[symp]test 
subjects that were used to further validate the classification and found no significant 
differences in any of the reported variables (Table 5.2). 
 
 
5.4.1 SVM classification based on structural MRI data  
 
The nested LOO-CV linear SVM-RFE framework was applied to neuroanatomical 
data alone and a combination of neuroanatomical, schizotypy and neurocognitive 
data.  
The SVM approach achieved 88% accuracy in predicting disease conversion based 
on structural MRI data alone (Table 5.3). Thirteen out of 17 subjects in the HR[ill] 
and all subjects in the HR[symp] group were correctly assigned to their group, 
(sensitivity/specificity: 76%/100%; PPV/NPV: 100%/81%; permutation test 
p=0.001).  
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Without the RFE method, the simple LOO CV linear classifier gave a classification 
accuracy of 63.5% (sensitivity/specificity: 57%/70%). When applied to the same 17 
HR[ill]-17 HR[symp] dataset, the RBF-SVM classifier, using the entire feature set, 
gave a mediocre performance in predicting transition to schizophrenia, with an 
accuracy of 55.8%, a sensitivity of 64.7% and a specificity of 47.05%.   
The spatially distributed network that discriminated between the two groups was 
quite extensive and consisted of GM abnormalities in a spatially distributed network 
covering all four lobes and the cerebellum. Although, with these methods, it is not 
possible to make local inferences on the discriminating regions, it is noteworthy that 
the anatomical regions with the highest contribution to the discrimination between 
groups include the cerebellum, the lateral and medial temporal lobe, the amygdala, 
the medial frontal lobe, the putamen and the superior parietal lobe covering the 
supramarginal gyrus bilaterally and extending to the right fusiform gyrus (Table 5.4). 
Table 5.4 presents a list of the most discriminating regions in the classification task, 
namely the brain regions with the highest (absolute) weight value that contributed 
relatively higher to the decision function. 
Discrimination maps showing the spatial pattern by which the groups differ are 
illustrated in Figure 5.3A. It must be emphasized that the discrimination map should 
not be interpreted as a standard statistical parametric map resulting from a mass-
univariate statistical test but rather as a spatial representation of the decision 
boundary, where no local inferences should be made based on the SVM weights. 
. 
 
Table 5.3 Diagnostic performance of the classifier, using sMRI data only. 














13 17 0 4 76.4 100 88.2 0 100 80.9 
HR[symp]test - 27 13 - - 67.5 - 32.5 - 100 
Overall 13 44 13 4 76.4 77.2 76.8 22.8 50 91.6 
Note: sMRI-analysis refers to the classification analysis when only baseline GM volume 
data were considered. The diagnostic performance was evaluated by means of sensitivity 
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(Sens), specificity (Spec), balanced accuracy (BAC), false positive rate (FPR) and 
positive/negative predictive value (PPV/NPV). 
 
 
Only 13 out of 40 independent HR[symp]test subjects were wrongly assigned to the 
HR[ill] group (specificity 67.5%, FPR 32.5%). The diagnostic performance in the 
entire dataset (the 17 HR[ill] and  57 HR[symp]) attained a balanced accuracy of 77% 




Table 5.4 List of the most discriminative regions for the HR[ill] vs HR[symp] 
contrast using sMRI data alone. 
 
Lobe Region/Hemisphere w 
Negative weights 



















Parietal Paracentral_Lobule_R -0.6526 
 
Paracentral_Lobule_L -0.5691 
Occipital Occipital_Sup_R -0.4378 
Limbic Amygdala_R -0.2295 
 
Cingulum_Mid_L -0.5633 






Cerebellum Cerebellum_4_5_L 0.2036 
 
Cerebellum_Crus1_R 0.1993 
Temporal Fusiform_R 0.6462 
 
Temporal_Inf_L 0.5056 









Limbic Hippocampus_R 0.6802 
 
Cingulum_Post_L 0.6145 




Inf, inferior; L, left hemisphere; Mid, middle; Med, medial; Orb, orbital; Oper, 
opercularis; Post, posterior; R, right hemisphere; Sup, superior; w, weight vector of 
corresponding features in the classification process. 
 
Note: The SVM weight vector is a linear combination or weighted average of the support 
vectors and defines the decision boundary. The weight vector is therefore a spatial 
representation of the decision boundary. Every feature contributes with a certain weight to 
the decision boundary or classification function. Given a positive and a negative class 
(+1=HR[ill]; -1=HR[symp] group), a positive weight means the weighted average in that 
voxel was higher for the HR[ill] group, and a negative weight means the weighted average 





5.4.2 SVM classification based on combination of sMRI and behavioural data 
 
Subsequent inclusion of baseline RISC and RAVLT scores delivered higher 
diagnostic accuracy than before. The proposed method achieved 94% accuracy in 
predicting at baseline subsequent transition to schizophrenia in HR for familial 
reasons subjects (Table 5.5). All subjects of the HR[ill] group were correctly 
assigned to their group while 2 subjects of the HR[symp] group were wrongly 
classified as HR[ill] (sensitivity/specificity: 100%/88%; PPV/NPV: 89%/100%; 
permutation test p<=0.001). Only 8 out of 40 independent HR[symp]test subjects 
were wrongly classified as HR[ill] (specificity 80%, FPR 20%). The diagnostic 
performance in the entire dataset attained 91% balanced accuracy (Table 5.5). 
Again without the RFE, the linear classifier gave a mediocre performance in 
distinguishing between HR[ill] and HR[symp] with a 56.5% accuracy 
(sensitivity/specificity: 65%/48%). Conversely, the RBF-SVM classifier applied to 
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the 17HR[ill] and 17HR[symp] individuals gave a higher predictive performance 
with the introduction of the RISC and RAVLT variables, with an accuracy of 73.5%, 
a sensitivity of 70.5% and a specificity of 76.5%.   
Baseline RISC and RAVLT scores were selected by the SVM-RFE method, 
implying their contribution in the discrimination process. The neuroanatomical 
decision function consisted of a less extensive spatial pattern than before that 
involved, however several cortical and subcortical brain structures and the 
cerebellum (Figure 5.3B – Table 5.6). Specifically, the regions contributing more to 
the classification of HR[ill] subjects included the left superior temporal lobe 
extending to the left fusiform gyrus, the left thalamus, right superior and inferior 
frontal lobe regions, the insula bilaterally and parts of the cerebellum bilaterally, 
whereas regions with a higher weighted average for the HR[symp] group were the 
right putamen, right hippocampus and fusiform gyrus and parts of the cerebellum. 
Please see Table 5.6 for a list of the most discriminating brain regions that jointly 




Table 5.5 Diagnostic performance of the classifier, using sMRI data combined with 


















17 15 2 0 100 88.2 94.1 11.7 89.4 100 
HR[symp]test 0 32 8 0  80  20  100 
Overall 17 47 10 0 100 82.5 91.2 17.5 62.9 100 
Combined sMRI-behavioural refers to the results when a combination of baseline 
GM, RISC and RAVLT data was employed in the analysis. Again, diagnostic 
performance was evaluated by means of sensitivity (Sens), specificity (Spec), 






Table 5.6 List of the most discriminative regions for the classification of HR[ill] vs 
HR[symp] in the combined analysis of baseline sMRI, RISC and RAVLT data 
 
Lobe Region/Hemisphere w 
Negative weights 





















Parietal Paracentral_Lobule_L -0.3965 
Occipital Occipital_Mid_L -0.262 
 
Cuneus_L -0.2818 
Limbic Thalamus_L -0.2449 









Temporal Fusiform_R 0.3337 
Frontal Frontal_Sup_Orb_L 0.3542 
 
Precentral_R 0.3201 
Parietal Parietal_Inf_R 0.0393 
 
Parietal_Inf_L 0.3 
Occipital Lingual_L 0.373 
 
Occipital_Sup_L 0.357 
Limbic Hippocampus_R 0.169 
 
Cingulum_Post_L 0.333 




Inf, inferior; L, left hemisphere; Mid, middle; Med, medial; Orb, orbital; Oper, 
opercularis; Post, posterior; R, right hemisphere; Sup, superior; w, weight vector of 
corresponding features in the classification process.  
Note: The SVM weight vector is a linear combination or weighted average of the support 
vectors and defines the decision boundary. The weight vector is therefore a spatial 
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representation of the decision boundary. Every feature contributes with a certain weight to 
the decision boundary or classification function. Given a positive and a negative class 
(+1=HR[ill]; -1=HR[symp] group), a positive weight means the weighted average in that 
voxel was higher for the HR[ill] group, and a negative weight means the weighted average 












Figure 5.3 Discrimination maps for the classification of HR[ill] vs HR[symp]: a) just 
baseline MRI data were considered and b) baseline MRI were combined with RISC 
and RAVLT variables. The colours represent the weight of each feature in the 
classification function (the red scale represents positive weights and the blue scale 
represents negative weights). The SVM weight vector is a linear combination or 
weighted average of the support vectors and defines the decision boundary. The 
weight vector is therefore a spatial representation of the decision boundary. Every 
feature contributes with a certain weight to the decision boundary or classification 
function. Given a positive and a negative class (+1=HR[ill]; -1=HR[symp] group), a 
positive weight means the weighted average in that region was higher for the HR[ill] 
group, and a negative weight means the weighted average was higher for HR[symp] 
group. Therefore, the discrimination map should not be interpreted as a standard 
statistical parametric map resulting from a mass-univariate statistical test to find 
group differences, and no local inferences should be made based on the SVM 
weights.Note: features correspond to GM volume measures in the AAL-defined 












5.4.3. Voxel-based morphometry 
 
For comparative purposes, I conducted a two-sample T-test in SPM5, contrasting the 
17 subjects of the HR[ill] and the 17 subjects in the HR[symp]. Group differences 
were assessed using the General Linear Model (GLM) on the smoothed normalized 
GM segments, examining results at different statistical thresholds. No significant 
volumetric between-group differences in GM were observed when conventional 
VBM analysis was employed using a family error rate (FWE) of p<0.05. Even at a p-
value uncorrected for multiple comparisons of p<0.001, very few differences in very 
small clusters could be detected using VBM. Lowering the VBM threshold to p<0.05 
(uncorrected) resulted in significant differences in voxels covering the right fusiform, 
left cerebellum, right inferior and left superior parietal lobe, right supramarginal 
gyrus, left superior temporal and frontal lobe, the left anterior cingulate and the right 
precentral gyrus. The output maps for the VBM analysis are presented in Figure 5.4. 
Overall, the regions identified in the VBM analysis were similar to regions identified 
by our classification method. 
 
                                                  
Figure 5.4 Results of the conventional VBM analysis for the smoothed and 





5.4.4 Additional analyses 
 
For purposes of clarity and thoroughness, classification results for other analyses that 
were conducted are reported in this section. Initially, I have ran the nested LOO-CV 
SVM-RFE method without performing any sampling and by using the total group of 
57 HR[symp] subjects against the 17 HR[ill] subjects. A classification bias towards 
the majority class (i.e. HR[symp] group) was observed, in that the classifier assigned 
every subject as HR[symp], resulting in very good specificity of 92% but zero 
sensitivity (accuracy: 70.3%), both when MRI data were used alone and when they 
were combined with baseline RISC and RAVLT variables.  
The class imbalance issue arises when there are more data examples in one class and 
fewer occurrences in the other class and it is a problem widely known in the machine 
learning community (Japkowicz 2000, Japkowicz & Stephen 2002, He & Garcia 
2009) and more recently acknowledged in imaging-based studies that employ 
machine learning methods (Dubey et al. 2014, Cuingnet et al. 2011, Yuan et al., 
2012). Class imbalance problems can be addressed in two ways (see Japkowicz & 
Stephen, 2002 for a review on this matter). 
One way is to adopt a model-based approach where the classifier is assigned 
different misclassification costs for each class. In soft-margin SVM, there is a C 
penalty that controls the trade-off between maximizing the margin and reducing 
misclassification error. By assigning a higher misclassification cost for the minority 
class instances than the majority class instances, the effect of class imbalance could 
be reduced. However, in the EHRS dataset, I did not observe any change in the 
behaviour of the classifier and again our model ended up with very good specificity 
(90-95%) and zero sensitivity. Other studies have also reported that this so-called 
reweighting (or cost sensitive learning) approach did not produce satisfactory results 
(Duchesnay et al. 2011,1).  
 




Using a data-driven approach is another way to deal with class imbalance issues. 
That is, one can either choose to oversample the minority class or undersample the 
majority class (He & Garcia 2009, van Hulse et al. 2007) or do both (Akbani et al. 
2004). Oversampling techniques randomly replicate (with or without replacement) 
existing (training) data from the minority class until a class balance is reached 
(Japkowicz 2000, Japkowicz and Stephen 2002). There are also oversampling 
techniques that generate new, synthetic data by randomly interpolating pairs of 
nearest-neighbour data instances (Chawla et al. 2002).  
The alternative to oversampling is undersampling. The simplest version is the 
random undersampling technique that removes data samples from the majority class 
at random until the classes are balanced. Cluster-based sampling techniques aim to 
group together data instances in the majority class into a number of clusters that is 
equal to the size of the minority class (Yen and Lee 2006). Here, I chose to perform 
random undersampling because it was the most straightforward technique to alleviate 
the class imbalance and also because other authors and imaging labs working with 
data in schizophrenia have done this before (Koutsouleris et al. 2009b, Koutsouleris 
et al. 2010, Koutsouleris et al. 2015b, Mourao-Miranda et al. 2012a). 
Therefore, an equal number of HR[symp] subjects was selected to match the 17 
individuals in the HR[ill] group and the rest of the HR[symp] subjects were used to 
further validate the classifier. 
 
Additionally, in order to alleviate the difference in RISC scores across the equally-
sized groups, I have repeatedly and randomly downsampled the original HR[symp] 
group that consisted of 57 subjects to groups of 17 subjects in order to match the 
HR[ill] group and repeated the entire SVM-RFE procedure 100 times in order to 
create a distribution of accuracies. In the case where only the neuroanatomical 
imformation in the AAL-defined brain regions were considered, the method 
produced an average accuracy of 98.1% (sensitivity/specificity: 96.9%/99.4%, p-
value= 0.09) whereas when baseline neuroanatomical information was combined 
with baseline RISC and RAVLT variables the mean accuracy of the method across 




To the best of the author’s knowledge, this is the first study to evaluate the feasibility 
of an individualised prediction of psychosis in a cohort of subjects at HR for familial 
reasons, by combining baseline neuroanatomical data with baseline schizotypal and 
neurocognitive features using a multivariate pattern recognition technique. The high 
accuracy of our classification method was obtained by leave-one-out cross-validation 
which provides an almost unbiased estimate of the generalizability. The diagnostic 
performance of our classifier was further validated by reliably classifying the 
HR[symp]test subjects. 
The neuroanatomical pattern associated with transition to schizophrenia was quite 
extensive and was primarily associated with grey matter abnormalities covering the 
frontal, orbito-frontal and occipital lobe regions bilaterally as well as parts of the 
superior and medial temporal lobe regions, the left inferior parietal lobe and parts of 
the cerebellum, in keeping with previous VBM studies that reported similar baseline 
neuroanatomical reductions in converters versus non-converters located in inferior 
frontal and superior temporal brain regions (Fusar-Poli et al. 2011), the hippocampus, 
cingulate cortex and the cerebellum (Smieskova et al. 2010, Pantelis et al. 2003, Job 
et al. 2006).  
A conventional VBM analysis failed to detect any significant between-group 
differences after performing corrections for multiple comparisons. At a lower VBM 
threshold of p<0.05, uncorrected for multiple comparisons, however, differences in 
brain regions similar to those detected by the SVM classifier were found.  
However, as stated before, VBM analyses consider each voxel as a spatially 
independent unit and cannot provide predictive value at a single-subject level. On the 
contrary, SVM is a multivariate technique that examines voxels jointly and considers 
inter-regional correlations. Therefore, individual brain regions may display high 
discriminatory power either because there is a large difference in volume between the 
study groups in that region or this region is highly inter-correlated with regions in a 
spatially distributed network of brain regions. For this reason, the neuroanatomical 
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maps derived by SVM should be interpreted as a spatially distributed pattern where 
all its constituent parts (i.e. brain regions) contribute to the classification rather than 
making assumptions on effects locally.  
The neuroanatomical pattern that distinguished the HR[ill] from the HR[symp] 
individuals was similar in both analyses, i.e. when only baseline MRI data were 
considered and when those were combined with baseline RISC and RAVLT 
measures (see Figure 5.2). The neuroanatomical pattern in both cases consisted of a 
deficit network, consisting of brain regions that were relatively reduced in HR[ill] 
compared to the HR[symp] subjects and an excess network, including brain regions 
of relative increased volume in the HR[ill] compared to the HR[symp] group. 
Roughly, the neuroanatomical pattern consisted of regions showing relative GM 
volume reductions in the left fusiform gyrus, the right orbitofrontal and superior 
medial frontal lobe, left fronto-parietal lobe, right superior temporal lobe and parts of 
the cerebellum in keeping with other studies in this area (Koutsouleris et al. 2009b, 
Koutsouleris et al. 2012a). 
Interestingly, GM volume increases were observed in HR[ill] subjects compared to 
the HR[symp] in the orbital frontal lobe, left temporal and inferior parietal lobe 
regions and the parts of the cerebellum, in line with previous studies (Borgwardt et al. 
2007b, Koutsouleris et al. 2015b). Similar networks of relative increases were also 
reported in other SVM-based studies in high-risk or first-episode cohorts 
(Koutsouleris et al. 2009b, Koutsouleris et al. 2012a, Mourao-Miranda et al. 2012a). 
While, this may be counter-intuitive in that the aim is to predict schizophrenia, a 
condition characterised by generalised and multifocal reductions in GM volume, it 
partly represents the common use of linear multivariate modelling techniques to 
produce weights of spatially distributed relative differences which reflect relative 
changes in index regions and their networks. In addition, however, there is evidence 
that large brains and constituent parts may predict schizophrenia in populations at 
high risk (Fusar-Poli et al. 2011). 
Both baseline RISC and RAVLT scores were significant in discriminating between 
the study groups, in keeping with previous studies both in the EHRS literature 
(Johnstone et al. 2005) and elsewhere (Riecher-Rossler et al. 2006, Lencz et al. 2006, 
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Koutsouleris et al. 2012b) that have shown that neurocognitive variables are good 
predictors of transition to schizophrenia and could possibly enhance the predictive 
power of multivariate models (Lencz et al. 2006, Riecher-Rossler et al. 2009). 
Our classification performance using structural MRI data alone is also comparable to 
findings of previous studies that applied neuroanatomical-based SVM to predict 
transition in clinical HR cohorts (Koutsouleris et al. 2009b, Koutsouleris et al. 
2012a). Koutsouleris and collegues (2009b) built a SVM classifier upon structural 
MRI data of individuals in early and late at-risk mental state of psychosis subjects 
and a group of matched HC and evaluated its performance by distinguishing MRI 
data derived from baseline scans of ARMS subjects who developed schizophrenia 
(ARMS-T), those who did not (ARMS-NT) and a second matched group of HC. All 
three-group and pairwise classifiers achieved classification performance above 80%. 
In the most critical in terms of clinical utility, their ARMS-T vs ARMS-NT classifier 
achieved an accuracy of 82% (sensitivity, specificity: 83%, 80%), whereas in a 
follow-up study, the same group (Koutsouleris et al. 2012a) validated their previous 
analysis by classifying an independent cohort of HC, ARMS-T and ARMS-NT and 
achieved an improved accuracy in the ARMS-T vs ARMS-NT pairwise classifier 
(84%). Both studies described ARMS as help-seeking subjects, at imminent risk of 
psychosis on the basis that they exhibited prodromal symptoms. In contrast, our data 
sample was acquired from a neuroleptic-naive cohort of subjects at familial HR for 
the disorder that also presented significantly lower transition rates (nearly 13%) than 
the ARMS cohorts with transition rates of up to 43% (Koutsouleris et al. 2012a).  
Moreover, the study presented here is different from the other studies in the field in 
that it consists of a homogenous sample of individuas who have familial risk rather 
than samples of subjects with mixed clinical and familial factors. Finally, in this 
study the aim is to predict later diagnosis of schizophrenia rather than a single 
psychotic episode as it is the case in clinical-based HR studies. 
Certain limitations have to be considered in this study. Firstly, the sample size is 
modest and therefore our findings should be interpreted with caution. The modest 
sample size can be, however, explained by the already known difficulties in 
recruiting subjects in HR studies and the relatively low overall conversion rate (13%) 
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of our familial HR sample. Therefore, replication of our findings using a larger 
independent cohort is required in order to further validate our learning model. In 
addition, it is not clear whether this predictive performance could generalise to other 
HR cohorts. The HR group studied here was recruited on the basis of familial history, 
thus representing a genetic risk for the disorder, but also had psychotic symptoms. It 
is, thus, unclear whether our findings could generalise to HR cohorts, presented to 
clinical services with psychotic symptoms or other disturbances. 
Another limitation pertaining to the generalizability of our results in the context of 
machine learning methods in general, and of SVM in particular here is the choice of 
cross-validation. While the leave-one-out cross-validation employed in this study has 
a low bias, it suffers, however, from high variance. More specifically, the LOO 
cross-validation underestimates the variance, due to the repeated use of subsets of the 
data in most training sets. Of course this is an issue for most cross-validation 
schemes, although other validation techniques such as splitting the original data in 
half, for training and testing purposes, or choosing a 10-fold cross-validation might 
produce better estimates of the actual performance of the classifier. However, in light 
of the small dataset here I reckoned that the LOO-CV would be the most suited 
choice for the evaluation of the classifier’s performance. 
Finally, I acknowledge the limitation for having performed a random sampling of the 
data set. From the original group of 57 HR[symp] subjects, I randomly selected 17 
individuals to match and contrast the 17 HR[ill] subjects. I acknowledge that in case 
of undersampling, removing examples (data instances) from the majority class might 
cause the classifier to miss out important clues and characteristics pertaining to the 
majority class. However, studies in this field have shown that class imbalance issues 
can significantly impact the classifier’s performance (Dubey et al. 2014, Duchesnay 
et al. 2011) and highlighted the importance of having balanced groups of data (Wei 
& Dunbrack 2013). In particular, Wei and Dunbrack (2013) highlighted the 
importance of training the classifier using balanced training sets, regardless of having 
a balanced representation of the groups in the test set. Two other neuroimaging 
studies in schizophrenia that employ SVM have used similar sampling approaches 
(Koutsouleris et al. 2015b, Mourao-Miranda et al. 2012a). Specifically, in 
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Koutsouleris and colleagues (2015b), 33 out of 40 ARMS-NT individuals were 
selected to contrast the 33 ARMS-T subjects, and the rest 7 ARMS-NT were used to 
further validate their classifier. In Mourao-Miranda and colleagues (2012a), 91 HC 
individuals were initially recruited, but in the SVM analysis only 28 of them were 


























We examined the diagnostic performance of a SVM classifier in predicting transition 
to schizophrenia using baseline MRI scans and also reported the neuroanatomical 
pattern that differentiated the HR subjects that developed schizophrenia from a 
matched group of HR subjects that did not develop the disorder but manifested 
psychotic symptoms.  Additionally, it was shown that the integration of 
neuroanatomical data with measures of neurocognitive functioning and schizotypal 
cognition can not only improve predictive performance but can indicate which 
features contribute to that prediction and hence are in some way discriminative of a 
pattern that predicts a later diagnosis of schizophrenia. To date, there are few 
schizophrenia studies that have examined the diagnostic performance of combining 
data from various sources into a unified learning model. Taking into consideration 
that clinical, neurocognitive and neuroimaging assessments can individually describe 
a different aspect of pathology in schizophrenia, I believe that integration of these 
variables into a single learning framework might provide a clearer view of the 





























































As discussed in Chapter 1, the onset of schizophrenia is usually preceded by a 
prodromal phase, which is often characterized by sub-threshold psychotic symptoms 
and a progressive decline in functioning. Individuals presenting with these 
characteristics are considered at an increased risk for developing schizophrenia and 
other psychosis-related disorders for clinical reasons and are identified as ultra-high 
risk (UHR) or at an at-risk mental state (ARMS) for psychosis. 
The aim of this chapter is to examine whether our previous findings can be replicated 
by evaluating the diagnostic performance of our MRI-based classifier in predicting 
disease conversion in subjects with an ARMS that were drawn from the FePsy 







Over the past 20 years, a focus on the early intervention of psychotic disorders has 
emerged. Initially early intervention strategies were aimed at helping individuals in 
their first episodes of psychosis (Perkins et al. 2005, Marshall et al. 2005) while over 
the last few years, early recognition and intervention has moved towards individuals 
exhibiting prodromal signs of the disorder. Early detection and intervention centers, 
such as the Personal Assessment and Crisis Evaluation (PACE) in Australia (Yung et 
al. 1996), the Prevention through Risk Identification, Management and Education 
(PRIME) in the US (McGlashan et al. 2003), and the Outreach and Support in South 
London (OASIS) clinic (Fusar-Poli et al. 2013b), have been set up worldwide 
(Edwards et al. 2005) with the aim of providing case management and provisional 
treatment for individuals presenting with subthreshold psychotic symptoms. 
Converging evidence suggests that early intervention in psychosis may substantially 
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ameliorate response to treatment and outcome for the illness (McGorry 2002a), and 
delay (McGorry et al. 2002b) or even prevent disease onset (Amminger et al. 2010, 
Phillips et al. 2007). However the question of whether and at what stage early 
intervention is indicated is still a matter of much debate (Riecher-Rossler et al. 
2006). A number of ethical considerations and implications arise from treating 
patients early (Candilis 2003), including the possibility of treating false positive 
cases (people who will not later develop psychosis but are falsely labelled as such), 
which may result in unnecessary distress and exposure to putative side effects of 
medication, not to mention the associated stigma for the individuals and their 
families. The best approach would, therefore, lie in the establishment of an accurate 
risk assessment system that would quantify the risk of psychosis while reducing the 
rate of false positives.  
As has been discussed before, schizophrenia and other psychosis-related disorders 
may begin many years before the emergence of frank, clear symptoms, with 
nonspecific changes, perceptual alterations and often sub-threshold psychotic 
disturbances. Although individuals that exhibit prodromal symptoms have an 
increased risk of developing psychosis, not all individuals do so. Thus in order to 
delineate the prodrome of psychosis from a state of heightened risk the ultra-high-
risk (UHR) or the at-risk mental state (ARMS) or clinical high-risk (HR) paradigms 
have been introduced.  
Operationalized criteria for identifying subjects with an ARMS or at clinical HR 
have been developed. These criteria are based on a combination of trait and state risk 
factors inferred as increasing psychosis risk and have been used to categorize 
individuals in the following three subgroups based on the criteria identified by the 
PACE clinic (Yung et al. 2008, Yung et al. 1998). The first two subgroups specify 
state risk factors and are defined by the presence of either transient psychotic 
symptoms, called brief limited intermittent psychotic symptoms (BLIPS) or sub-
threshold, attenuated psychotic symptoms (APS). The third subgroup involves trait 
and state risk factors that are operationally defined by a significant reduction in 
functioning plus either an affected relative with psychosis or a pre-existing 
schizotypal personality disorder. Within the concept of basic symptoms as defined by 
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the Bonn group, additional prodromal criteria have also been identified that describe 
a set of subtle and subjective changes in affect, thinking, emotional and cognitive 
processing and perceptual disturbances of the self and the world (Huber and Gross 
1989, Schultze-Lutter 2009). It should be noted that individuals defined with an 
ARMS or at clinical HR are all help seeking which effectively means this is part of 
the criteria. 
With regards transition rates to psychosis, significant variation has been observed 
across sites studying UHR samples, with recent studies reporting a decline in the risk 
of transition (Yung et al. 2007). Transition rates are an important tool for evaluating 
the predictive validity of the operationalized clinical HR criteria and thus certifying 
the need for preventative intervention. A recent meta-analysis of studies employing 
clinical HR samples estimated that 18% of HR individuals develop psychosis after 6 
months of follow-up, reaching 36% after 3 years (Fusar-Poli et al. 2012b) with the 
age of participants, any received treatment and the diagnostic criteria used being the 
most influential moderators of transition risk. 
Valid and reliable prognostic markers are, thus, needed in order to improve 
prediction of conversion rates and reduce false positive rates. A series of putative 
biomarkers have been recently identified, suggesting that the at-risk mental state is 
characterized by abnormalities in the neurocognitive domain (Lencz et al. 2006, 
Fusar-Poli et al. 2012a, Koutsouleris et al. 2012b) and alterations at the 
neuroanatomical (Fusar-Poli et al. 2011, Smieskova et al. 2010) and neurofunctional 
level (Fusar-Poli et al. 2007). As it has been discussed in previous chapters, 
conversion to psychosis in ARMS subjects has been associated with reduced grey 
matter volume in the prefrontal and temporal cortices and other subcortical brain 
structures (Smieskova et al. 2010). 
Recently, multivariate pattern recognition approaches, including SVM methodology, 
have provided important leads towards the translation of neuroimaging findings into 
clinical practice, by taking into account inter-regional correlations between brain 
regions and working at the single-subject level (Orru et al. 2012). These methods 
may thus provide the means for an individualized risk assessment and prediction of 
psychosis conversion and possibly deliver increased sensitivity and specificity, both 
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of which are essential for informing individualized prevention care.  
Previous machine learning studies have shown that a neuroanatomical-based 
prediction of psychosis is possible at the single-subject level (Koutsouleris et al. 
2009b), providing diagnostic accuracy up to 84% (Koutsouleris et al. 2012a). The 
high diagnostic performance of our MRI-based SVM classifier presented in Chapter 
5 brings additional evidence to the feasibility of an individualized prediction of 
psychosis. Here, I aimed to examine whether our SVM approach for the prediction of 
psychosis conversion could be replicated in a second, independent cohort of subjects 








The subjects included in this analysis were part of a large prospective, early 
psychosis study; the FePsy (Fruherkennung von Psychosen) study. Details regarding 
recruitment and screening procedures have been described in Chapter 4, section 4.1.2 
and can also been found in previous studies  (Riecher-Rossler et al. 2006, Riecher-
Rossler et al. 2007). All aspects of the study were approved by the Ethics Committee 
of Basel, Switzerland, and written informed consent was obtained for each 
participant before study inclusion. 
Briefly, 37 subjects were identified as having an at-risk mental state (ARMS) for 
psychosis using a screening procedure based on the Basel Screening Instrument for 
Psychosis (BSIP), the Brief Psychiatric Rating Scale (BPRS- see Table 6.1) and the 
Scale for the Assessment of Negative Symptoms (SANS). These assessments were 
used in order to elicit psychopathology and rate (pre-) psychotic and negative 
symptoms.  
The BPRS consists of 24 items and is one of the most frequently used research 
instruments for evaluating psychopathological symptoms in patients with 
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schizophrenia (Velligan et al. 2005). Although there is no widely accepted factorial 
structure of the BPRS, several authors have proposed a four factorial structure. In the 
FePsy bibliography, the BPRS total score was used along with four subscales (i.e., 
Depression/Anxiety, Psychosis/Thought Disturbance, Negative Symptoms, and 
Activation) derived from the factorial structure of Velligan et al. 2005. (See 
Appendix IV, Table 1 and Figure 1 for a description of the BPRS subscores and the 
4-factor analysis based on Velligan et al. 2005). 
Additionally, the SANS assessment consists of 19 items, which are grouped into five 
domains or factors (Affective flattening, Alogia, Avolition-apathy, Anhedonia- 
Asociality, and Inattention). In the present study, the SANS global score and the five 
original subscales were used. 
Matched groups of healthy controls and first-episode patients were recruited as well. 
In short, 22 healthy controls (HC) with no history of any psychiatric disorder and 25 
first-episode (FE) individuals, who met operationalized criteria for first-episode 
psychosis as described in Yung et al. 1998, were recruited. The ARMS, FE and HC 
individuals did not differ significantly with respect to sex, ethnicity, handedness and 
current and previous alcohol use (Riecher-Rossler et al. 2007).  
Individuals were followed up at monthly intervals during the first year, at 3-month 
intervals during the second and the third year and annually thereafter until transition 
to psychosis was established or until the end of the follow-up period (in 2007). In 
general, all ARMS subjects were followed up for over 4 years during which they 
were also offered supportive counseling and clinical management. 
Transition to psychosis was operationally defined by meeting criteria described in 
Yung et al. 1998 (Table 6.1) and further determined by a diagnostic interview using 
the ICD-10 criteria at the time of transition. Follow-up information for 2 ARMS 
subjects was not available. In this regard, 16 of the 35 ARMS individuals with 
retained follow-up information made a transition to psychosis (denoted as ARMS-T 
subjects) and 19 did not convert (ARMS-NT). Seven out of the 35 ARMS 
participants have received low doses of antipsychotic medication, some time prior to 
study inclusion (2 participants on olanzapine, 2 chlorprothixene and 3 risperidone), 
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all for less than 3 weeks. 
 
 
Table 6.1 ARMS inclusion and transition to psychosis criteria. 
ARMS Inclusion criteria 
 
Inclusion into the study was based on the BSIP checklist and required one or more of 
the following: 
1. Attenuated psychotic-like symptoms: at least several times a week and for 
more than 1 week duration (a score of 2 or 3 on the Brief Psychiatric Rating 
Scale (BPRS) 
2. Brief limited intermittent psychotic symptoms (BLIPS): scores of 4 or above 
on the hallucination item or 5 or above on the unusual thought content, 
suspiciousness, or conceptual disorganization items of the BPRS, with each 
symptom lasting less than 1 week before resolving spontaneously 
3. Genetic risk: a first or second-degree relative with a psychotic disorder plus 
at least 2 further risk factors for or indicators of beginning psychosis 
according to the BSIP screening instrument. 
 
Criteria for transition to psychosis 
1. BPRS scores of 4 or above on the hallucination item or scores of 5 or above 
on the unusual thought content, suspiciousness, or conceptual disorganization 
items  
2. Symptoms had to occur daily and persist for more than 1 week. 





Here, I am mainly interested in contrasting the ARMS group that converted to 




Table 6.2 Socio-demographic and clinical information of the 2 study groups 
 
           Study Groups   
  
ARMS-T ARMS-NT          P  
    Socio-demographic variables    
N 16 19  
Mean age at baseline, y (sd) 26.8 (6.5) 23.9 (6.2)        nsa 
Sex (male), n (%) 11 (69) 10 (52)        nsb 
Educational level          nsb 
     <9 y, n (%) 3 8  
        9-11 y, n (%) 7 7  
         12-13 y, n (%) 5 2  
      <13 y, n (%) 1 2  
Mean verbal IQ (MWT-B) (sd) 109.6 (12.6) 107.3(15.4)       nsa 
Cannabis use at baseline         nsb 
none 10 11  
rarely 1 1  
   Several times/month 0 2  
  Several times/week 4 0  
daily 1 5  
Antipsychotics before entry, n (%) 6 (37.5) 1 (5)      <0.05b 
Antidepressants at baseline, n (%) 7 (44) 5 (26)        nsb 
Family History          nsb 
No relative 15 16  
One 1rst degree 1 2  
One 2nd degree 0 1  
   Clinical variables    
Mean BPRS total score at baseline (sd) 42.3(10.6) 35.7 (7.1)        nsc 
Mean SANS global score at         
baseline (sd) 9.75(5.8) 7.7(4.2)        nsc 
Mean interval between MRI and 
disease onset, d (sd)              306.3 (318.3) na  
 
 
ARMS-T: at-risk mental state individuals that later developed psychosis; ARMS-NT: 
at-risk mental state subjects that did not make a transition. BPRS: the Brief 
Psychiatric Rating Scale; SANS: the Scale for the Assessment of Negative 
Symptoms. Verbal IQ Mehrfach-Wortshatztest-B 
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 a Student’s T-test.  b Fisher’s exact test. c  Mann-Whitney U-test 
 
 
6.3.2 Image Acquisition and Preprocessing 
 
Subjects were scanned using a Siemens (Erlangen, Germany) Magnetom Vision 1.5 
T scanner at the University Hospital Basel. Head movement was minimized by foam 
padding and velcro straps across the forehead and chin. A three-dimensional 
volumetric spoiled gradient recalled echo sequence generated 176 contiguous, 1 mm 
thick sagittal slices. Imaging parameters were: time-to-echo, 4 msec; time-to-
repetition, 9.7 msec; flip angle, 12; matrix size, 200 x 256; field of view, 25.6 x 25.6 
cm matrix; voxel dimensions, 1.28 x 1 x 1 mm. 
Before preprocessing, all structural MRI scans were converted from a sagittal 
orientation (i.e. slices were recorded from right to left) to an axial orientation (Figure 




















Figure 6.1 FSL view of the orientation of MRI scans. (a) Initially MRI scans had a 
sagittal orientation (b) and then an axial orientation. 
 
 
Study-specific templates and customized prior probability maps were constructed 
using data from all subjects in the Basel study (i.e. 35 ARMS, 22 HC and 25 FE). A 
detailed description of their creation can be found in Chapter 4, section 4.2.2. 
After inspection for gross abnormalities and artefacts, the baseline MRI scans 
entered a pre-processing pipeline in SPM5 (Wellcome department of Cognitive 
Neurology, London, UK).  A detailed description of the steps followed can be found 




6.3.3 Multivariate Pattern Classification Analysis 
 
6.3.3.1 Support Vector Machine 
 As described in detail in previous chapters, a linear SVM classifier was 
implemented for the analysis of baseline neuroanatomical data derived from the 
FePsy study. The steps in the pattern classification analysis were exactly the same as 
the ones described in Chapter 5, section 5.3.4. 
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6.3.3.2 Feature Extraction 
This step is identical to the one described in Chapter 5 section 5.3.4.2. The result of 
this step is a 116-length vector consisting of GM density values. Again features were 
scaled to [0 1] before entering as input into the linear classifier. 
 
6.3.3.3 Feature Selection 
The rationale and implementation of the feature selection step is identical to what 
was presented and described in Chapters 5 and 4. Briefly, a recursive feature 
elimination (RFE) technique was implemented, which was embedded in a nested 
leave-one-out cross-validation (LOO-CV) in order to increase diagnostic 
performance of the classifier. A graphical representation of the SVM-RFE and the 
nested LOO-CV adjusted for the ARMS groups of the FePsy study is given below 
(Figure 6.2).  
A discrimination map was again generated based on the weight coefficients of the 
features that were selected by the RFE method (Figure 6.3). The discrimination map 
consists of brain regions that according to the RFE methodology are the most 
distinctive in the classification task and provides a spatial representation of the 
decision function in that every feature contributes with a certain weight to this 
function (or hyperplane). The SVM weight vector is a linear combination or 
weighted average of the support vectors and defines the decision boundary. The 
weight vector is therefore a spatial representation of the decision boundary. Every 
feature contributes with a certain weight to the decision boundary or classification 
function. Given a positive and a negative class (+1=ARMS-T; -1=ARMS-NT group), 
a positive weight means the weighted average in that region was higher for the 
ARMS-T group, and a negative weight means the weighted average was higher for 
ARMS-NT group. Since the SVM classifier is multivariate by nature, it should be 








Figure 6.2 Representation of the nested LOO-CV SMV-RFE method. We employed 
a nested LOO-CV where I repeatedly excluded one subject to comprise the testing 
set and the remaining subjects were again repeatedly repartitioned in an internal 
validation loop where one subject was left out for validation and the rest formed the 
internal training group. In this loop, RFE was repeatedly performed and the mean 
accuracy on the validation group at each elimination level was recorded until all 
features were removed. The feature set that produced the maximum accuracy on the 
validation set was selected and applied to the testing set of the outer testing loop. 






6.3.3.4 Permutation testing 
Again, permutation testing was performed in order to derive a p value for the 
accuracy of our classifier. A detailed description of the permutation testing was given 






6.4.1. Socio-demographic and clinical findings 
 
The rate of conversion to psychosis was 45.7 % in this ARMS sample of 35 subjects. 
The mean interval between the baseline scan and disease conversion scan was 306 
days (median: 263, range: 25–1137 days). There were no significant differences 
between converters and non-converters to psychosis with regards to age, gender, 
educational level, verbal IQ, cannabis use at study entry, baseline global BPRS and 
SANS scores (Table 6.2). There were also no significant differences on any BPRS 
and SANS subscales between converters and non-converters, with the exception of 
the SANS subscale of Asociality/Anhedonia that was significantly different between 
the two groups (Mann-Whitney U-test= 92.5, p-value= 0.048), in keeping with 
previous findings in the FePsy study literature (Riecher-Rossler et al. 2007), where 
among the individuals who later developed psychosis, anhedonia and asociality were 
more frequent than in individuals who did not convert.  Additionally, the two groups 
significantly differed in terms of antipsychotic medication before study entry, with 6 
subjects that later developed psychosis (ARMS-T) and 1 subject later categorized as 
AMRS-NT having been taking neuroleptics some time before study inclusion (Table 
6.2). In fact, it could be that the difference in the SANS Asociality/Anhedonia scale 
reflects the higher use of antipsychotic medication in the ARMS-T group rather than 
any difference in psychopathology or symptom severity, with the consequent 
invalidation of the claim that this subscale can serve as a predictor of subsequent 
transition to psychosis since it might be not an aspect in the disease course itself but 
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merely a byproduct of medication. Previous studies have specifically linked the 
clinical ratings of anhedonia to antipsychotic medication through dopamine 
antagonism (Gard et al. 2008, Erhart et al. 2006). 
 
 
6.4.2 SVM classification analysis 
 
The application of our LOO-CV SVM-RFE methodology to baseline structural MRI 
data of the ARMS groups achieved 74% accuracy in predicting conversion to 
psychosis (Table 6.3). Six out of 16 subjects in the ARMS-T group were wrongly 
classified as ARMS-NT, while only 3 out of 19 subjects in the ARMS-NT group 
were incorrectly labeled as ARMS-T (sensitivity/specificity: 63%/84%; PPV/NPV: 
77%/73%; permutation test p=0.002).  
The likelihood ratio of a positive test result was LR+= 3.95 (Table 6.3), meaning that 
a positive prognostic test in a given ARMS subject would increase the probability of 
a subsequent transition to psychosis from 45.7% to 77% (posttest 
probability=posttest odds/posttest odds+1, posttest odds=pretest odds*LR+).  
The misclassified ARMS-NT subjects did not significantly differ from the correctly 
classified ARMS-NT in any of the socio-demographic or clinical variables (Table 
6.4). On the contrary, the misclassified ARMS-T subjects were significantly different 
from the correctly classified ARMS-T individuals in terms of gender distribution and 
use of antipsychotic medication before study entry (Table 6.4). This may partly 
explain the lower sensitivity of the SVM-RFE method, since the ARMS-T group 
consisted of a more inhomogenous group of individuals with regards to anti-
psychotic medication, which in turn might have hindered the identification of a 
common neuroanatomical signature across subjects in this group. The effect of 
antipsychotic medication in brain structure is widely acknowledged by the scientific 
community (Smieskova et al. 2009, Navari and Dazzan 2009), and might have 
played a major role in the classification of the ARMS subjects here, despite the fact 
the exposure was before study entry and relatively brief. 
In addition, while no other significant differences with regards to the rest of the 
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demographic and clinical variables (SANS global score and its subscales, BPRS total 
score and subscales of Psychosis/Thought Disturbance, Negative Symptoms, and 
Activation) were observed, the scores in the Depression/Anxiety subscale of the 
BPRS scale were significantly different between the correctly and misclassified 
ARMS-T subjects (p-value <0.05, Mann-Whitney U-test), again possibly suggesting 
the existence of a cluster of individuals within the ARMS-T group that exhibited 
more severe psychotic symptoms which may have warranted the use of anti-
psychotic medication, which in turn may have impacted on brain structure.  
 
Table 6.3 Classification performance  





































The diagnostic performance was evaluated by means of sensitivity (Sens), specificity (Spec), 
balanced accuracy (BAC), false positive rate (FPR) and positive/negative predictive value 




The spatially distributed network that discriminated between the two groups was 
quite extensive and consisted of GM abnormalities in a spatially distributed network 
covering all four lobes and the cerebellum. Table 6.5 presents the most 
discriminating regions in the classification task, namely the brain regions with the 
highest (absolute) weight value that contributed relatively higher to the decision 
function. Specifically, the regions that contributed more in the classification of the 
ARMS-T subjects included the cerebellum, parts of the superior temporal pole 
bilaterally, the right anterior cingulate cortex, the right superior medial frontal and 
left orbitofrontal cortex and the insula bilaterally, whereas regions with a higher 
weighted average for the ARMS-NT group consisted of the right inferior parietal 
lobe, right medial temporal lobe, the right orbitofrontal cortex and the left pallidum 
(Table 6.5).  
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Table 6.4 Misclassification analysis 
 
























      
N 6 10  3 16  
Mean age at baseline, y (sd) 29.2(9) 25.4(4.5) nsa 24.8(7.2) 23.8(6.2) nsa 
Sex (male), n (%) 2(33) 9(90) <0.05
b 
1 (33) 9(56) nsb 
Educational level   nsc   nsc 
<9 y, n (%) 1 2  2 6  
9-11 y, n (%) 2 5  1 6  
12-13 y, n (%) 2 3  0 2  
<13 y, n (%) 1 0  0 2  
Cannabis use at baseline   nsc   nsc 
none 4 6  2 9  
rarely 1 0  0 1  
Several times/month 0 0  1 1  
Several times/week 1 3  0 0  
daily 0 1  0 5  
Antipsychotics before entry 5 1 <0.05
b 
0 1 nsb 
Anti-depressants at baseline 3 4 nsb 2 3 nsb 
Clinical variables       
Mean BPRS total score at 
baseline (sd) 
45.7(11.5) 40.2(10.2) nsc 38.3(12.9) 37.5(6.2) nsc 
Mean BPRS 
Depression/Anxiety score (sd) 
12(3.5) 7.5 (2.3) <0.05
c 
7.3(2.1) 7.9 (3) nsc 
Mean SANS global score at 
baseline (sd) 
9.7(7.7) 9.8(4.8) nsc 10.3(5) 6.3(4.7) nsc 
Mean interval between MRI 
and disease onset, d (sd) 
427.5(483.6) 245.7(215.3) nsa    
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A discrimination map showing the spatial pattern by which the groups differ is also 
illustrated in Figure 6.3. We emphasize that this spatially distributed pattern should 







Figure 6.3 Discrimination maps for the classification of ARMS-T vs ARMS-NT. 
The colours represent the weight of each feature in the classification function (the red scale 
represents positive weights and the blue scale represents negative weights). The SVM weight 
vector is a linear combination or weighted average of the support vectors and defines the 
decision boundary. The weight vector is therefore a spatial representation of the decision 
boundary. Every feature contributes with a certain weight to the decision boundary or 
classification function. Given a positive and a negative class (+1=ARMS-T; -1=ARMS-NT 
group), a positive weight means the weighted average in that region was higher for the 
ARMS-T group, and a negative weight means the weighted average was higher for ARMS-
NT group. Note: features correspond to GM volume measures in the AAL-defined brain 




Finally, I used the EHRS dataset (the 17 HR[ill] and the 17-matched HR[symp] 
subjects described in Chapter 5) to train the SVM-RFE method and then tested it 
using the FePsy data in order to examine the performance of the method  when using 
one HR sample and testing on another. A 65.7% accuracy (sensitivity/specificity: 
37.5%/89.5%) was observed, with the method failing to classify above chance levels 
the ARMS subjects that later developed psychosis. This low sensitivity and 
classification performance might imply a divergent neuroanatomical pattern between 
clinical and familial HR cohorts. Additionally, it should be borne in mind that the 
HR[ill] sample in the EHRS was labelled as such on the basis of a later diagnosis of 
schizophrenia (according to PSE criteria and later the ICD-10), whereas the ARMS-
T subjects in the FePsy study were characterised as making a transition to psychosis, 
not schizophrenia per se, based on transition criteria of the PACE clinic (see Table 
 140 













Negative weights   
Cerebellum   
 Cerebellum_Crus2_R -0.0128 
 Cerebellum_3_R -0.0194 
 Cerebellum_4_5_R -0.0207 
 Cerebellum_6_L -0.0127 
 Cerebellum_7b_R -0.0146 
 Cerebellum_10_L -0.0247 
 Vermis_8 -0.0147 
Temporal   
 Temporal_Sup_R -0.0067 
 Temporal_Pole_Sup_L -0.0084 
 Temporal_Mid_L -0.0075 
Frontal   
 Frontal_Sup_L -0.0197 
 Frontal_Sup_Orb_L -0.0166 
 Frontal_Mid_R -0.0089 
 Frontal_Inf_Tri_R -0.0106 
 Frontal_Sup_Medial_R -0.0084 
 Frontal_Med_Orb_R -0.0098 
 Precentral_R -0.0176 
Parietal   
 Postcentral_R -0.0102 
 Paracentral_Lobule_R -0.012 
Limbic   
 Cingulum_Ant_R -0.017 
 Cingulum_Post_L -0.0081 
Basal ganglia   
 Putamen_R -0.0172 
Perisylvian   
 Insula_L -0.0134 
 Insula_R -0.0206 
Positive weights   
Temporal   
 Temporal_Mid_R 0.0069 
 Heschl_R 0.0069 
Frontal   
 Frontal_Sup_Orb_R 0.0101 
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Parietal   
 Parietal_Inf_R 0.0137 
Basal ganglia   
 Pallidum_L 0.0072 
 
Ant, anterior; Crus, crust; Inf, inferior; L, left hemisphere; Mid, middle; Med, medial; Orb, 
orbital; Post, posterior; R, right hemisphere; Sup, superior; w, weight vector of 
corresponding features in the classification process. Note: The SVM weight vector is a linear 
combination or weighted average of the support vectors and defines the decision boundary. 
The weight vector is therefore a spatial representation of the decision boundary. Every 
feature contributes with a certain weight to the decision boundary or classification function. 
Given a positive and a negative class (+1=ARMS-T; -1=ARMS-NT group), a positive 
weight means the weighted average in that voxel was higher for the ARMS-T group, and a 






6.4.3. Voxel-based morphometry analysis 
 
No significant GM volume differences between the ARMS-T and ARMS-NT 
subjects were observed when conventional VBM analysis was employed using a 
family error rate (FWE) of p<0.05. At p<0.001 uncorrected for multiple comparisons, 
volumetric differences were observed within the cerebellum, left and right medial 
and inferior frontal lobe regions and the medial temporal lobe bilaterally. To 
compare our SVM results with those from the VBM analysis, I lowered the p-value 
at p<0.05 (uncorrected) and observed widespread volumetric between-group 
differences in the superior and medial temporal lobe bilaterally, the inferior and 
superior frontal lobe bilaterally, the left superior and inferior parietal lobe, the 










Figure 6.4 Results of the conventional VBM analysis for the smoothed and 






The present findings replicate the previous ones in that MRI-based classification 
methods were able to predict transition to psychosis in subjects at high clinical risk 
for developing the disorder using neuroanatomical data at study inclusion. The SVM-
RFE classifier achieved 74% accuracy in classifying ARMS-T against ARMS-NT 
subjects.  
The neuroanatomical decision function that discriminated the two groups was 
associated with GM abnormalities relying on a distributed network of regions 
covering most cortical and sub-cortical brain structures and the cerebellum. Our 
present findings agree with findings from a recent voxel-based meta-analysis that 
reported GM volume reductions in subjects that convert to psychosis in the insular 
and superior temporal lobe cortices (Fusar-Poli et al. 2011) and also with previous 
VBM findings on the same dataset (Borgardt et al. 2007a).  
Few significant between-group GM differences were detected using conventional 
VBM analysis at a p<0.001 but none was detected when correction for multiple 
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comparisons was performed. At a lower statistical threshold, p<0.05, significant GM 
volume differences were detected in a network of regions that was largely in 
agreement with the one identified by the SVM method. However, as stated in 
previous chapters, an SVM-based classification analysis is advantageous to the 
conventional VBM analyses in that it can detect subtle neuroanatomical alterations 
that are not confined to a circumscribed set of few brain regions but rather span 
across a complex network of inter-correlated brain structures that jointly produce a 
maximal degree of separation between converters and non-converters. The finding of 
complex and widespread networks of differentiation that can be achieved through 
SVM is in line with current disconnection hypotheses of schizophrenia (Friston 
1999) that state that the pathology of schizophrenia is associated with highly 
distributed brain alterations across a number of cortical and subcortical structures.  
Despite the fact that the classification accuracy observed in this investigation is 
significant, it is, however, lower than the accuracy observed in the familial high-risk 
group (Chapter 5) and that reported in another recent study that similarly 
implemented a MRI-based SVM classifier from the same ARMS cohort 
(Koutsouleris et al. 2012a). 
In the study conducted by Koutsouleris and co-workers, (2012a), their MRI-based 
SVM classifier achieved 84.2% accuracy in the critical ARMS-T versus ARMS-NT 
analysis, with only 2 ARMS-T subjects being misclassified as ARMS-NT and 4 
ARMS-NT subjects wrongly labeled as ARMS-T (sensitivity/specificity: 
81%/87.5%). However, their implementation of the SVM classifier was completely 
different and relied upon the construction of nonlinear SVM ensembles that 
incorporated feature selection, model training and predictive learning wrapped 
together in a repeated nested cross-validation framework. Ensemble learning 
approaches are usually selected on the basis that they can achieve higher predictive 
performance than single classifiers, by combining multiple weak learning models 
that decide upon the classification of a new instance through majority voting (Polikar 
2006). In contrast, our approach is based on a simpler SVM framework that is known 
to provide better generalization performance whereas more complex models tend to 
overfit the data in that they provide great training accuracy (small error on the 
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training set) but often misclassify unknown data instances (higher test error). 
Compared to the diagnostic performance of our classifier in the genetic high-risk 
cohort of the EHRS, the classification performance in the ARMS groups of the 
FePsy study was notably lower, contrary to what would be expected since the ARMS 
groups represent help-seeking individuals, most of whom already manifest putative 
transient and/or sub-threshold psychotic symptoms. Interestingly, 5 out of the 6 
ARMS-T subjects that were misclassified received anti-psychotic medication some 
time before study inclusion (Table 6.4) while the other misclassified ARMS-T 
subject was prescribed tranquilizers (Lorazepam). Many studies have reported the 
effect of antipsychotic medication on grey matter volume in the direction of 
significant regional reductions (Navari and Dazzan 2009, Smieskova et al. 2009), 
thus possibly suggesting a neuroanatomical heterogeneity expressed with divergent 
pathophysiological trajectories between subjects receiving and subjects not receiving 
any anti-psychotic treatment. Additionally, the misclassified ARMS-T subjects had 
significantly higher scores on the Depression/Anxiety subscale of the BPRS list 
compared to the correctly classified ARMS-T individuals (p<0.05; Table 6.4) while 
there were no differences between the groups in terms of anti-depressant medication 
use at baseline (Table 6.4). Depressive symptomatology is a common feature in 
populations at high clinical risk for psychosis (Hafner et al. 2005). However it 
remains unclear whether these symptoms are reflected at the neuroanatomical level 
and thus possibly suggest a depressive sub-syndrome in sub-threshold psychosis or 
the established state in the same way as positive, negative and disorganized sub-
syndromes in schizophrenia could be discerned (Nenadic et al. 2010, Zhang et al. 
2015). 
Despite the lower diagnostic performance, our MRI-based classifier managed to 
increase the diagnostic certainty from 45.7% to 77% in case of a positive test result, 
suggesting that an MRI-based pattern classification system could, with refinement, 
become a useful part of a multi-step diagnostic procedure that would reliably 
quantify the risk for conversion to psychosis and inform appropriate care and 
treatment strategies.  
Certain limitations of this study have to be considered. Again the sample size in this 
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investigation is small. The rate of transition to psychosis amounted to nearly 46%, 
which is generally in keeping with other clinically at-risk cohorts (Koutsouleris et al. 
2009b, Yung et al. 2003, Klosterkotter et al. 2001). However, it is not clear how the 
classifier would perform if presented with an ARMS cohort with significantly lower 
conversion rates. Finally, the administration of antipsychotic and antidepressant 
medication might have confounded our results, despite the fact that any drug 

























In this investigation, previous classification results have been replicated, with current 
findings suggesting that an early diagnosis of psychosis based on neuroanatomical-
based classifier is feasible for cohorts present with sub-threshold disturbances and 
early signs of psychosis. It remains to be elucidated, however, whether these findings 
can be generalized to larger cohorts of at-risk samples that are recruited using 
different assessment criteria and scanned on different scanners and/or using different 

























Towards the identification of neuroimaging-based biomarkers for the 



























In the previous chapters, the diagnostic performance of SVM in predicting 
conversion to schizophrenia and psychosis-related disorders was examined in cohorts 
at high-risk either due to familial or clinical reasons. However, it remains unclear if it 
is feasible to detect biomarkers that generalize across research sites, where 
differences in the recruitment process, MRI scan acquisition and pre-processing 
might exist.  
In this chapter, I attempt a preliminary study of the feasibility of identifying MRI-
based biomarkers that can predict transition to psychosis among high-risk individuals 
recruited at two different research centers, using different assessment criteria and 





Neuroanatomical pattern classification has recently facilitated the identification of 
imaging biomarkers for the diagnosis and early prediction of various 
neuropsychiatric disorders such as Alzheimer’s disease (Fan et al. 2008b, Kloppel et 
al. 2008b) and schizophrenia (Davatzikos et al. 2005b, Koutsouleris et al. 2009b), 
and has pointed in the direction of a translational application of MRI into clinical 
practice by evaluating distinct patterns of differentiation at the single-subject level.  
An important step in the investigation of the clinical utility of imaging biomarkers is 
to test their generalization performance in independent cohorts (Phillips et al. 2006). 
This, however, implies a need for large data sets, which is not always possible in 
single-site, MRI studies. A limited number of studies in schizophrenia have 
attempted to build classification models based on sets of patients and matched groups 
of control subjects and then tested their models’ performance by classifying 
independent samples of patients and controls (Kawasaki et al. 2007, Nieuwenhuis et 
al. 2012, Schnack et al. 2014), and reported good levels of classification accuracy 
ranging from 70% to 90%. For a detailed review of these studies, please see Chapter 
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3.  
The requirement for large data sets could be satisfied by pooling data across different 
research sites with the added benefit of both increasing statistical power and possibly 
enhancing the classifier’s performance by virtue of the higher number of samples 
used for training (Kloppel et al. 2009, Nieuwenhuis et al. 2012, Abdulkadir et al. 
2011). An increasing number of multi-center studies aim to combine data acquired 
on different sites (Mwangi et al. 2012, Koutsouleris et al. 2015b), despite any 
methodological and between-scanner variability (Stonnington et al. 2008, Moorhead 
et al. 2009, Suckling et al. 2011, Abdulkadir et al. 2011).  
In the first and, to date, only MRI-based cross-center study of prediction of 
psychosis, Koutsouleris and co-workers combined together two independent cohorts 
of subjects with an ARMS, recruited and scanned at two different early recognition 
centers, and examined the prognostic accuracy of their MRI-based SVM ensemble 
classifier (Koutsouleris et al. 2015b). Their classification system achieved a balanced 
accuracy of 80.3% in the pooled data set (sensitivity=75.8%, specificity=84.8%) and 
also enabled a risk staging procedure through additional Kaplan-Meier survival 
analyses that simultaneously quantified the risk of an ARMS subject in making a 
transition to psychosis along with an estimation of the time to transition.  
In this investigation, our aim is to pool baseline neuroanatomical data from high-risk 
subjects drawn from the Edinburgh High Risk Study (EHRS) and the Basel FePsy 
study and examine the feasibility of identifying MRI-based biomarkers across the 
two high-risk cohorts. No other study to date has attempted to pool genetic and 
clinical HR cohorts together and examine the existence of a neuroanatomical 
signature that exists across differently ascertained HR populations.  
 
Differences between the two high risk paradigms begin at the very conceptualization 
of the underlying risk to psychosis. As described in previous chapters, 
genetic/familial high-risk cohorts include monozygotic and dizygotic twins 
discordant for schizophrenia and/or individuals with first- or second-degree relatives 
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affected with the disease. On the other hand, clinical HR populations are presented 
with different aspects of sub-threshold positive and negative symptomatology and/or 
possibly mild cognitive and functioning impairments. The identification of clinical 
HR individuals presents some variability that is attributed to each early detection 
center and the corresponding high-risk criteria used (Smieskova et al. 2010). As a 
result, rates of transition to psychosis vary significantly across sites (Fusar-Poli et al. 
2012, Fusar-Poli et al. 2013a), with some reporting as many as 35% of subjects at 
clinical HR developing psychosis (Pantelis et al. 2003, Yung et al. 2004). It has been 
estimated that the average transition rate for clinical HR cohorts amounts to 30% 
whereas only 10% on average of the subjects identified at high-risk for genetic or 
familial reasons develops psychosis (Smieskova et al. 2013).  
Despite their discrepancies, several aspects of familial and clinical HR paradigms 
overlap, as several individuals identified at a clinical HR have a family history of 
psychosis and many individuals at familial HR often exhibit pre-psychotic 
symptoms. In addition, at a structural level clinical and familial HR cohorts seem to 
share similar volumetric abnormalities (Bois et al. 2015), especially in prefrontal, 
medial temporal and limbic regions, with individuals showing prodromal psychotic 
signs exhibiting additional insular and caudate structural deficits (Smieskova et al. 
2013). For a detailed discussion of structural MRI studies in HR cohorts see Chapter 
2 (section 2.3.2). 
In the following section, a comparative presentation of the familial and clinical HR 












The pooled dataset consists of 69 individuals at high risk for psychosis that were 
recruited in the prospective studies conducted independently in Edinburgh, at the 
Department of Psychiatry (Edinburgh High Risk Study, EHRS) and at the University 
of Basel, Switzerland (‘Fruherkennung von Psychosen’, FePsy). A detailed 
description of the studies was given in the three previous chapters. All aspects of the 
studies were reviewed and approved by the appropriate local ethics committees at 
both research sites. 
Briefly, a familial high-risk paradigm was employed in the EHRS, in that high-risk 
individuals were identified and included in the study on the basis of having one or 
more first- or second-degree relatives affected with schizophrenia. All high-risk 
subjects had no previous history of psychosis or any neuropsychiatric disorder and 
none of those subjects received anti-psychotic medication at any point during the 
study or until they fulfilled operational criteria for schizophrenia (when appropriate 
clinical management was advised and follow-up assessments were discontinued). As 
described in detail in chapter 4 (sub-section 4.1.1.1), psychopathology in HR subjects 
in the EHRS was assessed using the PSE criteria (Wing et al. 1974), which allowed 
the classification of subjects into a 5-scale system based on their PSE subscores 
(Johnstone et al. 2000). For facilitating future studies in the data set, the HR subjects 
were stratified based on the presence/absence of (psychotic) symptoms according to 
the PSE as:  fully or partially held psychotic symptoms (scores 2 and 3) HR[symp], 
absence of psychotic symptoms, (scores 0 and 1) HR[well]  or diagnosis of 
schizophrenia (score 4), HR[ill]. 
Additionally, all HR subjects underwent baseline and follow-up assessments to 
evaluate neuropsychological measures (such as verbal learning and memory- RAVL 
test, executive function, general IQ etc.), schizotypal cognitions via the Rust 
Inventory of Schizotypal cognitions (RISC) and the Structured Interview for 
Schizotypy (SIS; Miller et al. 2002b) and elicit psychopathological indices and 
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transition to schizophrenia again using the PSE. For a detailed review of the clinical 
and neuropsychological assessments see Johnstone et al. 2002a, Johnstone et al. 2005 
and Byrne et al. 2003. (Additionally, a detailed description of the PSE and the RISC 
items can be found in Chapter 4 (subsection 4.1.1.1) and Chapter 5 (5.3.2) 
accordingly). 
From those HR subjects who provided complete clinical assessments and had a MRI 
scan, 17 were diagnosed at follow-up with schizophrenia (after an average of 929 
days, SD=138) based on the ICD-10. Among the rest, 57 subjects experienced 
psychotic symptoms (HR[symp]) but these were too transient or mild to warrant a 
diagnosis of schizophrenia (Johnstone et al. 2000). The rest of the HR subjects 
remained well, with no symptoms (HR[well]). In this investigation I was mainly 
interested in the HR[ill] and HR[symp] groups. Again, as seen in Chapter 5, 17 out 
of the 57 HR[symp] subjects were used to train the classifier, and the remaining 40 
HR[symp] were used to further validate the classification performance.  
In the FePsy study, ARMS (at-risk mental state) subjects were identified on the basis 
of the ultra-high risk criteria of the well-established Personal Assessment and Crisis 
Evaluation (PACE) definitions (Yung et al. 2003). Briefly, ARMS inclusion required 
(a) Attenuated Positive Symptoms, and/or (b) Brief Limited Intermittent Psychotic 
Symptoms (both fulfilling specific time criteria) or (c) decline in global functioning 
combined with family history of psychosis. Additionally prodromal symptoms were 
assessed with the Brief Psychiatric Rating Scale (BPRS) and the Scale for the 
Assessment of Negative Symptoms (SANS). For a detailed description of the ARMS 
inclusion, exclusion and assessment criteria see Chapter 4 (subsection 4.1.2.1) and/or 
Chapter 6 (subsection 6.3.1 and Table 6.1). 
All subjects were followed up for over 4 years and were offered supportive 
counselling. Transition to psychosis was monitored monthly in the first year and 
quarterly thereafter and was based on the BPRS severity thresholds (see sections 
4.1.2.1 and Table 6.1) and further corroborated using the ICD-10. Based on these 
criteria, the ARMS groups were subdivided in 16 subjects with transition to 
psychosis (ARMS-T; diagnosed after an average of 306.3 days, SD= 318.3) and 19 
non-conversion individuals (ARMS-NT). Six out of the 16 ARMS-T subjects were 
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administered low doses of antipsychotic medication for behavioural control before 
study inclusion (1 participant on olanzapine, 2 Chlorprothixene and 3 risperidone) 
and also 1 ARMS-NT subject was on olanzapine before study entry. 
As it is clear from the descriptions above, the high-risk groups recruited across the 
two research sites differed in terms of criteria for inclusion and with regards to the 
assessment of psychopathological indices to elicit psychotic symptomatology and 
transition to schizophrenia and psychosis-related disorders. A comparative 
presentation of the PSE and BPRS items to be used as a reference is given in 
Appendix II (Table 1). Despite the fact that several aspects of psychopathology 
might overlap between the two assessments tools (such as the depression, anxiety or 
hallucinations items), severity ratings are appraised differently. For example the PSE 
scores symptoms as absent, partially/transiently or definitely present. As detailed 
previously (Johnstone et al. 2000), partial delusions and/or transient hallucinations 
were regarded as psychotic symptoms and correspond to the clinical high risk 
literature category of attenuated and/or brief psychotic symptoms. Non-psychotic 
symptoms are not, however, recorded in the same way between the two assessment 
tools nor is functional decline assessed in the PSE. Therefore, a direct comparison 
between the clinical and familial high-risk assessment criteria is not feasible- other 
than that similar positive psychotic symptomatology was assessed.  
To build the MRI-based classifier, 33 converters (17 HR[ill] and 16 ARMS-T) were 
pooled together to contrast 36 nonconverters (17 HR[symp] and 19 ARMS-NT), 
while the data of the remaining 40 HR[symp] subjects were used to further validate 





















Table 7.1 Demographic and clinical details 
 
ARMS-T:  subjects at a clinical risk mental state that later developed psychosis; ARMS-NT: at-risk 
mental state subjects that did not make a transition. HR[ill]: individuals at high familial risk who 
developed schizophrenia during follow-up period. HR[symp]: individuals at high familial risk who 
remained well but developed psychotic symptoms during follow-up period. Fisher’s exact tests were 
performed for variables of sex, handedness, cannabis use, antipsychotic medication and family 
history, and standard T-test was applied to the rest.  
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7.3.2 Image Acquisition and Preprocessing 
 
Baseline scanning in the EHRS was performed on a 1.0 T Siemens Magnetom 
scanner (Erlangen, Germany) and for the FePsy study on a 1.5 Siemens Magnetom 
Vision scanner (Erlangen, Germany). Details of the acquisition protocols can be 
found in Chapters 5 (section 5.3.3) for the EHRS scans and Chapter 6 (section 6.3.2) 
for the FePsy images.  
The preprocessing pipeline has been extensively described in Chapter 4, section 4.2 
and additional information has been given in relevant sections of chapters 5 and 6. 
The same pre-processing steps (and specific parameters) were applied to all brain 
images of the EHRS and the FePsy study. 
 
 
7.3.4 Multivariate Pattern Classification Analysis 
 





7.4.1 Socio-demographic findings 
There were no significant differences between subjects in the study groups, within 
each research center, in terms of age, sex, handedness, cannabis use and family 
history (Table 7.1). However, as noted before, the use of antipsychotic medication 
was significantly different for converters and nonconverters in the Basel, FePsy 
study and thus in the pooled data set. Additionally, there were no significant ‘center 
* group’ effects for any of these variables, whereas there was a significant main 
effect of research center on age (factorial ANOVA; F=21.135, df=2, p=0.0001). 
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7.4.2 SVM classification analysis 
In the pooled dataset (N=69), the MRI-based system correctly classified converters 
and nonconverters with a balanced accuracy of 82.6% (Table 7.2, 
sensitivity/specificity: 79%/86%, permutation test p<0.001). From the independent 
set of 40 non-converters, HR[symp] subjects only 9 were wrongly classified as 
converters (specificity: 77.5, FPR: 22.5%). Thus the classification performance on 
the entire dataset (N=109) attained a balanced accuracy of 80.7% 
(sensitivity/specificity: 79%/82%). Given a pre-test probability of 30.3% (equals to 
transition rate: 33/109), the positive/negative likelihood rations of 4.3/0.26 indicate 
that an HR person with a positive/negative MRI finding will have a post-test 
probability of 65%/35% of developing psychosis.  
 
Both the misclassified HR-T and the misclassified HR-NT subjects did not 
significantly differ from the correctly classified HR-T and HR-NT individuals 
accordingly, on any of the socio-demographic variables (Table 7.3). Direct 
comparison on any clinical, neurocognitive and behavioural variables was not, 
however, possible becaure the EHRS and FePsy data samples did not use the same 
assessments to record these variables. 
 
Table 7.2 Classification performance 













Pooled 26 31 5 7 78.8 86.1 82.6 13.9 83.8 81.5 5.67/0.25 
HR[symp]test 0 31 9 0 - 77.5 - 22.5 - 100 - 
Overall 26 62 14 7 78.8 81.5 80.7 18.4 65 89.8 4.26/0.26 
The diagnostic performance was evaluated by means of sensitivity (Sens), specificity 
(Spec), balanced accuracy (BAC), false positive rate (FPR) and positive/negative 
predictive value (PPV/NPV). LR+ was also calculated as sensitivity/1-specificity and 





The neuroanatomical decision function discriminating between converters and non-
converters involved an extensive spatial network of regions covering the superior 
temporal lobe bilaterally, the left middle temporal lobe, the prefrontal cortex 
bilaterally covering superior, orbitofrontal and ventromedial lobe structures and 
extending to inferior frontal and insular structures. These brain regions included the 
regions that contributed higher in the classification of the HR-T subjects; that is the 
regions that were more important in classifying HR-T instead of HR-NT subjects. In 
contrast, the regions contributing more to the classification of the HR-NT group 
consisted of regions covering the left inferior temporal lobe extending to perisylvian 
structures (right temporal pole, left insula), the right superior orbital and left medial 
orbital frontal lobe, the right inferior parietal lobe covering the right precuneus, the 
left parahippocampal gyrus and the vermal lobule 6 and cerebellar lobule 9. Table 



















Table 7.3 Missclassification analysis 
 













 HR-T → 
 HR-NT 








      
N 7 26  5 32  




























1 5 nsb 
 
0 1 nsb 
 
Cannabis at baseline   ns
b 
 
  nsb 
 
none 3 15  2 22  
occassionally 2 4  2 7  
frequent/severe 2 7  1 3  
Family History   ns
b 
 
  nsb 
 
no relative 2 13  3 13  
one 1rst degree 0 1  0 3  
one 2nd degree 3 4  1 5  
one 1rst & 2nd degree 2 5  0 9  
two 2nd degree 0 3  1 2  
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Table 7.4 List of the most discriminative regions in the classification of the pooled 
dataset 
 
Lobe Region/Hemisphere w 
Negative weights 





























































































Ant, anterior; Crus, crust; Inf, inferior; L, left hemisphere; Mid, middle; Med, medial; Orb, 
orbital; R, right hemisphere; Sup, superior; w, weight vector of corresponding features in the 
classification process. Note: The SVM weight vector is a linear combination or weighted 
average of the support vectors and defines the decision boundary. The weight vector is 
therefore a spatial representation of the decision boundary. Every feature contributes with a 
certain weight to the decision boundary or classification function. Given a positive and a 
negative class (+1=HR-T; -1=HR-NT group), a positive weight means the weighted average 
in that voxel was higher for the HR-T group, and a negative weight means the weighted 





Figure 7.1 Discrimination maps for the classification of the pooled dataset of HR-T 
vs HR-NT. The colours represent the weight of each feature in the classification 
function (the red scale represents positive weights and the blue scale represents 
negative weights). The SVM weight vector is a linear combination or weighted 
average of the support vectors and defines the decision boundary. The weight vector 
is therefore a spatial representation of the decision boundary. Every feature 
contributes with a certain weight to the decision boundary or classification function. 
Given a positive and a negative class (+1= HR-T; -1=HR-NT group), a positive 
weight means the weighted average in that region was higher for the HR-T group, 
and a negative weight means the weighted average was higher for HR-NT group. 
Note: features correspond to GM volume measures in the AAL-defined brain 







This chapter provides a preliminary analysis and evidence for the identification of an 
MRI-based signature that exists across two independent HR populations that were 
recruited using different ascertainment criteria and scanned with different scanners 
and imaging protocols. The predictive power of the classifier was tested using cross-
validation and by assigning an independent group of 40 HR subjects that did not 
develop schizophrenia at follow-up (HR-NT). The generalization performance of the 
SVM-RFE classifier in the entire dataset attained a balanced accuracy of 81%. 
The neuroanatomical pattern that distinguished between HR-T and HR-NT subjects 
revealed a network of spatially distributed regions in the brain cortex, covering 
prefrontal, temporal and cerebellar structures and extending to a few subcortical 
areas such as the caudate nucleus bilaterally that had a higher weighted average for 
the HR-T grop. These results are in keeping with previous findings that were 
described in Chapter 5 and 6, and other imaging studies reporting similar GM 
abnormalities (Fusar-Poli et al. 2011, Smieskova et al. 2013, Koutsouleris et al. 
2009b, Koutsouleris et al. 2011, Koutsouleris et al. 2015b). In contrast, regions 
contributing more to the classification of the HR-NT group included the orbito-
frontal, inferior temporal, parietal lobe and parts of the cerebellum, partly in line with 
previous studies (Borgwardt et al. 2007b, Koutsouleris et al. 2015b). 
To date, only one study has attempted to pool data together from subjects that were 
recruited and scanned at two different early psychosis centers and achieved 
comparable classification accuracy (Koutsouleris et al. 2015b). In this study, 
Koutsouleris and colleagues combined together data from 73 ARMS subjects that 
were recruited in two independent early recognition sites, in Munich and in Basel. 
Contrary to our case, both research sites employed the same ultra-high-risk inclusion 
criteria corresponding to the PACE definitions and transition to psychosis was 
corroborated using similar severity threshold scales, corresponding to criteria by 
Yung et al. 1998. Participants in both sites were scanned using the same platform, 
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Siemens Magnetom Vision 1.5T scanners, but different imaging parameters were 
selected at each site. No calibration of the scanners was performed but a voxel-level 
adjustment of the group-level means was performed post-hoc in order to correct for 
inter-scanner differences.  
Despite the same rationale for pooling data together, a direct comparison of the 
present study with the study conducted by Koutsouleris and colleagues is not feasible 
due to the differences in the recruitment, assessment, scanning and pre-processing 
procedures of the study samples and the different implementation of the SVM 
methodology. However, both studies achieved comparable diagnostic accuracies in 
classifying HR-T against HR-NT subjects and share similar networks of relative GM 
volume reductions and increases of the neuroanatomical predictor, as discussed 
above. 
There are numerous advantages to pooling data from multiple sites together. The 
opportunity to accrue larger numbers of subjects allows the introduction of a 
phenotypic and demographic diversity of the cohort under study along with the 
possible inclusion of more rare cases of the diseased population. Additionally, the 
increased number of subjects allows for increased sensitivity and may also ensure 
enough statistical power to detect more subtle effects or even subgroups within a 
cohort that might share structural commonalities. All these combined may result in a 
deeper understanding of the under-study disease. 
On the other hand, combining data from multiple research sites may introduce some 
variability. In the case where the data are, also, acquired from different MRI scanners 
and imaging protocols, potential scanner-related confounds may be introduced that in 
turn may affect the integrity and robustness of the results and make their 
interpretation difficult.  
Variations in image intensity and the resulting necessity for standardizing intensity 
values is not a problem specific to multisite studies but also applies to longitudinal 
and/or cross-sectional studies where scanner drifts or upgrades may impact on the 
quality of the scans. Nonuniformity in the imaging sequence and the RF field coils 
and differences in the positioning of the patient inside the scanner can introduce 
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variability in image intensity with any given scanner. Intensity inhomogeneity, 
partial volume effects and variability in image quality (as measured with the signal to 
noise ratio) can in turn impact on segmentation (Clark et al. 2006, Acosta-Cabronero 
et al. 2008, Li et al. 2005, Klauschen et al. 2009). However, some of this variation 
can be attenuated with the use of segmentation processes that do not solely rely on 
voxel intensities but also incorporate spatial information and correction for bias field 
inhomogeneity as well. In this analysis, the use of the unified segmentation method 
in SPM5, which involves fitting spatial priors to the image and bias-field corrections 
to account for differences in head shape and positioning, ensured the robustness of 
the segmentation and the consistency of image intensities. 
A significant limitation of this preliminary analysis is, however, the potential 
introduction of confounds that might have occurred as a result of systematic 
between-site differences, which might have confounded ‘actual’ disease-related 
effects. As briefly described above, calibration and/or intensity standardization 
processes can be performed either before or after scanning in order to effectively 
account for scanner-related intensity differences.  
Briefly, test-retest and calibration studies can ensure the reliability and comparability 
of multi-center scans by repeatedly scanning a number of participants in all sites and 
measuring a phantom (van Haren et al. 2003, Jovovich et al. 2006, Tofts 1998). It is 
not, however, always possible to have a (sub) group of participants available to be 
scanned in all research sites in order to measure reliability between scans and ensure 
consistency and quality control.  
Post-scanning procedures are, thus, more attractive and include histogram matching 
or histogram standardization techniques that are designed to bring MRI intensities to 
a common scale, where similar intensities would have similar tissue meaning. 
Histogram matching methods try to match the subjects’ histogram to a standard 
(reference) histogram by either matching the intensities in a series of chosen 
landmarks (Nuyl & Udupa 1999) or by minimizing some information criteria (Jager 
& Hornegger 2009). Recently, advanced histogram matching techniques that employ 
spatial correspondence (between the image volumes and the reference image) and 
nonlinear transformations to account for the ‘nonlinear’ impact of the MRI scanner 
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to voxel intensities have also been proposed (Robitaille et al. 2012). (A thorough 
presentation and comparison of histogram matching techniques is out of the scope of 
the present thesis and the interested reader is referred to the listed citations for more 
information.) 
In the analysis presented here, the initial intention was to scale the image intensities 
between the two datasets, the EHRS and FePsy sMRI data, by matching their 
intensity histograms (that is by finding a correspondence between the study 
histograms), after pre-processing was completed and right before the smoothed, 
normalized GM maps entered the SVM analysis. However, the most reasonable thing 
to do would be to perform any histogram matching or equalization technique over the 
whole brain in order to account for the variance for all tissue types because from the 
segmentation step and downwards each preprocessing procedure depends on some 
point on voxel intensity values. Due to time constraints, however, this was not 
feasible in the present study and after observing similarities in the intensity 
histograms of the smoothed, normilized GM segments in the EHRS and FePsy 
datasets, it was decided to proceed with the data pooling without any scaling or 
matching. Please see Appendix V for the histograms of the two data sets and a more 
detailed discussion as to why scaling was not performed. 
It is not yet certain if and how scanner-related heterogeneity can impact on the 
performance of pattern recognition classifiers and specifically SVM. Previous SVM-
based studies have reported an improvement in performance when larger numbers of 
subjects were used for training (Kloppel et al. 2008, Abdulakadir et al. 2011), despite 
any scanner differences. However, these studies used structural MRI data acquired 
from different scanners for training and testing purposes separately and did not pool 
them together. It is, therefore, not clear how scanner-related differences affect the 
diagnostic performance and the robustness of the results, if data pooling and no 
correction for scanner effects is employed. 
 
Apart from scanner-related differences, differences in the assessments of 
psychopathology and transition criteria may have confounded the present analysis. It 
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is important to note that subjects in the FePsy study had significantly shorter 
transition intervals than subjects in the EHRS. This is, however, reflective of the at-
risk mental state, in which individuals already exhibit putative transient or sub-
threshold symptoms and are considered at an imminent risk for conversion. In 
contrast, HR-T subjects from the EHRS sample had their baseline MRI scan 
approximately 2.5 years before making a transition to psychosis. This heterogeneity 
in conversion times, from the baseline MRI scanning until conversion to psychosis 
was corroborated, might have been reflected at the neuroanatomical level, with 
divergent pathophysiological processes leading up to psychosis, which may have in 
turn confounded our results. Additionally, the heterogeneity in terms of 
psychopathological indices, clinical and neurocognitive measures did not enable the 
integration of sMRI data with other variables to test the classification performance. 
Further, one cannot exclude the possibility that the use of anti-psychotic medication 






This preliminary investigation extends previous investigation of the EHRS sample by 
pooling these data and those of the FePsy study, which involved high-risk subjects, 
identified employing different high-risk paradigms, recruited using different 
assessment criteria and examined using different MRI scanners. We provide 
preliminary evidence for the identification of a sMRI biomarker that exists across 
independent high-risk cohorts. However, additional work is required in order to 
clarify the effect of center-related differences on the diagnostic procedure and more 
























































































The work described in this thesis has used machine learning in order to examine the 
diagnostic performance of MRI data, neurocognitive and behavioural variables in 
predicting transition to psychosis in individuals at high risk for the disorder. The 
classification method implemented in this thesis was used to classify subjects 
identified as high-risk for psychosis either due to familial or clinical reasons, derived 
from the Edinburgh High Risk Study and the Basel, FePsy study accordingly. 
As described in Chapter 1, schizophrenia is a highly complex brain disorder, 
expressed with heterogeneous constellations of symptoms across patients and 
variable clinical course. Diagnosis of schizophrenia is almost entirely based on self-
reported symptomatology and observation of behavioural signs and therefore is 
subject to the patient’s ability to collaborate and the clinical expertise and experience 
of the clinician. To avoid bias in clinical decision-making, objective biomarkers are 
pressingly needed in order to aid diagnosis of schizophrenia and support treatment 
strategies where needed. The potential of a biomarker, however, depends on its 
predictive capacity at the individual level (Phillips et al. 2006). 
It is likely that schizophrenia is associated with neuroanatomical abnormalities that 
are not limited to a circumscribed set of a few brain regions but rather span over 
spatially distributed, and possibly intercorrelated, networks. Structural MRI studies 
have significantly improved our understanding of the underlying pathophysiology of 
the disorder by systematically studying group-level differences in brain tissue but 
nevertheless have so far failed at impacting clinical practice. Mass-univariate 
methods of analyses such as voxel-based morphometry (VBM) examine differences 
between the experimental groups in localized brain regions at a mean-level. More 
recently used pattern recognition-based methods on the other hand, look for 
differences in patterns within the brain that could optimally discriminate between the 
study groups and furthermore have the potential of making inferences about new 
subjects at a subject-level. Additionally, by virtue of their multivariate nature, 
machine learning approaches allow the integration of localized differences over the 
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whole brain that would otherwise be too weak or too variable to detect if considered 
on their own.   
As described in detail in previous chapters, subjects presented with a family history 
of schizophrenia and/or sub-threshold, prodromal psychotic symptoms are 
considered at an elevated risk for developing schizophrenia and psychosis-related 
disorders. Studies examining subjects at high risk for developing schizophrenia and 
psychosis-related disorders have stimulated two HR paradigms; i) the clinical and ii) 
the genetic or familial high risk for psychosis. Magnetic resonance imaging-based 
studies of high-risk for psychosis cohorts can serve to delineate the extent to which 
neuroanatomical alterations form part of an underlying risk and vulnerability for the 
development of psychosis or are exclusively associated with the illness itself. To 
further disentangle the issue of whether (and which) specific volumetric 
abnormalities are associated with transition to psychosis, researchers have begun to 
study those HR subjects that develop psychosis against those HR individuals that do 
not. Identifying the neuroanatomical alterations that could distinguish at baseline 
those HR subjects that will later develop psychosis from those who will not would 
have significant implications in further elucidating the pathophysiology and 
aetiology of the disorder and possibly providing an opportunity for early intervention 
with the aim of either relieving the disorder’s symptom burden or even prevent its 
onset.  
 
This thesis, therefore, aimed: 
1) To identify neuroanatomical-based markers of transition to schizophrenia in 
subjects at high familial risk drawn from the Edinburgh High Risk Study, 
using an implementation of Support Vector Machine that includes subject 
classification and also feature selection. In addition to baseline structural MRI 
data, other neurocognitive and behavioural variables were included in the 
analysis with the aim of testing the classification performance and also 
replicating previous findings in the EHRS literature (Johnstone et al. 2005) 
 170 
 
2) To examine whether the implemented classifier would be able to generalize 
to clinical high-risk cohorts, using neuroanatomical data from the FePsy 
study. 
3) And finally, in a strictly exploratory and preliminary analysis, to test the 
diagnostic performance of our classifier by pooling structural MRI data of the 
EHRS and the FePsy study together, despite the differences in the 
recruitment, assessment and imaging procedures.  
 
To do that, data from high-risk subjects that later developed psychosis were 
contrasted to data from high-risk subjects that did not make the transition. There 
were no specific hypotheses regarding the number or which brain regions would 
constitute the pattern based on which the study groups would be optimally 
discriminated against, although it was expected that previous findings, especially in 
the EHRS literature might be replicated. However, based on the multivariate nature 
of the SVM method, I expected that a host of brain structures across cortical and 
subcortical brain areas would comprise the decision function in each case. 
Additionally, it was hypothesized that the diagnostic ability of the classification 
method would be increased when baseline clinical and behavioural variables were 
combined with neuroanatomical data of the EHRS groups.  
 
Since each of the previous chapters contains a separate discussion section, the aim of 
this chapter is to offer a more general discussion integrating the main results from the 
previous chapters, discussing limitations of the current findings, and suggesting 







Figure 8.1 Potential clinical setting for a pattern recognition-based system. 
Neuroimaging data are acquired in a specialized clinic and can then be combined 
with other variables. The classifier is trained using these features. Gold standard 
diagnosis can be established using i.e. post-mortem histological examination. The 
trained classifier could then, be used at another research/clinical site and applied 
directly to a new patient. Classification results for this patient could then be fed to 





8.2 Summary of main results 
 
In this thesis, it was shown that it is feasible to make an early diagnosis of psychosis, 
and primarily schizophrenia, in subjects at high clinical or familial risk for the 
disorder, by using baseline neuroanatomical information. The findings presented here 
suggest that high-risk subjects who will subsequently develop psychosis may be 
already distinguished at baseline, above chance levels and before illness onset, from 
those high-risk individuals that will not make the transition. The diagnostic 
performance of the SVM classifier was mainly tested using cross-validation and also 
by classifying an independent cohort of high-risk subjects drawn from the EHRS 
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study that did not develop schizophrenia, yet showed psychotic symptoms at follow-
up (Results sections of Chapters 5 and 7). Table 8.1 provides a comparison of the 
classification results from the experimental Chapters 5, 6 and 7 of this thesis. 
The high-dimensional discriminative morphological map comparing high risk 
subjects with later transition to psychosis and high-risk subjects without illness 
transition revealed a complex pattern of regional volumetric abnormalities affecting 
grey matter across most lobar brain structures and the cerebellum. Although, the 
discriminating decision maps were different for each analysis of the EHRS, the 
FePsy and the pooled datasets, there were however common brain regions that 
comprised the discrimination maps in all cases-analyses. The brain regions that 
contributed the highest in discriminating between the study groups in all cases 
included superior and inferior frontal and superior temporal lobar structures, parts of 
the cingulate gyrus and the cerebellum, all which have been consistently reported as 
important in the pathophysiology of schizophrenia.  
 
 




sMRI data alone sMRI+ clinical data 
 
N/N                  BAC (%) N/N                   BAC (%) 
HR[ill] vs HR[symp] 17/17                  88.2 17/17                   94.1 
ARMS-T vs ARMS-NT 16/19                  74.2  -                              - 
HR-T vs HR-NT 33/36                   82.6  -                              - 
   The number of subjects in each diagnostic group (N/N) and the balanced accuracy 
are shown for the classifications based on baseline structural MRI data alone, and the 
combination of baseline MRI with clinical variables (just for subjects in the EHRS). 
Note: HR[ill] and HR[symp] refer to subjects from the EHRS, ARMS-T and ARMS-
NT refer to subjects drawn from the FePsy study and HR-T, HR-NT refer to the 




Despite the very encouraging results presented in this thesis, it is my personal 
opinion that neuroimaging-based pattern recognition methods have a long way to go 
before making an impact in the current diagnostic and prognostic clinical context of 
schizophrenia.  I believe that the research and imaging community is not yet in place 
to speak about imaging-based biomarkers in schizophrenia research but rather about 
neuroanatomical patterns that can differentiate one diagnostic group (in this case 
schizophrenia, or converters to schizophrenia) from another (healthy controls or non-
converters). Pattern recognition-based methods implemented to date are still rather 
crude to accommodate the idea of identifying neuroanatomical biomarkers, that 
warrant large effect sizes and therefore larger data samples, replication to 
independent cohorts, consistency in classification performances across cohorts, data 
samples that are representative of routine clinical cases (and therefore eliminate the 
associated selection bias), a meaningful and widely acknowledged interpretation of 
the classification results (i.e. classifiers weights) and effective ways and methods of 
dealing with confounding variables such as medication effects or comorbidity. These 
issues have yet to be examined and resolved, and could be probably best dealt with in 
large muti-site, longitudinal studies (please see section 8.4 for a more detailed 
discussion of the challenges and future directions of imaging-based machine 
learning) 
The ultimate goal for imaging-based machine learning is, however, to develop tools 
that could aid clinicians in everyday routine care and management. That is, machine 
learning-based systems, like the one depicted in Figure 8.1, that will be able to 
combine together various imaging, clinical and neuropsychological data and provide 
results for an individual that could be fed back quickly to the clinician in a way that 
would be helpful for clinical management. The major challenge for neuroimaging-
based pattern classification in significantly impacting clinical practice is, however, in 
the early diagnosis of individuals at an imminent risk of developing schizophrenia 
and other psychosis-related disorders and in refining prognostic distinctions; that is 
questions of whether an individual will develop schizophrenia over bipolar disorder 
or whether he/she will develop unipolar depression over bipolar disorder and 
ultimately whether the patient will benefit from one treatment over another. These 
are the clinical questions that could bear added benefit in clinical routine and would 
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likely help clinicians in a way that will move the field of clinical psychiatry forward, 
alongside the majority of other medical specialties where biological and clinical tests 
are routinely used to guide clinical decision-making and care. 
 
 
8.3 Strengths and Limitations 
 
One of the main strengths of the present thesis is the ability to include prospective 
studies of both familial and clinical high-risk cohorts. Additionally, the high-risk 
subjects from the EHRS cohort were anti-psychotic naïve at the time of study 
inclusion, which means that our results were completely unconfounded by 
medication effects.  
In this thesis, Support Vector Machine was chosen to implement the classification 
task. Among the machine learning algorithms, Support Vector Machine is one of the 
most frequently used multivariate approaches, mainly on account of its good 
classification performance and ability to deal effectively with high-dimensional data. 
The latter characteristic is due to the fact that in determining the optimal separating 
hyperplane the SVM only takes into account data samples that are closely located to 
it (these samples are called support vectors) in the feature space. In that way, the 
SVM classifier inherently focuses on subtle between-group morphological 
differences and not on gross differences that might be more easily identifiable. 
Additionally, as all pattern-classification methods do, the SVM enabled the 
prediction of illness onset at an individual level, which has added potential for 
clinical translation.  
In order to identify the most informative features in the classification process and 
possibly increase the diagnostic performance of the classifier, recursive feature 
elimination (RFE) was implemented in a nested cross-validation scheme. The RFE 
algorithm is a well-validated technique that iteratively removes the most redundant 
and least informative features while identifying the most discriminative ones. A 
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significant number of MRI-based pattern recognition studies have used RFE for the 
identification of the most discriminative features in the feature space and/or for 
improving the generalization performance (Ecker et al. 2010, Zacharaki et al. 2009, 
Marquand et al. 2011, Mourao-Miranda et al. 2012b, De Martino et al. 2008, Fan et 
al. 2007). 
Another important strength of the current thesis is the validation of the classifier 
using data from an independent high-risk cohort; a step that is crucial in the 
development and verification of imaging-based biomarkers in clinical settings (Fu & 
Costafreda 2013). Pooling together data from different research sites is additionally 
beneficial in examining whether prediction is robust enough to differences in 
prevalence, recruitment and image acquisition strategies.   
As stated before, taken together this thesis leads to the conclusion that machine 
learning can significantly impact the identification of MRI-based biomarkers for the 
early prediction of psychosis in high-risk cohorts. That is, even at the early stages of 
psychosis, subjects who later develop schizophrenia demonstrate already at baseline 
distinct patterns of grey matter volume differences that differentiate them from high-
risk subjects that do not develop the disorder. However, many challenges and 
limitations remain. The limitations encountered here arise either as a result of 
limitations inherent in the datasets or limitations attributed to the chosen 
preprocessing or analysis methodologies.  
The relatively modest sample size, especially in the cases where subjects from the 
EHRS and the FePsy study were considered separately (Chapters 5 and 6 
accordingly), is one of the main limitations of this study, which is also observed in 
most neuroimaging-based studies in this field. As a result of the limited sample size 
and the recruitment criteria followed, the study cohorts included only a limited 
representation of the whole spectrum of clinical and psychopathological 
manifestations of the high-risk state, which is not always the case in standard clinical 
practice. Comorbid substance abuse and comorbidities with other disorders such as 
depression or anxiety were part of the exclusion criteria, which is not a realistic 
mirroring of the cases encountered in health services. 
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Both in the EHRS and the FePsy study, more males than females developed 
schizophrenia, possibly confounding our classification results. The construction of 
different classifiers for males and females, as presented in the work of Fan et al. 
2007, was not feasible due to the already limited number of cases in the HR-T 
groups. The finding of the higher male morbidity may be, however, attributed to the 
higher incidence of schizophrenia in males than females (Aleman et al. 2003).  
Antipsychotics and other medications have been administered to some high-risk 
subjects in the FePsy study, some time prior to MRI scanning, and therefore one 
cannot rule out the possibility that medication effects may have contributed to the 
observed classification results (Chapter 6). Interestingly enough, most of the subjects 
that received antipsychotic medication were misclassified by the classifier possibly 
suggesting a divergent pathophysiology at the neuroanatomical level.  
Another potential limitation is the use of a 1.0T scanner in the EHRS samples that 
compared to most widely used 1.5T scanners (as in the FePsy study) might have 
failed to provide enough spatial detail to characterize subtle structural abnormalities.  
Regarding the classification task, one limitation of the SVM method and other 
machine learning methods in general, is that the features comprising the optimal 
decision function (that is often illustrated as a weighted brain map) are not easily 
interpretable, mainly due to their multivariate nature. As stated before, the brain 
regions constituting the discrimination map all contribute to the classification 
function (with a certain weight that indicates the degree of the contribution) and it is 
not possible to make inferences about localized alterations.  
Additionally, while the leave-one-out cross-validation is a well-validated and highly 
used technique in evaluating the performance of the classifier due to its almost 
unbiased estimation of the true error rate, it underestimates variance due to the 
repeated use of any subset of data in most training sets. The ideal scenario of 
splitting the dataset into non-overlapping sets of training data and test data instances 
could be realized in large, multisite cohort studies.  
Finally, one of the most important limitations with the data pooling is the 
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introduction of systematic scanner-related differences that may have confounded 
both the preprocessing of the baseline scans and downstream from there to the 
classification task. Future studies would be required that would account for scanner-
related differences between sites and tackle the issue of intensity standardization at 
the initial stage, before any preprocessing, by matching histograms for every tissue 
type (i.e. grey matter, white matter, cerebrospinal fluid etc.).  
 
 
8.4 Future work 
 
As seen and discussed in depth in previous chapters of this thesis, brain imaging and 
more specifically magnetic resonance imaging has contributed much in our current 
understanding of the pathophysiology of schizophrenia and psychosis-related 
disorders. However, it has so far made little impact in routine clinical practice where 
a MRI scan is usually ordered in order to exclude organic diseases, such as a brain 
tumour or brain haemorrhage and not to diagnose or inform targeted theurapeutic 
plans. Therefore, one of the basic aims for clinical psychiatry to move into the future 
is to develop objective, biologically based markers (biomarkers) that could map 
psychiatric disorders to brain structure and function. A careful investigation of the 
feasibility and main challenges in translating imaging research findings into routine 
clinical practice is necessary in order to pave the way for the development of 
clinically useful biomarkers for establishing diagnosis and illness course or treatment 
outcome in schizophrenia. 
In order for a diagnostic biomarker to be valid, it needs to attain certain levels of 
sensitivity and specificity. A perfect biomarker, with 100% sensitivity and 100% 
specificity, would detect only true positives and no false negatives and thus would 
accurately reflect the prevalence of schizophrenia in the true population. However, in 
practice such diagnostic levels are not always possible and thus the norm is to 
develop biomarkers that can minimize the error for false positives and false negatives 
as much as possible. Addtionally, the lack of consistency in the classification 
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performances observed in current diagnostic studies of schizophrenia and lack of 
replication studies that would confirm previous classification results hinder the 
identification of diagnostic biomarkers. 
The development of clinically relevant biomarkers for shcizophrenia is also hindered 
by the lack of a diagnostic gold standard for the disease. In traditional medicine, a 
biological test, such as a blood test, often suffices for a definitive pathological 
diagnosis. For Alzheimer’s disease, neuropathological confirmation can be achieved 
by post-mortem histopathological examination. On the contrary, there is no definite 
examination to confirm diagnosis of schizophrenia that leads directly back to brain 
structure (or function), and currently the closest one can get to a ‘gold-standard’ 
diagnosis for schizophrenia is the DSM/ICD criteria, which are empirically based 
and often limited by the patient’s willingness to cooperate and the clinical expertise 
and acumen of the clinician conducting the interview. 
Additionally, linking back to the importance of specificity in the development of a 
biomarker, most imaging-based studies have examined and contrasted schizophrenia 
patients to perfectly healthy, normal participants (see Chapter 3). In clinical practice, 
however, it is rarely the case that a clinician would wonder about whether to 
categorize (or label) an individual as a patient or as a healthy control and more often 
the question raised involves whether this patient has schizophrenia, or bipolar 
disorder etc. This is not to say that imaging findings contrasting schizophrenia 
patients to healthy controls were conducted in vain since these have provided the 
research community with invaluable information and insight into the 
pathophysiology of the disease, but to highlight the importance of including more 
pragmatic scenarios that could have an added benefit to clinical care. 
The differential diagnosis of schizophrenia from other psychosis-spectrum disorders 
such as bipolar disorder and mood disorders such as depression presents a major 
clinical challenge. Recent structural and functional MRI-based multivariate pattern 
recognition studies have achieved very promising classification performances in 
distinguishing schizophrenia patients from patients with bipolar disorder (Costafreda 
et al. 2009, Costafreda et al. 2011, Calhoun et al. 2008, Schnack et al. 2014, Bansal 
et al. 2012) or major depression (Koutsouleris et al. 2015a, Bansal et al. 2012). 
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However, future studies will be needed that would comprise of larger cohorts and 
possibly integrate various imaging modalities in order to unravel the 
neuroanatomical and neurophysiological correlates that differentiate schizophrenia 
from other psychosis- or mood-related disorders (Lawrie et al. 2011). This research 
direction will hopefully shed light into the question of whether these nosological 
entities are characterized by distinct and/or non-overlapping pathopshysiological 
abnormalities and help identify patterns of brain structure that are unique to 
schizophrenia. Unsupervised or semi-supervised machine learning methods could aid 
in that direction by grouping together (into clusters) subsets of patients that share 
similar neuroanatomical and/or clinical profiles and then possibly exploit supervised 
pattern recognition to examine the diagnostic differentiation between the clusters.  
Imaging findings need to be replicated in independent study cohorts in order to 
ensure the validity of imaging-based biomarkers in their way towards incorporation 
to routine clinical care. Currently, most researchers tried to develop diagnostic tools 
using one cohort of patients at a time while only a few have tested their classifiers 
using independent cohorts (Nieuwenhuis et al. 2012, Schnack et al. 2014, Kawasaki 
et al. 2007) with classification performance being lower on the independent sets, and 
ranging from 70% to 80% accuracy. Despite little effort being done, machine-
learning techniques could really contribute to the effort of replicating imaging 
findings across research sites because different teams could train classifiers using 
their own data sets and then once the classification functions are found, they could be 
shared among collaborating research sites in the context of creating a classifiers’ 
repository. 
Additionally, incorporating more ‘pragmatic’ cases for both patient and healthy 
control cohorts is another major clinical challenge. Apart from the limiting case of 
contrasting schizophrenia patients with healthy control individuals presented above, 
it should be noted that most control participants recruited include perfectly healthy 
individuals (‘hyper-normal’ cases) while excluding any individual presenting with 
any substance abuse or even family history of psychiatric conditions. Similarly, 
schizophrenia cohorts often exclude patients with any comorbid psychiatric disorder, 
or substance abuse, which is not the norm for cases of schizophrenia presenting in 
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everyday clinical practice. The need for more realistic representation of 
schizophrenia and healthy participants is in alignment with the need for larger data 
samples; a well-known hindrance in most research studies in terms of recruiting 
procedures and findings’ robustness. Multi-site studies could address the need for 
large data samples and additionally ensure the sufficient phenotypic and 
demographic representation of the under-study population. Prospective, longitudinal 
multi-site studies for the early diagnosis and management of early and first episode 
psychosis, such as the PSYSCAN and PRONIA projects have recently been launched 
with the aim of developing multimodal biomarkers for the prediction of onset, course 
and outcome of psychosis. However, multi-site initiatives warrant further calibration 
and standardization efforts in order to ensure the compatibility and reproducibility of 
imaging data across sites. Standardization procedures in the pre-processing and/or 
analysis pipelines as the ones suggested by the ENIGMA consortium could be used 
in order to reduce variability in findings. Test-retest reliability studies and novel 
histogram matching techniques could be used to account for site differences and 
guarantee the quality and standardization between follow-up scanning.  
 
To further understand which structural brain alterations take place before psychosis 
onset and/or are responsible for the transition from a state of heightened risk to 
psychosis, further longitudinal studies are needed that could perhaps involve follow-
up scanning before the onset of psychosis and while the subject still meets HR 
criteria. This might clarify the nature and extent of longitudinal changes that predate 
the onset of illness that are possibly not confounded by effects of antipsychotic 
medication and illness-specific alterations. Additionally, longitudinal studies of HR 
subjects with low probability of conversion to psychosis (Smieskova et al. 2012) 
and/or those HR subjects without transition (Addington et al. 2011) could reveal 
protective, resilience factors that would be clinically relevant in early intervention 
approaches. In the same context, longitudinal imaging–based studies in healthy 
control populations would help the research community in mapping normal, brain 
developmental trajectories in an effort to elucidate normal structural and functional 
variability before characterizing deviant, illness-specific trajectories.  
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Within the context of technical challenges, probabilistic machine learning might also 
be a promising tool in neuroimaging-based schizophrenia research. More 
specifically, probabilistic classification approaches such as Gausian Process classifier 
(GCP) (Rasmussen & Williams, 2006) and Relevance vector machine, can be used to 
quantify a degree of uncertainty in the prediction and could thus be applied in the 
context of predicting transition to psychosis or future clinical outcome, indicating for 
example a percentage of confidence for classification into one group or another (e.g. 
75% risk transition to schizophrenia and 25% not making a transition.). There are 
several examples of studies that have used probabilistic classifiers employing 
structural MRI data (Tognin et al. 2013), neurophysiological imaging data (either 
PET or fMRI) (Marquand et al. 2010, Phillips et al. 2011, Mourao-Miranda et al. 
2012b) and a multimodal approach where structural and functional imaging data 
together with genotype information are combined in the same probabilistic learning 
framework (Young et al. 2013). 
It is a priority that future studies also address the challenge and opportunity of fusing 
neuroimaging data from various imaging modalities, along with genetic and clinical 
information, that seem likely to interact in determining the development and outcome 
in schizophrenia (Lawrie et al. 2011). It would be reasonable to assume that the 
introduction of neurocognitive and other clinical measures could possibly enhance 
diagnostic power of the classifier. Just as a clinician takes a detailed report of 
symptoms and other clinical measures to diagnose a patient with schizophrenia, so 
might the integration of symptom severity measures and other neurocognitive scores, 
along with MRI scans aid to the classification process. Early studies have already 
shown that classification performance might well be improved (Yang et al. 2010, Sui 
et al. 2012), as in Karageorgiou et al. (2011) where the authors observed a 92% 
accuracy in classifying recent-onset schizophrenia when structural MRI data and 
neuropsychological variables (NP) were combined than when employing either 
quantitative measure alone (86.7% when only NP data were used and 70.7% with 
sMRI data alone). Other neuroimaging technologies such as arterial spin labeling 
(ASL) perfusion MRI and diffusion tensor imaging (DTI) have shown very 
promising leads in unraveling the neurobiological substrate of several psychiatric and 
neurological disorders (Pinkham et al. 2011, Sussmann et al. 2009, van Essen et al. 
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2012), and might as well be combined with MRI methods in schizophrenia research. 
The interpretability of such data is not, however, necessarily straightforward and, as 
a general rule, each additional diagnostic variable increases sensitivity at the expense 
of specificity. It is overdue, though, that combined features, such as symptoms, 
duration of illness, genomics and proteomics along with various brain imaging 
modalities are incorporated into imaging and other evaluations in clinical research 
studies, with the scope of making more reliable and objective judgements about the 
diagnosis of schizophrenia and to classifying patients into more homogenous 
subgroups (Lawrie et al. 2008). 
In conclusion, despite the fact that the medical and research community is currently 
far away from utilizing automated neuroimaging-based classification methods to 
diagnose schizophrenia and possibly predict its onset, clinical outcome and treatment 
response, in the long run MRI-based machine learning could significantly impact 
everyday clinical practice. Indeed, these methods could add value to current 
diagnostic procedures and aid clinicians in a complementary fashion in order to reach 
diagnosis and possibly inform appropriate treatment strategies after evaluating the 
risk of transition to psychosis in subjects at an increased risk. Clinical decisions 
based on imaging data could, thus facilitate the stratification of patient care and 
potentially reduce health-care costs. Further studies are, however, necessary that 
would involve large sample sizes, possibly using multicenter, longitudinal designs 
that could additionally examine the classification performance of combined data 
types, such as multi-modal imaging data, clinical, neurocognitive and genetic 
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Derivation of the dual form of SVM 
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We need to minimize this Lagrangian with respect to w and b and simultaneously  
require that the derivative with respect to a  vanishes , all subject to the constraints 
that 0≥ia .  
 
 









































We substitute the above into the equation ),,( abwp

Λ  and obtain the dual 



















We seek to maximize the above Lagrangian with respect to a , subject to the 













• The F-score (Fisher score) is a simple and effective criterion to measure the 
discrimination between a feature and the label. Based on statistic 
characteristics, it is independent of the classifiers. Following Chen and Lin 
(2006), a variant of F-score is used. Given training instances lixi ,...,1, =

, the 




















































 are the average of the jth feature of the whole, positive-labeled 










  is the jth feature of the ith 
positive/negative instance. The numerator denotes the inter-class variance, while 
the denominator is the sum of thye variance within each class. A larger F-score 
indicated that the feature is more discriminative.  
Although, the F-score is easy to implement, its deficiency, however, lies in that it 






• the Pearson correlation coefficient, whose use in feature selection is closely 
related to that of the t-Test (Guyon and Elisseef 2003), measures the 
relevance of each feature to the classification task. The larger the absolute 
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value of the Pearson correlation coefficient, the more relevant the feature to 
the classification. Given a location, u , in the template space, the Pearson 
correlation coefficient between a feature, )(uf i  , of tissue i and class label y  























where j denotes the jth sample in the training dataset. Thus, )(uf ij  is a 
morphological feature of tissue i in the location u of jth sample, and )(uf i  is 
the mean of )(uf ij  over all samples. Similarly, jy  is a class label (controls -1 





























Table 1. A comparative presentation of the PSE and BPRS subscales  
PSE sub-categories BPRS subcategories 
-Situational Anxiety  -Somatic concern 





-Changed Perception -Elevated mood 
-Hallucinations -Grandiosity 
-Thought Disturbance  -Suspiciousness 
-Delusional Construction  -Hallucinations 
-Outside Control  -Unusual thought content 







































Figure 1. Factorial analysis of the BPRS subscores and the derived four-scale model. 

















Here, I present the histograms, generated after concatenating all voxel intensity 




Figure 1. Histogram of the EHRS data set 
 
 
It should be noted that values in the x-axis correspond to probabilities of the voxels 
being GM, and the y-axis represent the number of voxels having the relevant 
probabilities.  The only noticeable difference between the histograms of the EHRS 
and the FePsy scans (Figure 1 and 2 accordingly) lies in the assignment of higher 
probability values in the EHRS data set relative to the FePsy one (the far-right side of 
the distributions). However, this can not be attributed to any difference in the 
preprocessing stage, since the pre-processing pipeline was exactly the same for the 
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two data sets but can be reasonably due to a much more accurate segmentation of the 
scans in the EHRS set.  
In this context, given the similarity of the distributions between the EHRS and the 
FePsy data sets, it was safe to assume that pooling together the data from the two 
data sets without performing any type of scaling or histogram matching would work 




Figure 2. Histogram of the FePsy data set 
 
It should also be noted here, that even in the case where the distributions between the 
data sets were different, it would be most reasonable to perform some type of scaling 
or matching before any pre-processing is done and try to match all tissue types, that 
is GM, WM and CSF, and not just GM. However, this endeavour is quite complex 
and could be a project on its own and that is why it was decided not to attempt this 
and stick to pooling all of the available data without performing any scaling 
whatsoever.  
